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CHAPTER 1 
Review of the Literature 
1.1  The toxicity of arsenic 
Arsenic (As) is a toxic metalloid that displays some of the properties of both 
metals and nonmetals. Arsenic has two biologically important oxidation states, As(V) 
and As(III). Arsenate is also called arsenic acid (H3AsO4). And arsenite is called 
arsenous acid (H3AsO3) or arsenic trioxide (As2O3). Arsenic is widely distributed in the 
whole biosphere, which our life is dependent on. Human are exposed to arsenic by 
drinking water or eating food contaminated with arsenic. Antimony (Sb) is another toxic 
metalloid in the same group as arsenic in the period table. They share similar chemical 
properties. Chronic exposure to arsenic is related to skin lesions, neurological effects, 
high blood pressure, diabetes mellitus, diseases of the respiratory system, 
cardiovascular disease, and cancers typically involving the skin, lung, and bladder 
(Rahman et al., 2009).   
1.1.1 Ubiquitous existence of arsenic in the environment 
Arsenic is widely distributed throughout the earth’s crust at an average 
concentration of 2-3 mg/kg; arsenopyrite (FeAsS) is the most abundant arsenic-
containing mineral (Cullen and Reimer, 1989; Peters et al., 1996). Natural processes 
like weathering of rocks and volcanic emissions, and human activities such as 
combustion of fossil fuels, mining, smelting of ores or the application of arsenical 
pesticides, herbicides and wood preservatives, are the main sources which contribute to 
arsenic contamination in the environment.  
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Weathering of rocks leads to mobilization of the soluble oxoanions, arsenite and 
arsenate, and these are the dominant forms of arsenic in fresh water and in seawater. 
The concentrations of arsenic in fresh water vary between 1 to 100 μg/L or even more. 
The concentration of arsenic in the world’s oceans is at ~1-2 μg/L (Francesconi, 2005). 
Arsenic in ground water is largely the result of minerals dissolving from weathered rocks 
and soils. High concentrations of arsenic in ground water became a problem in recent 
years, due to the shortage of usable surface water. The use of deep tubewells for water 
supply in the Ganges Delta causes serious arsenic poisoning to large numbers of 
people in India (Kim et al., 2002). Arsenic contamination of ground water is prevalent in 
many countries throughout the world including India, Bangladesh, Thailand, Taiwan, 
and Mainland China. 
Anthropomorphic sources include arsenical-containing fungicides, pesticides and 
herbicides, insecticides, rodenticides, wood-preservatives, animal feeds, paints, dyes, 
and semiconductors.  Lead arsenate was used to control the codling moth from the 
1800s to the 1940s (when DDT became available). CCA (chromated copper arsenate) 
is the best known of the arsenical wood preservatives. The treated wood has a 
characteristic greenish tint. This wood has been widely used in decks and play 
structures. Arsenic is still being used in lawn and turf herbicides. Products with names 
like All-In-One Weed Killer, Crabgrass Killer, and Liquid Edger contain various arsenic 
compounds. Conventional poultry farmers often feed chickens roxarsone, one of many 
drugs approved by the Food and Drug Administration for the purpose to kill microbes 
but actually containing arsenic. Arsenic helps remove impurities during glass making. It 
is also used as a colorant in fireworks and a doping material in semiconductor 
  
3
manufacturing. In the end, all of these arsenics will end up somewhere, usually in 
topsoil and water, where arsenic could be enriched by crops and enters the food chain.  
Arsenic will accumulate in crops if the crops are irrigated with arsenic 
contaminated water or grown in the soils contaminated by arsenic from herbicide or 
insecticide. As one of the most popular crops in the world, rice is of particular concern 
(Williams et al., 2005). Flooded soils, in which paddy rice is cultivated, lead to rapid 
mobilization of arsenite (As(III)), which becomes available for rice to take up (Xu et al., 
2008). Among the cereals, rice accumulates relatively high proportions of arsenic in its 
edible parts. Rice grain contains arsenic that range from 0.08 to 0.20 mg/kg if grown on 
non-contaminated soils (Zavala and Duxbury, 2008). It could be as high as 2.0 mg/kg if 
rice is grown in contaminated areas (Tripathi et al., 2007). 
Arsenic contamination of drinking water is a serious environmental problem 
worldwide because of the large number of contaminated sites that have been identified 
and the large number of people at risk (Chappell et al., 1997). An estimated 100 million 
people in more than 70 countries are at risk of exposure to unacceptable arsenic levels 
in either well water or ground water. This has become a major public health issue in the 
developing world, primarily Bangladesh and surrounding countries, where many 
thousands of individuals are suffering from precancerous arsenic-related disease. In 
2001, the US Environmental Protection Agency lowered the Maximum Contaminant 
Level (MCL) in drinking water from 50 μg/L to 10 μg/L. The World Health Organization 
(WHO) standard is also 10 μg/L. There are many locations in the United States where 
groundwater contains arsenic concentrations in excess of the new standard of 10 μg/L 
<http://water.usgs.gov/nawqa/trace/arsenic/>.  
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 As a consequence of its environmental pervasiveness, exposure and health 
effects, arsenic ranks first on the United States Government’s Comprehensive 
Environmental Response, Compensation, and Liability (Superfund) Act Priority List of 
Hazardous Substances. <http://www.atsdr.cdc.gov/cercla/05list.html>  
1.1.2  Health effect of arsenic 
Humans are exposed to arsenic mainly through either oral or inhalation routes. 
Oral exposure occurs via consumption of contaminated water, food and drugs. 
Occupational exposure occurs mainly through inhalation via semiconductor and glass 
manufacturing, or power generation by the burning of arsenic-contaminated coal (Yager 
and Wiencke, 1993). Large dose of arsenic exposure will cause acute toxicity including 
gastrointestinal discomfort, vomiting, diarrhea, bloody urine, anuria, shock, convulsions, 
coma, and death. The toxicity of arsenic is related to the chemical form and its oxidative 
state. Dimethyl arsenate (DMAs(V)) and methylarsenate (MAs(V)) are less toxic, than 
As(V). The sequence is as the following, DMAs(V),MAs(V)<As(V)<As(III)<MAs(III) 
(Hughes, 2002). General noncarcinogenic symptoms of chronic arsenic poisoning in 
humans are weakness, loss of appetite and energy, loss of hair, hoarseness of voice, 
loss of weight, and mental disorders (Hindmarsh and McCurdy, 1986). Following 
absorption of trivalent or pentavalent arsenic compounds, arsenic is initially 
accumulated in the liver, kidney, lung, spleen, aorta, and skin. One of the hallmarks of 
chronic toxicity in humans from oral exposure to arsenic are skin lesions, which are 
characterized by hyperpigmentation, hyperkeratosis, and hypopigmentation (Cebrian et 
al., 1983). In Taiwan, Blackfoot Disease, a peripheral vasoocclusive disease which 
leads to gangrene of the extremities, is also observed in individuals chronically exposed 
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to arsenic in their drinking water (Tseng, 1977). Other targets include nervous system 
(peripheral neuropathy) (Valentine et al., 1982), and vascular system (Wu et al., 1989).  
 Inorganic arsenic is classified by the International Agency for Research on 
Cancer (Higginson and DeVita, 1980) and the U.S. Environmental Protection Agency 
(EPA, 1988) as a human carcinogen. Epidemiological studies have revealed an 
association between arsenic concentrations in drinking water and increased incidences 
of skin cancers (including squamous cell carcinomas and multiple basal cell 
carcinomas), as well as cancers of the liver, bladder, respiratory and gastrointestinal 
tracts (Chen et al., 1985; Chen et al., 1986; Smith et al., 1992).  In the past few 
decades, arsenic exposure has attracted great interest, due to occupational disease of 
lung cancer among copper smelter workers, and the connection with increased risk of 
skin, lung and bladder cancers. 
1.1.3  Medical application of arsenic 
Although arsenic is toxic, few things in this world are completely evil. Arsenic 
compounds have also been used to treat diseases like trypanosomiasis and 
promyelocytic leukemia. Roughly a century ago, arsenic formed the structural 
centerpiece of arsphenamine, known as Salvarsan or Compound 606, this molecule 
was the first wonder drug: the cure for syphilis. Arsphenamine was soon followed by 
neoarsphenamine, which was water-soluble and easier to administer (Sneader, 1985). 
These drugs were used for syphilis chemotherapy for forty years, until the advent of 
penicillin rendered them obsolete.  
 In the realm of inorganic arsenic, arsenic trioxide (As2O3), solubilized as the 
arsenite salt of an alkali metal, is a prominent medicinal compound. In the 18th century, 
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Dr. Thomas Fowler developed a therapeutic agent known as Fowlers solution by 
combining arsenic trioxide with potassium bicarbonate (Scheindlin, 2005). Throughout 
the 19th century Fowler’s Solution was deemed a useful alternative to quinine for 
malaria, and there were also claims of beneficial effects in syphilis and sleeping 
sickness. It was also sporadically tried for the treatment of leukemia and found effective 
for inducing remission in chronic myelogenous leukemia (CML). In the early 1970s, 
some Chinese physicians, analyzing a number of traditional preparations used in 
treating cancer, found As2O3 to be a common component of these products. They 
proceeded to test the compound in a variety of cancers, and obtained remission rates of 
90% in relapsed acute promyelocytic leukemia (APL) (Niu et al., 1999). Recent studies 
show that arsenic directly targets to cysteine residues in zinc fingers within PML-
RARalpha and PML. Arsenic binding induces PML oligomerization, which increases its 
interaction with the small ubiquitin-like protein modifier (SUMO)-conjugating enzyme 
UBC9, resulting in enhanced SUMOylation and degradation (Zhang et al., 2010). 
Further research on anticancer activity of arsenic is still going on. Preliminary results 
have been reported on various diseases such as multiple myeloma (MM), acute 
lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS) (Verstovsek and 
Estrov, 2004).  
 There are also organic arsenic derivatives under development. Organic 
phenylarsenic acid (PAA) compounds with potent in vitro activity against human acute 
lymphoblastic leukemia cells showed 50% inhibition of cell growth (Liu et al., 2003). S-
dimethylarsino-glutathione has been identified as a lead compound among more than 
100 derivatives and is currently being developed for clinical use by ZIOPHARM 
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Oncology, Inc. A Phase II trial is nearing completion in patients with primary liver cancer 
and advanced myeloma, a Phase II trial is ongoing in patients with lymphomas, and a 
Phase I oral trial is in progress.  
1.1.4  Mechanisms of arsenic toxicity 
 Arsenic occurs predominantly in inorganic form as arsenate (As(V)) and arsenite 
(As(III)). Pentavalent Arsenate is an analogue of phosphate and thus interferes with 
essential cellular processes such as oxidative phosphorylation and ATP synthesis. For 
example, arsenate reacts in vitro with glucose to form glucose-6-arsenate, which 
resembles glucose-6-phosphate, can inhibit hexokinase (Lagunas, 1980). At both the 
substrate and mitochondrial level, arsenolysis diminishes in vitro formation of ATP by 
the replacement of phosphate with arsenate in the enzymatic reactions. Depletion of 
ATP by arsenate has been observed in cellular systems (Gresser, 1981). ATP levels 
are reduced in rabbit (Delnomdedieu et al., 1994b) and human erythrocytes (Winski and 
Carter, 1998) after in vitro exposure to arsenate.   
 The toxicity of trivalent arsenite is due to its propensity to bind to sulfhydryl 
groups, with consequent detrimental effects on general protein functioning. A main 
target is pyruvate dehydrogenase (PDH), which is a multi subunit complex that requires 
the cofactor lipoic acid, a dithiol, for enzymatic activity.  Arsenite inhibits PDH (Szinicz 
and Forth, 1988), perhaps by binding to the lipoic acid moiety. Lipoate is needed in the 
formation of acetyl-CoA from pyruvate and in the formation of succinyl-CoA from alpha-
ketoglutarate. Therefore, arsenic blocks the Krebs Cycle and interrupts oxidative 
phosphorylation, resulting in a marked depletion of cellular ATP and eventually death of 
the metabolizing cell. Other targets include numerous other cellular enzymes, which are 
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involved in cellular glucose uptake, gluconeogenesis, fatty acid oxidation and production 
of glutathione. The binding of arsenite to the critical sulfhydryl groups in these enzymes, 
interferes the normal protein function and lead to toxicity. 
 Reactive oxygen species can be induced by arsenite that can eventually alter the 
redox status of the cell and present a stressful and toxic situation and induce large 
deletion mutations in hamster-human hybrid cells (Hei et al., 1998). Many mechanism of 
arsenic carcinogenicity have been proposed, including genotoxicity, cell proliferation, 
altered DNA repair and DNA methylated oxidative stress, co-carcinogenesis, and tumor 
promotion (Hughes, 2002). DMAs has the potential to promote rat urinary bladder 
carcinogenesis and one of the mechanisms involved is its stimulation of cell proliferation 
in the urinary bladder epithelium (Wanibuchi et al., 1996). A significant dose-dependent 
decrease in activity of a DNA repair enzyme, poly-(ADP-ribose)polymerase by arsenite 
was observed (Yager and Wiencke, 1997).  
1.2  Arsenic detoxification  
 In response to the ubiquity of arsenic in the environment and to counteract the 
deleterious effects of arsenic, nearly every organism, from E. coli to human, evolved 
resistance strategies, including arsenite oxidation or methylation into less toxic species, 
as well as active extrusion of arsenite from the cell (Rosen, 2002).  
1.2.1 Arsenic uptake systems 
 In solution at neutral pH, arsenic acid exists as the arsenate oxyanion. Since 
arsenate is very similar with phosphate, the phosphate transporters are usually hijacked 
to catalyze the arsenate uptake. In the prokaryote E. coli, there are two phosphate 
transporters, Pit and Pst (Rosenberg et al., 1977). Both catalyze arsenate uptake, but 
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the Pit system appears to be the predominant system for arsenate (Willsky and Malamy, 
1980). Similarly, in the eukaryote Saccharomyces cerevisiae several phosphate 
transporters, such as PHO84 (Bun-Ya et al., 1992), PHO86 and PHO87 (Bun-ya et al., 
1996), participate in arsenate uptake. Specific arsenate transporters have been 
identified in plant that are believed to mediate a large part of the observed arsenate 
influx and these include the A. thaliana Pht1;1 and 1;4 high and medium affinity 
phosphate uptake systems (Shin et al., 2004).  Human AQP9 expressed in Xenopus 
laevis oocytes increased the uptake of MAs(V) and DMAs(V), two major pentavalent 
arsenic cellular metabolites (McDermott et al., 2010). 
 The pKa of arsenous acid is 9.2. At neutral pH, it is present in solution primarily 
as neutral As(OH) 3 (Ramirez-Solis et al., 2004), which might be considered an inorganic 
equivalent of glycerol. Recently, arsenite uptake was found through aquaglyceroporins 
in bacteria, yeast and mammalian cells. A screen of a random mutagenesis E. coli 
library turned up that mutation in GlpF leads to resistance to Sb(III) (Sanders et al., 
1997). The chemical properties of Sb(III) and As(III) are very close, and, even though 
the mutant did not exhibit increased arsenite resistance, GlpF was shown to increase 
As(III) uptake if it is overexpressed in E. coli (Meng et al., 2004). S. cerevisiae cells with 
FPS1 gene deleted are more sensitive to arsenite, indicating that the glycerol channel 
Fps1p mediates uptake of arsenite and antimonite (Wysocki et al., 2001).  Xenopus 
laevis oocytes microinjected with either mouse AQP7 or rat AQP9 cRNA exhibited 
increased transport of As(III), which suggests that AQP9 and AQP7 may be major 
routes of arsenite uptake into mammalian cells (Liu et al., 2002). The ability of the four 
known human members of the aquaglyceroporin family, hAQP3, hAQP7, hAQP9, and 
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hAQP10, to facilitate As(OH)3 movement in Xenopus oocytes was also examined. The 
order of effectiveness as an As(III) transporter was found to be hAQP9 > hAQP7, with 
little or no transport by hAQP3 or hAQP10 (Liu et al., 2004b). AQP9 was also shown to 
be able to transport MAs(III) (Liu et al., 2006b). In S. cerevisiae cells, hexose 
permeases are found to be involved in arsenite uptake (Liu et al., 2004a). Human and 
rat GLUT1 catalyzed uptake of both As(OH)3 and CH3As(OH)2 in oocytes (Liu et al., 
2006a). Plants take up arsenite significantly if they are grown in reducing environments 
such as paddy-grown rice and aquatic species. It was hypothesized that plants also 
take up arsenite through aquaporins (Meharg and Jardine, 2003), although the 
molecular identity of the proteins that participate in uptake, efflux, compartmentation 
and long-distance transport of As(III) is largely unknown. Heterologous expression of 
NIPs, a subfamily of plant aquaporins, in yeast, confirmed the arsenite transport 
capacity of AtNIP7;1 and OsNIP2;1, but in addition showed that all group II NIPs are 
capable of arsenite transport (Bienert et al., 2008).  
1.2.2  Arsenic metabolism 
 After arsenic is taken up into the cells, usually it is metabolized intentionally or 
adventitiously by reduction, oxidative methylation and glutathione conjugation, and then 
it is pumped out of the cell or sequestered in intracellular organelles.  
 When the pentavalent oxyanion arsenate is taken up, it is reduced to As(III) prior 
to extrusion or sequestration. Three independently evolved families of arsenate 
reductase enzymes have been recognized (Mukhopadhyay et al., 2002). The product of 
arsC, the last gene of the ars operon of E. coli plasmid R773 is an arsenate reductase, 
which belongs to the first family. R773 ArsC uses glutaredoxin as the reducing agent 
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and only has one cysteine residue participating in the reaction. The crystal structure of 
the 16-kDa R773 ArsC has been reported with bound substrate (arsenate) and product 
(arsenite) (Martin et al., 2001).  A second family of arsenate reductases also widely 
distributed in bacteria is represented by the arsC gene product of Staphylococcus 
aureus plasmid pI258 (Ji and Silver, 1992). The pI258 enzyme uses thioredoxin as the 
source of reducing potential (Ji et al., 1994) and has two intramolecular cysteine 
residues that participate in the catalytic cycle (Messens et al., 1999). The crystal 
structure of the pI258 ArsC has been solved and this enzyme is related to low 
molecular-weight protein tyrosine phosphatases and exhibits low-level phosphatase 
activity (Zegers et al., 2001). The third family of arsenate reductases is related to the 
superfamily of protein phosphatases that includes CDC25a, a cell cycle phosphatase. 
Yeast Acr2p and Leishmania LmACR2 both belong to this family. Acr2p has a single 
active site cysteine residue and uses glutaredoxin and glutathione as reductants 
(Mukhopadhyay et al., 2000). LmACR2 is a bifunctional protein with both protein 
tyrosine phosphatase activity and pentavalent antimony reduction activity. It’s proposed 
that the physiological function of LmACR2 is to dephosphorylate phosphotyrosine 
residues in leishmanial proteins but not to reduce the pentavalent antimony for 
detoxification (Zhou et al., 2006). Specific arsenate reductases have been identified in 
many plant species including Arabidopsis (Dhankher et al., 2006), P. vittata (Ellis et al., 
2006), and rice (Duan et al., 2007). Many plant arsenate reductases are also 
bifunctional and show tyrosine phosphatase activity. They are homologous to the 
human cell-cycle dual-specificity phosphatase CDC25.  
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 Metabolic conversion of inorganic arsenic into methylated products is a multistep 
process that yields mono-, di-, and trimethylated arsenicals. The methylation is 
proposed to occur by a series of reductions of pentavalent to trivalent arsenicals 
coupled to oxidative methylations (Challenger, 1945).  In recent years, it has become 
apparent that formation of methylated metabolites of inorganic arsenic is not necessarily 
a detoxification process, since intermediates and products formed in this pathway may 
be more reactive and toxic than inorganic arsenic.  Toxicity of the arsenic metabolites is 
DMAs(III),MAs(III)>As(III)>As(V)>DMAs(V),MAs(V)>TMAsO (Akter et al., 2005). But the 
final major pentavalent products, DMAs(V) and TMAsO are approximately a hundred-
fold and a thousand-fold less toxic than As(III), respectively (Hirano et al., 2004).  
Arsenic methylation by fungi and other eukaryotes has been well documented (Bentley 
and Chasteen, 2002) . In rat liver, a novel SAM-dependent pathway has been 
discovered that involves a 42-kDa methyltransferase (designated cyt19) linked to 
thioredoxin-thioredoxin reductase system (Thomas et al., 2004; Zakharyan et al., 1995). 
Only recently its homolog, ArsM, has been identified in 125 bacteria and 16 archaea, 
and was characterized in Rhodopseudomonas palustris. ArsM not only conferred 
arsenic resistance, but also generates trimethyl arsine gas (TMAs(III)). Reduced 
glutathione was used as the electron donor (Qin et al., 2006). Cyanidioschyzon sp. 
isolate 5508 oxidized As(III) to As(V), reduced As(V) to As(III), and methylated As(III) to 
form TMAsO and DMAs(V). Two arsenic methyltransferase genes, CmarsM7 and 
CmarsM8, were cloned from this organism and demonstrated to confer resistance to 
As(III) in an arsenite hypersensitive strain of Escherichia coli. The two recombinant 
CmArsMs were purified and shown to transform As(III) into MAs(V), DMAs(V), TMAsO, 
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and TMAs(III) gas, with an optimum temperature around 60-700C (Qin et al., 2009). 
Since ArsM homologues are widespread in nature, arsenic methylation by microbes is 
proposed to have an important impact on the global arsenic cycle.   
1.2.3  Extrusion systems 
 There are two basic mechanisms of arsenite extrusion. One is carrier-mediated 
efflux via an arsenite carrier protein, and the other by an arsenite-translocating ATPase 
(Dey and Rosen, 1995). The most common mechanism of arsenite resistance is efflux 
from cells catalyzed by members of two different and unrelated families of permeases, 
ArsB and Acr3.  
Majority of bacteria use ArsB, which is found in most ars operons, to extrude 
arsenite. By itself, ArsB is a secondary efflux protein coupled to the protonmotive force 
and confers a moderate level of arsenite resistance (Kuroda et al., 1997). ArsB 
transports As(III) but has higher affinity for Sb(III). ArsB is an antiporter that catalyzes 
the exchange of trivalent metalloid for protons, coupling arsenite efflux to the 
electrochemical proton gradient (Meng et al., 2004). When ArsA is co-expressed with 
ArsB, an ArsAB complex is formed that is obligatorily coupled to ATP. ArsB associates 
with the ArsA ATPase to form a pump that confers high level resistance. ArsB is unique 
in that it exhibits a dual mode of energy coupling depending on the subunit composition 
(Dey and Rosen, 1995).  Some bacteria have three-gene arsRBC operons and extrude 
arsenite by ArsB alone, while others have five-gene arsRDABC operons and use the 
ArsAB pump (Rosen, 1999). It has been proposed that the five-gene operons arose by 
insertion of the arsDA genes into a three-gene operon (Rosen, 1999, 2002). Recently, 
ArsD was shown to be an arsenic chaperone. ArsD sequesters the free arsenite in the 
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cell cytosol, delivers it to the ArsAB pump for extrusion thus confers higher resistance to 
arsenite than ArsAB pump alone (Lin et al., 2006). 
The Acr3 family includes members found in bacteria, archaea and fungi.  
Unfortunately, many members of the Acr3 family have been given the name ArsB even 
though they exhibit almost no sequence similarity to ArsB. The first identified member is 
from in the SKIN element of B. subtilis (Sato and Kobayashi, 1998). S. cerevisiae Acr3p 
confers arsenite resistance (Ghosh et al., 1999; Wysocki et al., 1997). Yeast Acr3p 
favors As(III) as substrate rather than Sb(III).  C. glutamicum ATCC 13032 has been 
shown to have three genes for Acr3 homologues, each of which contribute to the high 
level of arsenite resistance in this organism (Ordonez et al., 2005). Expression of C. 
glutamicum or Alkaliphilus metalliredigens acr3 genes in an arsenite-hypersensitive 
strain of E. coli in which all ars genes were deleted confers resistance to As(III). This 
heterologously expressed Acr3 catalyzes efflux of arsenite from E. coli.  It exhibits 
significant differences from R773 ArsB.  While ArsB exchanges As(III) with protons, 
Acr3 does not, but how it is coupled to the proton-motive force is unknown at this point.  
Like the yeast Acr3p, the C. glutamicum Acr3 is also more specific for As(III) than Sb(III), 
in contrast to ArsB, which has higher affinity for Sb(III) than As(III) (Fu et al., 2009).  
 In eukaryotic cells, arsenite resistance is mainly conferred by members of the 
MRP (multidrug resistance-associated protein) group of the ABC superfamily of 
transport ATPases (Cole et al., 1994; Deeley et al., 2006), which physiologically 
catalyze export of GS-conjugates such as leukotriene C4 (LTC4) (Leier et al., 1994). 
MRP1-catalyzed export of glutathione from cells was increased by arsenite, suggesting 
that MRP1 functions as an As(GS)3 carrier (Zaman et al., 1995). In the liver MRP2 
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extrudes arsenic glutathione complexes into bile and may be a major route of arsenic 
detoxification in humans (Kala et al., 2000). PgpA, another MRP homolog, was also 
demonstrated to transports As(GS)3 in Leishmania (Legare et al., 2001). In S. 
cerevisiae, an MRP homolog, Ycf1p, has been shown to transport As(GS)3 into the 
vacuole and confers arsenite resistance in yeast (Ghosh et al., 1999).  
1.3  ArsA and ArsD from E. coli R773 plasmid 
 In bacteria, the genes for arsenic detoxification are usually encoded by arsenic 
resistance (ars) operons. Nearly every sequenced bacterial genome contains an ars 
operon. Many ars operons have only three genes, arsRBC, where ArsR is an As(III)-
responsive transcriptional repressor, ArsB is a As(OH)3/H+ antiporter that extrudes 
As(III), conferring resistance (Meng et al., 2004), and ArsC is an arsenate reductase 
that converts As(V) to As(III), the substrate of ArsB, hence extending the range of 
resistance to include As(V) (Mukhopadhyay and Rosen, 2002).  Some ars operons have 
two additional genes, arsD and arsA, such as the arsRDABC operon in E. coli plasmid 
R773, and cells expressing the arsRDABC operon are more resistant to As(V) and 
As(III) than those expressing arsRBC operons because ArsA forms a complex with 
ArsB that catalyzes ATP-driven As(III)/Sb(III) efflux. While ArsD exhibits weak repressor 
activity (Chen and Rosen, 1997; Wu and Rosen, 1993), its primary function has recently 
been shown to be as an arsenic metallochaperone that delivers As(III) to the ArsA 
ATPase (Lin et al., 2006). Interaction with ArsD increases the affinity of ArsA for As(III), 
producing increased efflux and resistance at environmental concentrations of arsenic.  
1.3.1  Co-existence of ArsA and ArsD in ars operons 
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 Nearly every sequenced bacterial genome contains an ars operon. Although the 
majority is three-gene arsRBC operons, to date, there are more than fifty bacterial and 
archaeal arsenic resistance operons and gene clusters that contain arsA and arsD 
genes. It is striking that arsA and arsD genes are always found together in ars operons. 
The order of the genes in those operons may differ from each other, but the arsD gene 
nearly always precedes an arsA gene. The linkage of these two genes suggests first, 
that ArsD and ArsA co-evolved before their association with ArsB, second that the 
arsDA genes moved laterally into an ars operon as a unit and third, that ArsD has a 
biochemical function related to ArsA in arsenic detoxification.   
1.3.2  ArsA ATPase 
 The 583-residue ArsA ATPase is a member of a family of ATPases that probably 
arose from GTPases (Leipe et al., 2002). It is normally bound to ArsB (Dey et al., 1994), 
but, in the absence of ArsB, ArsA is found in the cytosol and can be purified as a 
soluble protein. ArsA has two halves, A1 and A2, that are connected by a 25-residue 
linker (Li and Rosen, 2000). The crystal structure of the enzyme has been determined 
(Zhou et al., 2000).Three types of domains can be resolved. First, there are two 
nucleotide-binding domains (NBDs). The NBDs are folded structures that both contain 
residues from both A1 and A2. A metalloid binding domain (MBD) that binds three 
As(III) or Sb(III) is located about 20 Å from the NBDs. This is an allosteric site at the 
opposite end of the protein from the NBDs (Figure 1-1). Of the three Sb(III), one is 
connected to Cys113 and Cys422 (MBS1), a second to Cys172 and His453 (MBS2), 
and the third to His148 and Ser420 (MBS3) (Zhou et al., 2000). Each metalloid is bound 
by two ArsA residues. The highest affinity site is composed of Cys-113 and Cys-422 
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(Ruan et al., 2006), and a third cysteine, Cys-172, can participate in high affinity binding 
(Ruan et al., 2008).  Binding of As(III) or Sb(III) brings the two halves of ArsA together, 
activating ATP hydrolysis. Connecting the single MBD to the two NBDs are two 
signature sequences that serve as signal transduction domains (STDs), 
D142TAPTGH148TIRLL in A1 (STD1) and D447TAPTGH453TLLLL in A2 (STD2), that 
corresponds to the Switch II region of many other nucleotide binding proteins and have 
been proposed to be involved in transmission of the energy of ATP hydrolysis to 
metalloid transport (Zhou and Rosen, 1997). In the ArsA structure these sequences are 
seen as extended stretches of residues physically linking the NBDs through Asp142 and 
Asp447 at the N-terminal end to the MBD through His148 and His453. Asp142 and 
Asp447 are Mg2+ ligands in NBD1 and NBD2, respectively, and His148 and His453 are 
Sb(III) ligands in the MBD (Zhou et al., 2000). This physical connection between the 
domains allows ATP hydrolysis at the NBDs to alter the affinity for As(III), and, 
reciprocally, allows metalloid binding at the MBD to alter the affinity for and rate of 
hydrolysis of ATP.  
 Specific spectroscopic probes, single tryptophan residues, were introduced into 
strategic locations in ArsA. The fluorescent properties of these tryptophan residues 
change in response to nucleotide binding, hydrolysis and/or conformational changes in 
domains. The intrinsic fluorescence of Trp159 has allowed real time monitoring of the 
conformation of ArsA during the individual steps of the catalytic cycle and has allowed 
modeling of the reaction cycle (Walmsley et al., 1999, 2001). The results suggest that 
the rate-limiting step in the overall reaction in the absence of metalloid activation is the 
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isomerization of a longlived conformation of the enzyme, and that binding of metalloid 
overcomes this rate-limiting step, increasing the rate of hydrolysis.  
 In the crystal structure NBD1 is occluded and has ADP bound. NBD2 is more 
open, and ATP can be exchanged into the site (Zhou et al., 2000). This gives the 
appearance of an alternation of sites, and alternating site mechanisms are found in 
other transport ATPases. There is good evidence to suggest non-equivalence of the two 
sites. NBD1 hydrolyzes ATP in the absence of activation while NBD2 does not (Kaur, 
1999). For this reason, basal hydrolysis has been termed unisite catalysis. In the 
presence of metalloid, both sites hydrolyze ATP and participate in multisite catalysis. 
Two single tryptophan residues, Trp141 and Trp446, had been used to study either 
NBD1 or NBD2. Trp141 is adjacent to NBD1 and to the N-terminal Asp142 of the A1 
signature sequences. Trp446 is in the equivalent position in NBD2, next to Asp447 of 
the A2 signature sequence. The fluorescent properties of these two mutants allow 
measurement of the rate of hydrolysis in each site singly. The fluorescent properties of 
Trp141 clearly show that NBD1 hydrolyzes ATP during unisite catalysis (Zhou and 
Rosen, 1997). In contrast, Trp446 fluorescence indicates that NBD2 is catalytically 
inactive until metalloid is bound, that is, only under multisite conditions (Zhou et al., 
2002). Although the two NBDs are not equivalent in all respects, the existing data 
cannot yet distinguish between different functions for the two or alternating sites 
catalysis.  
1.3.3  Evidence for physical interaction between ArsD and ArsA  
 Yeast two-hybrid analysis demonstrates that ArsD and ArsA physically and 
specifically interact (Lin et al., 2006).  Among the four soluble proteins encoded by the 
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R773 arsRDABC operon, ArsA was found to interact with ArsD but not with the ArsR 
repressor or the ArsC arsenate reductase;  ArsD interacted with ArsA and with itself, 
which would be expected since ArsD is a homodimer (Chen and Rosen, 1997), but not 
with ArsR or ArsC; ArsR, which is a homodimer, also interacts with itself, but not with 
the other proteins. Since there is no arsenic or antimony in yeast cells, ArsD and ArsA 
must interact in the absence of metalloid. However, when Cys12, Cys13 or Cys18, the 
residues in ArsD that form the metalloid binding site (described in more detail below), 
were mutated to serines, the serine-substituted ArsD mutants neither activate ArsA 
ATPase activity nor bind Sb(III) in this mutated site (Y.F. Lin and B.P. Rosen, 
unpublished), consistent with the idea that it is the metalloid-bound form of ArsD that 
activates ArsA. These data suggest that ArsD interacts with ArsA with high affinity when 
metalloid is bound but with low affinity in the absence of metalloid such as in the yeast 
cytosol in the two-hybrid assays. 
 Direct physical interaction between ArsD and ArsA was observed by chemical 
crosslinking with dibromobimane (dBBr), a fluorogenic, homobifunctional thiol-specific 
crosslinking reagent that becomes highly fluorescent when its two alkylating groups 
react with cysteine residues within 3 to 6 Å of each other (Kosower et al., 1980). When 
the mixture of ArsD and ArsA was reacted with dBBr, a crosslinked species was 
detected that reacted with both anti-ArsA and anti-ArsD antibodies. MgATP is required 
for the formation of ArsD-ArsA crosslinked product. These results suggest first that ArsD 
and ArsA interact at their cysteine-rich metalloid binding sites and second that ArsD 
interacts with nucleotide-bound form of ArsA. 
1.3.4  Cell biology of ArsD function 
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 That arsD and arsA genes are nearly always found together in ars operons 
implies co-evolution for a common function, most likely arsenic detoxification. Cells co-
expressing arsDAB were more resistant to high concentrations of As(III) compared to 
cells expressing only arsAB, consistent with interaction of ArsD with ArsA increasing the 
efficiency of the ArsAB pump  (Lin et al., 2006).  The concentration of arsenic in such 
growth experiments is usually in the millimolar range, which might be found in a volcanic 
area such as Yellowstone National Park, but such concentrations are much greater than 
would be found under most environmental conditions. To examine whether the 
presence of a functional arsD gene conferred an growth advantage to cells at lower 
levels of arsenic, two batches of cells of an E. coli strain in which the chromosomal ars 
operon had been deleted were mixed together and grown at equal amount in the 
presence of 10 μM sodium arsenite, a concentration present in many deep tube wells in 
Bangladesh. One batch of cells had a plasmid with only the arsAB genes, and the other 
had the arsDAB genes. After a little more than a week, the cells with arsDAB had 
largely replaced those with only arsAB, demonstrating that ArsD provides a competitive 
advantage for growth in soil or water with moderate amounts of arsenic contamination. 
 Examination of As(III) accumulation in intact cells revealed that ArsD enhances 
the ability of the pump to extrude As(III) and reduces the intracellular arsenic 
concentration to subtoxic levels. Cells expressing only arsB were able to lower the 
intracellular level of As(III) compared to a strain with no ars, reflecting the ability of ArsB 
to catalyze As(OH)3/H+ exchange (Meng et al., 2004). When  arsA and arsB were co-
expressed, the cells have more efficient As(III) extrusion than with arsB alone (Dey and 
Rosen, 1995).  When arsD was co-expressed with arsAB, the cells exhibited a further 
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reduction in As(III) accumulation (Lin et al., 2006). These lines of evidence support the 
idea that ArsD increases the efficiency of the ArsAB pump.  The competitive advantage 
provided by direct interaction of ArsD with ArsA provides a driving force for the co-
evolution of the two genes. 
1.3.5  Biochemistry of ArsD function 
 The hallmark of metallochaperones is delivery of metal ions directly to target 
proteins (Rosenzweig, 2002). The ability of ArsD to transfer Sb(III) to ArsA  was  shown 
by mixing Sb(III)-loaded ArsD with ArsA, separating the two proteins and determining 
how much Sb(III) was bound to ArsA. In the presence (but not the absence) of 
magnesium and a nucleotide, ArsA was able to extract Sb(III) from ArsD.  
 Metalloid transfer studies of the transfer of As(III) or Sb(III) from ArsD to ArsA are 
consistent with a mechanism in which this metallochaperone accelerates the rate of 
transfer to its partner. However, for ArsD and ArsA, this transfer process is 
thermodynamically unfavorable because ArsD has higher affinity for metalloid than does 
ArsA.  However, if the metalloid bound to the ArsAB pump is pumped out of the cell, 
mass action will provide the directionality of the reaction. This suggests that ArsD might 
not only serve a role in protecting the cell from free metalloid but also in loading ArsA for 
metalloid extrusion.  Indeed, because ArsD has higher affinity for metalloid than ArsA, it 
can ‘scavenge’ the cytosol for free metalloid for delivery to ArsA, allowing the ArsAB 
pump to confer resistance at significantly lower concentrations of As(III).  The Km of 
ArsB as a secondary carrier is 0.14 mM (Kuroda et al., 1997), but natural waters range 
in concentration of total inorganic arsenic from 7 nM to 70 µM, and concentrations of 
arsenic in drinking water in worst arsenic-contaminated wells in West Bengal and 
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Bangladesh are approximately 40 µM (Smedley and Kinniburgh, 2002).  By lowering the 
concentration of substrate at which the pump functions efficiently, ArsD and ArsA 
provide cells with a mechanism to respond to environmental concentrations of metalloid. 
 ArsD not only delivers metalloids to ArsA but also enhances its ATPase activity 
at low metalloid concentrations. In the presence of ArsD, the apparent affinity of ArsA 
for As(III) is largely increased but the Vmax remains unchanged in ATPase reactions (Lin 
et al., 2006). ArsD makes the enzyme more effective at low concentrations of metalloid, 
a property expected for a metallochaperone. As(III) or Sb(III) activates the ATPase 
activity of ArsA, so that the increase in affinity of ArsA for metalloids in the presence of 
ArsD can simply be attributed to the higher affinity of ArsD in the ArsD-ArsA complex, 
that is, ArsD allows for activation of ArsA ATPase at lower metalloid concentrations.  
This explains how cells expressing arsDAB can rapidly replace cells expressing only 
arsAB at a subtoxic concentration of As(III).   
 In summary, the increase in ArsA efficiency resulting from interaction with ArsD 
leads in vitro to augmented activity of the ArsAB extrusion pump, to greater resistance 
in organisms with the arsDAB genes, and finally to increased fitness for growth in the 
low but ubiquitous levels of environmental arsenic. 
1.3.6  Metalloid binding sites in ArsD 
 R773 ArsD has three vicinal cysteine pairs, Cys12-Cys13, Cys112-Cys113 and 
Cys119-Cys120. Alignment of the primary sequence of homologues of R733 ArsD 
indicates that the cysteine pair Cys12-Cys13 and a single additional cysteine, Cys18 
are conserved in homologues. Two other cysteine pairs, Cys112-Cys113 and Cys119-
Cys120, are found in some homologues but not others. A series of cysteine mutants 
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and truncations of ArsD were constructed, purified and studied for the metalloid binding 
(Lin et al., 2007a). Mutants or truncations with only a single vicinal cysteine pair can still 
bind to a phenylarsine oxide affinity column, which indicates indirectly that each 
cysteine pair can form an independent metalloid binding site (Li et al., 2001).  In more 
recent experiments, binding of Sb(III) was measured directly (Lin et al., 2007a).  Wild-
type R773 ArsD binds three Sb(III) per monomer. If two of the three cysteine pairs were 
changed to alanine or serine residues, or if the C-terminal vicinal pairs were removed by 
construction of truncated versions, variants with only a single vicinal pair were found to 
bind one Sb(III) per monomer, showing directly that each cysteine pair forms an 
independent metalloid binding site. If the conserved cysteine Cys18 was mutated, the 
mutant with the only first cysteine pair, Cys12-Cys13, was unable to bind Sb(III).  This 
suggests that the cysteine pair Cys12-Cys13 and Cys18 form a 3-coordinate thiolate 
metalloid binding site, which has been termed MBS1. The metalloid binding sites 
formed by cysteine pairs Cys112-Cys113 and Cys119-Cys120 are designated MBS2 
and MBS3, respectively. All three binding sites have similar affinity to Sb(III), 
approximately 1 μM. 
 A truncated ArsD lacking both MBS2 and MBS3 (ArsD1-109), still interacted with 
ArsA in the yeast-two-hybrid assay and had the same stimulatory effect on ArsA 
ATPase activity as wild-type ArsD (Lin et al., 2007a).  In contrast, an ArsD derivative 
lacking MBS1 but retaining MBS2 (ArsD1-118,C12A/C13A) was unable to interact with ArsA 
in yeast-two-hybrid assay and did not stimulate ArsA activity. These results suggest that 
MBS1, but not MBS2 or MBS3, participate in metalloid transfer to ArsA and in activation 
of ArsA ATPase activity. Cells expressing a mutated arsD1-118, C112A/C113A gene, which 
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encodes an ArsD derivative having only MBS1, in trans with arsAB accumulated As(III) 
to nearly the same extent as those expressing wild type arsDAB. These cells also have 
a modest reduction in arsenite resistance compared to cells expressing wild type 
arsDAB. However, the cells expressing other ArsD mutants lacking MBS1 (arsDC12/C13A 
or arsDC18A) accumulate slightly more As(III) than cells with only arsAB and were no 
more resistant to As(III) than cells with only arsAB. These in vivo results strongly 
support the hypothesis that MBS1 (Cys12, Cys13 and Cys18), but not MBS2 or MBS3, 
is required for metallochaperone activity. 
1.3.7  Proposed mechanism of metalloid transfer from ArsD to ArsA 
 The fact that the MBSs in ArsA and MBS1 in ArsD appear to be involved in 
interaction suggests that metalloid binding sites in both proteins are brought into close 
proximity, allowing transfer of metalloid directly from the binding site on ArsD to the 
binding site on ArsA.  It is plausible that this interaction destabilizes the metalloid 
binding sites on ArsD, reducing its affinity, while stabilizing the metalloid binding sites on 
ArsA by occluding the metalloid within the complex, thus enabling transfer of metalloid 
to ArsA. In this manner, the thermodynamically unfavorable process of transferring the 
metalloid from a high to a low-affinity site could be overcome, although, as mentioned 
above, this might not be a concern if the transferred metalloid is rapidly extruded from 
the cell.  While the details of metalloid transfer from ArsD to ArsA are unknown at this 
time, the mechanism of transfer of copper from the metallochaperone CCS to the 
superoxide dismutase SOD1 is instructive (Lamb et al., 2001; Torres et al., 2001).  The 
cysteine residues of CCS project into the active site of SOD1.  By doing so, Cu(I) 
bridges the donating cysteine residues of CCS and the receiving histidine residues, 
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stabilizing the heterodimer and facilitating metal transfer. In effect, transfer of copper 
between the Atx1 and Ccc2p is ‘catalyzed’ by the metallochaperone.  We propose a 
similar mechanism of As(III) transfer from ArsD to ArsA in which there is a step-wise 
exchange of sulfur ligands from ArsD cysteines to ArsA cysteines (Figure. 2-12). The 
MBS1 (metalloid binding site 1) of ArsD and MBSs of ArsA come close to each other, 
then the As(III) bound by ArsD will be released by one cysteine of ArsD and coordinated 
by the cysteine of ArsA to form an As(III) intermediated complex. Through step by step 
change of the thiol-ligands of As(III) from ArsD to ArsA, finally As(III) is coordinated by 
the three cysteines from ArsA. 
1.4  Other metallochaperones 
Arsenic is a non-essential element in any organism. ArsD functions to sequester 
toxic arsenic and deliver it to the extrusion pump. Similar metal-chaperones have been 
found for essential but toxic metals such as copper and iron. They sequester free metal 
in cells and specifically deliver to target proteins. Though copper and iron are essential, 
both Cu(I) and Fe(II) could undergo Fenton or Fenton-like chemistry to generate highly 
toxic hydroxyl radical. Accumulation of free Cu(I) and Fe(II) is detrimental to the cell. On 
one hand, the metal-chaperone could sequester the metal and keep the concentration 
of free metal at very low concentration. On the other hand, the chaperones specifically 
deliver metal to the target proteins, which could be the enzyme requiring the metal as 
cofactor, the extrusion pump or the metal-storage protein.  
 Metal-chaperones deliver metals to the target proteins. Usually without a metal, 
the chaperone protein does not interact with the target protein or does so very weakly. 
In the presence of metal, the interaction is strengthened. After the metal is delivered, 
  
26
the chaperone protein dissociates from the target protein, and a new cycle starts. For 
this cycle to be efficient, the chaperone-target interaction should be transient and weak. 
This is one reason that it’s difficult to study how chaperone proteins interact with their 
target proteins. 
1.4.1  Copper chaperones 
Copper chaperone has been found from prokaryotic cells to eukaryotic cells. In 
vitro, most copper enzymes easily acquire their metal without the help of any auxiliary 
proteins.  However, in living cells such as yeast, the cytoplasmic free copper 
concentration is estimated to be less than 10-18 M since SOD1 cannot get Cu(I) even 
though the total copper concentration is very high. Almost no free copper exist in the 
cells, and copper chaperone proteins are required for the maturation of the enzyme 
(Rae et al., 1999).   
 Enterococcus hirae has a copYZAB operon encoding proteins involved in copper 
homeostasis. CopA and CopB are P-type ATPase pumps, importing and exporting 
copper, respectively. CopY is a operon repressor in the absence of Cu(I). CopZ is 
required for delivery of Cu(I) to CopY to activate transcription of the operon (Odermatt 
and Solioz, 1995). Through gel-filtration, Cu(I)-CopZ transfer Cu(I) to CopY. But these 
two proteins do not come off the gel-filtration column as a complex (Cobine et al., 1999). 
The interaction between CopZ and CopY was suggested to be mediated by charged 
residues. MNKr2, a homolog of CopZ, the second copper binding site of human Menkes 
ATPase, can be engineered to gain the function similar of CopZ to transfer Cu(I) to 
CopY through changing the different charged residues (Cobine et al., 2002), suggesting 
CopZ and CopY interact through these charged residues. Surface Plasmon Resonance 
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show that CopZ specifically interacts with CopA immobilized on the chip. Cu(I) 
increased the affinity of interaction between CopZ and CopA 15-fold by decreasing the 
dissociation rate of the two proteins. Mutation of Cys to Ser of the N-terminal copper 
binding motif CXXC of CopA abolishes the modulation of interaction affinity by Cu(I), but 
the mutant still binds to CopZ as well as wild-type CopA in the absence of Cu(I) 
(Multhaup et al., 2001). Recent studies show that N-terminal copper binding site of 
CopA may only serve as a regulatory site, while CopZ is able to directly transfer Cu(I) to 
TM-MBS, the transmembrane copper binding site (Gonzalez-Guerrero and Arguello, 
2008).  
 CopZ homologues are Atx1 in yeast and HAH1 in human. Ccc2 in yeast and 
Menkes (ATP7A) and Wilson (ATP7B) ATPase in humans are CopA homologues that 
also have several copies of CopZ-like copper binding motif in their N-termini. These 
MBDs (metal binding domain) have been proposed to accept Cu(I) from chaperone 
proteins. Atx1 interacts with the N-terminal MBD of Ccc2 in the yeast two-hybrid system 
(Pufahl et al., 1997). The transfer from Atx1 to the MBD of Ccc2 is reversible, which 
suggests the transfer from Atx1 to Ccc2 is not due to higher affinity for Cu(I). But Atx1 
can protect Cu(I) from other copper scavengers in the cell such as glutathione, and 
directly bring Cu(I) to the target protein through protein-protein interaction (Huffman and 
O'Halloran, 2000). The binding interface between Atx1 and the first MBD of Ccc2 has 
been characterized by NMR. By following the 15N and 1H chemical shifts, a new species 
is detected. This species is in fast exchange with the parent species on the NMR time 
scale. Nuclear relaxation data are consistent with the formation of an adduct (Arnesano 
et al., 2001). Based on NMR chemical shift mapping information, a structure model of 
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the transient complex was proposed through in silico docking. The model shows that the 
interaction is mainly of an electrostatic nature with hydrogen bonds stabilizing the 
complex (Arnesano et al., 2004). Coupling site-directed mutagenesis and NMR study, 
the contribution of copper and cysteine residues of the binding site was studied. The 
copper is essential for the weak and transient metal-mediated interaction (Banci et al., 
2006). Recently, a new target protein, copper amine oxidase Cao1 is also shown to 
accept Cu(I) from Atx1. And these two proteins were shown to interact with each other 
in yeast two-hybrid system (Peter et al., 2008).        
 Hah1 compensates for the function of Atx1 in atx1Δ yeast (Hung et al., 1998). 
Coimmunoprecipitation experiments revealed that HAH1 interacts with both the Wilson 
(ATP7B) and Menkes (ATP7A) proteins and that this interaction depends on available 
copper. This provides a mechanism for the function of HAH1 as a copper chaperone in 
mammalian cells to transfer to ATP7A and ATP7B (Hamza et al., 1999). Yeast two-
hybrid experiments show copper-dependent interaction between HAH1 and the 2nd or 
4th MBD of ATP7B (van Dongen et al., 2004), also with 2-6 MBD of ATP7A (Larin et al., 
1999). The interaction between HAH1, and the second or the fifth soluble domains of 
ATP7A (MNK2 and MNK5, respectively), was investigated in solution using 
heteronuclear NMR. The copper-transfer properties of MNK2 and MNK5 are similar, 
and differ significantly from those previously observed for the yeast homologous 
system. No stable adduct is formed between either of the MNK domains and HAH1. The 
copper(I) transfer reaction is slow on the time scale of the NMR chemical shift, and the 
equilibrium is significantly shifted towards the formation of copper(I)-MNK2/MNK5 
(Banci et al., 2005). NMR titration show the formation of an adduct by Cu(I)-HAH1 with 
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WLN4 that is in fast exchange on the NMR time scale with the isolated protein species 
as confirmed by 15N relaxation data. A similar interaction is also observed between 
Cu(I)-HAH1 and WLN2; however, the relative amount of the adduct in the protein 
mixture is lower. In both cases the interaction interface can not be mapped by NMR 
(Achila et al., 2006).  
 Another example of a copper chaperone is the chaperone protein involved in the 
maturation of superoxide dismutase (SOD1). In Saccharomyces cerevisiae, it’s LYS7 
and in human it’s CCS. They are responsible for the delivery of copper to copper/zinc 
superoxide dismutase (Culotta et al., 1997). Interaction of the yeast copper chaperone 
yCCS in complex with its partner protein, superoxide dismutase (SOD1), has been 
elucidated crystallographically using a mutant SOD1 (Lamb et al., 2001). In this mutant 
SOD1, His48, one of the ligand for copper was mutated to Phe. yCCS, and this mutant 
SOD1 form a stable complex (Lamb et al., 2000).  
1.4.2  Iron chaperones 
 Frataxin, the protein lacked in the neurological disease Friedreich's ataxia, 
functions as a mitochondrial iron chaperone for iron-sulfur cluster and heme 
biosynthesis. Frataxin interacted with aconitase in a citrate-dependent fashion, reduced 
the level of oxidant-induced inactivation, and converted inactive [3Fe-4S]1+ enzyme to 
the active [4Fe-4S]2+ form of the protein. Thus, frataxin is an iron chaperone protein that 
protects the aconitase [4Fe-4S]2+ cluster from disassembly and promotes enzyme 
reactivation (Bulteau et al., 2004). Yeast frataxin was shown to interact with 
ferrochelatase by NMR (He et al., 2004). This model was proposed based on the 
structural information to show the channel of iron transfer from frataxin to ferrochelatase 
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for the heme synthesis (Bencze et al., 2007). Yeast frataxin Yfh1 binds to the central 
Fe/S-cluster (ISC)-assembly complex, which is composed of the scaffold protein Isu1 
and the cysteine desulphurase Nfs1. Association between Yfh1 and Isu1/Nfs1 was 
markedly increased by ferrous iron, but did not depend on ISCs on Isu1. Functional 
analyses in vivo showed an involvement of Yfh1 in de novo ISC synthesis on Isu1 
(Gerber et al., 2003). The iron-bound form of ISU is viable for assembly of holo ISU, 
either by subsequent addition of sulfide or by NifS-mediated sulfur delivery. Without 
sulfur delivery, isothermal titration calorimetry (ITC) shows that holo human frataxin 
forms a complex with ISU with sub-micromolar binding affinities, while apo frataxin does 
not bind to ISU, suggesting an important role for iron in cross-linking the two proteins 
and/or stabilizing the structure of frataxin that is recognized by ISU (Yoon and Cowan, 
2003). In Drosophila, holo frataxin also forms a complex with ISU that can be trapped 
without the sulfide delivery and can be detected by ITC (Kondapalli et al., 2008). 
 Ferritins are the main iron storage proteins found in animals, plants, and bacteria. 
The capacity to store iron in ferritin is essential for life in mammals. Human ferritins 
expressed in yeast contain little iron. Human poly (rC)-binding protein 1 (PCBP1) 
increased the amount of iron loaded into ferritin when expressed in yeast. 
Coimmunoprecipitation shows PCBP1 binding to ferritin. In vitro, PCBP1 binds iron and 
facilitates iron loading into ferritin (Shi et al., 2008).  
1.5  Summary 
 Arsenic is widely distributed throughout the earth’s crust and is brought into water 
and soils due to natural weathering process and human activities. Severe health effects 
have been observed in populations exposed to arsenic, which include cancer, 
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cardiovascular disease, peripheral neuropathies and diabetes mellitus. Because of the 
prevalence of arsenic in the environment, nearly every organism, from E. coli to humans, 
has genes for arsenic detoxification.  
The ArsAB pump in E. coli, encoded by the ars operon of plasmid R773, confers 
resistance to arsenicals and antimonials.  ArsA is the catalytic subunit of the pump that 
hydrolyzes ATP in the presence of arsenite or antimonite.  ArsB is a membrane protein 
containing arsenite-conducting pathway. ArsA forms complex with ArsB, therefore ATP 
hydrolysis is coupled to extrusion of As(III) or Sb(III) through ArsB. Upon 
overexpression, ArsA exists primarily as a soluble protein in the cytosol.  Purified ArsA 
is an As(III)/Sb(III)-stimulated ATPase.  
ArsD is an arsenite chaperone for ArsA. ArsD sequesters free As(III) in the cell 
and then delivers to ArsA. ArsD increases the apparent affinity of ArsA for As(III) by 
about 60 fold from 1.2mM to 20μM (Lin et al., 2006). This effect is more significant at 
‘physiological’ concentration of As(III) in the cell. There is no data of the maximum 
concentration of free As(III) inside the cells, at which the cells can tolerate.  Most likely it 
is less than 50μM suggested by measuring growth of E. coli cells, lacking arsenic 
resistance operon, with addition of As(III) in the medium. 50μM As(III) inhibits cell 
growth. The free As(III) inside the cell should not be higher than outside of the cell 
(Hung-Chi Yang, Barry Rosen, unpublished). By increasing affinity of ArsA for As(III), 
ArsD also increased ArsA ATPase activity at the ‘physiological’ concentration of As(III). 
Therefore, ArsAB pump efficiency is increased and less As(III) will be accumulated in 
the cells. On the other hand, since ArsD is a protein with higher affinity for As(III), there 
is less chance for free As(III) to bind to other proteins interfering their function after the 
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formation of ArsD-As(III) complex. So ArsD also confers the cell with the advantage of 
low availability of free As(III), therefore decreasing the deleterious effect of free As(III).   
ArsD has been shown to transfer Sb(III) to ArsA in the presence of Mg2+ and ATP. 
ArsD and ArsA can be crosslinked by dibromobimane, a homofunctional cysteine 
crosslinker with arm length about 6Å. The N-terminal metal binding site of ArsD, formed 
by Cys12, Cys13 and Cys18, is required for the metallochaperone function. From ArsA 
crystal structure, three cysteine residues, Cys113, Cys172 and Cys422 are found to 
near each other and involved in As(III) binding. Since both ArsD and ArsA use cysteine 
residues as ligands for As(III), all these results suggest that ArsD interacts with ArsA 
through their arsenic binding sites. However, the interaction detail is not known yet and 
the process of arsenic transfer is also not known. I approached the answers from three 
directions in chapters 2, 3 and 4. In chapter 2, the binding affinity of ArsD for As(III) was 
determined, and ATP hydrolysis was shown to be required for As(IIII) transfer from ArsD 
to ArsA. The results suggest that ATP hydrolysis changes ArsA to a conformation with 
higher affinity for As(III), and As(III) is transferred at this step. In chapter 3, the relation 
between ArsD dimerization and metallo-chaperone function was studied. In chapter 4, 
yeast two-hybrid analysis was used to select mutations affecting the interaction between 
ArsD and ArsA, which shed light on the interface between ArsD and ArsA. 
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CHAPTER 2 
Arsenic binding and transfer by the ArsD As(III) metallochaperone 
2.1 Introduction 
In bacteria and archaea various ars operons encode ArsAB ATPases that pump 
the trivalent metalloids As(III) or Sb(III) out of cells. In these operons, an arsD gene is 
almost always adjacent to the arsA gene, suggesting a related function. Most transition 
and heavy metal ions do not exist as free ions in the cytosol but are sequestered by a 
variety of proteins variously called metal ion chaperones, scaffolds or intracellular 
carriers (Field et al., 2002).  ArsD was recently shown to be a chaperone for transfer of 
cytosolic As(III) to the 583-residue ArsA ATPase, the catalytic subunit of the efflux pump 
(Lin et al., 2006; Lin et al., 2007a).  ArsD is a 120-residue protein with three conserved 
cysteine residues, Cys12, Cys13 and Cys18 required for chaperone activity (Lin et al., 
2007a). ArsA exhibits a low, basal rate of ATPase activity in the absence of As(III) or 
Sb(III) and a higher, activated rate in their presence.  ArsA has a high affinity metalloid 
binding site composed of Cys113 and Cys422 (Ruan et al., 2006), and a third residue, 
Cys172, that participates in high affinity binding and activation of ATP hydrolysis (Ruan 
et al., 2008).  In analogy with the mechanism of copper transfer from chaperones to 
copper pumps or enzymes (Boal and Rosenzweig, 2009), we previously proposed a 
step-wise transfer from the cysteines of ArsD to the cysteines of ArsA (Lin et al., 
2007b). ArsD increases the affinity of ArsA for As(III), permitting detoxification of 
environmental concentrations of arsenic. 
 In this study the properties of As(III) binding by ArsD and subsequent transfer to 
ArsA were examined.  X-ray absorption spectroscopy was used to show that As(III) is 
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coordinated with three sulfur atoms, consistent with Cys12, Cys13 and Cys18 forming 
the As(III) binding site. Assays with single-tryptophan derivatives of ArsA have been 
informative about As(III) or Sb(III) binding properties and catalysis (Walmsley et al., 
1999, 2001; Zhou et al., 2001; Zhou and Rosen, 1997; Zhou et al., 2002), so an assay 
using intrinsic protein fluorescence was developed as a probe of metalloid binding to 
ArsD.  Two single tryptophan derivative of ArsD were constructed by changing either 
Thr15 or Val17 to tryptophan in a tryptophan-free background. Both exhibited quenching 
of fluorescence upon binding of As(III) or Sb(III), from which the apparent affinity for 
metalloid could be estimated. Since it is likely that cytosolic As(III) is bound to reduced 
glutathione (GSH), the effect of GSH on binding to ArsD was examined.  GSH greatly 
increased the rate of binding As(III) to ArsD, suggesting that ArsD accepts metalloid 
from the As(GS)3 complex. In contrast, GSH did not affect the As(III)-stimulated ArsA 
ATPase activity, suggesting that As(III) is directly transferred from ArsD to ArsA, as 
opposed to release from ArsD, binding to GSH and then interaction of ArsA with the 
As(GS)3 complex.  To differentiate between these two possibilities, the effect of the 
As(III) chelator dimercaptosuccinic acid (DMSA) was examined.  The chelator did not 
affect transfer, indicating channeling of As(III) from ArsD to ArsA.  Transfer occurs only 
under conditions where ArsA hydrolyzes ATP, suggesting that ArsD transfer As(III) to 
an ArsA conformation transiently formed during catalysis and not simply to the closed 
conformation that ArsA adopts when As(III) and MgATP are bound (Zhou et al., 2001). 
2.2 Materials and Methods 
2.2.1 Strains, plasmids and media 
E. coli cells were grown in Luria-Bertani (LB) medium (Sambrook et al., 1989) at 
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37°C.  Ampicillin (100 µg/ml) or kanamycin (40 µg/ml) was added as required. E. coli 
strain JM109 [recA1 supE44 endA1 hsdR17 gyrA96 relA1 thiΔ(lac-proAB) F’ (traD36 
proAB+ lacIq lacZΔM15)] was used for molecular cloning. E. coli strain BL21(DE3) [F- 
ompT hsdSB (rB-mB-) gal dcm (DE3 [lacI lacUV5-T7 gene1 ind1 Sam7 nin5]) was used 
for protein expression and purification. ArsA with a C-terminal 6-histidine tag was 
expressed from plasmid pAlter-dAhB (Li and Rosen, 2000). ArsD contains three vicinal 
cysteine pairs, of which the last two are not required for chaperone activity, so the last 
11 residues containing those two cysteine pairs were removed, creating the ArsD1-109 
truncation. N-terminal MBP-fused ArsD1-109 (henceforth designated MBP-ArsD109) was 
expressed from plasmid pMAL-ArsD109 (Lin et al., 2007a). ArsD1-109 with an N-terminal 
six-histidine tag (henceforth designated as wild type ArsD109) was expressed from 
plasmid pET28a-ArsD109. The codons for the two native ArsD tryptophan residues, 
Trp35 and Trp97, were mutated to tyrosine codons by site directed mutagenesis in 
plasmid pET28a-ArsD109, generating pET28a-ArsD109W35/97Y. In this plasmid Thr15 
and Val17 codons were mutated to tryptophan codons, generating pET28a-
ArsD109T15W and pET28a-ArsD109V17W, respectively. The codon for Cys12, Cys13 and 
Cys18 was individually mutated to glycine codons in pET28a-ArsD109, generating 
pET28a-ArsD109C12G, pET28a-ArsD109C13G and pET28a-ArsD109C18G, respectively. 
The codons for Cys12, Cys13 and Cys18 were mutated to glycine codons in pET28a-
ArsD109T15W, generating pET28a-ArsD109C12G,T15W, pET28a-ArsD109C13G,T15W and 
pET28a-ArsD109C18G,T15W. Growth in liquid culture was estimated from the absorbance 
at 600 nm. The strains and plasmids are listed in Table 2-1. 
2.2.2 DNA manipulation and mutagenesis 
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Plasmid extraction, DNA restriction endonuclease analysis, ligation and other 
general molecular biological procedures were performed as described (Sambrook et al., 
1989).  Transformation of E. coli cells was carried out using a BIO-RAD MicroPluser 
(BIO-RAD, Hercules, CA). DNA purification kits were obtained from QIAGEN (Valencia, 
CA).  Either a Qiaprep Spin Miniprep kit or a Qiaquick gel extraction kit (QIAGEN) was 
used to prepare plasmid DNA for restriction enzyme digestion, sequencing, and 
recovering DNA fragments from agarose gels. The sequence of new plasmid constructs 
was confirmed by DNA sequencing of the entire gene. Site-directed mutagenesis was 
performed using Quick-change Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA) 
and confirmed by sequencing.  DNA sequencing was performed using a CEQ2000 DNA 
sequencer (Beckman Coulter, Brea, CA).  The primers used are listed in Table 2-2. 
2.2.3 Protein expression and purification 
Cells bearing the indicated plasmids were grown in LB medium overnight at 37°C 
and then diluted 50-fold into 1 L of the same medium. Proteins were expressed by 
induction with 0.3 mM isopropyl-ß-D-thiogalactopyranoside at A600 of 0.6-0.8 for 3 hrs. 
MBP-ArsD109 was purified from E. coli strain BL21(DE3) bearing plasmid pMAL-
ArsD109 as described (Lin et al., 2006). Cells were harvested by centrifugation and 
washed once with a buffer containing 50 mM MOPS, pH 7.5, 0.5 M NaCl, 5 mM DTT 
and 10 mM 2-mercaptoethanol (Buffer A). The cells were suspended in 5 ml of Buffer A 
per gram of wet cells and lysed by a single passage through a French press at 20,000 
psi.  Diisopropyl fluorophosphate (DIFP) (Sigma) was added at 2.5 μl/g wet cells 
immediately following French press. Unbroken cells and membranes were removed by 
centrifugation at 150,000 x g for 1 hr at 4oC. The supernatant was loaded to 10 ml 
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amylose column (New England Biolabs, Ipswich, MA) pre-equilibrated with Buffer A.  
Unbound proteins were washed by 200 ml of buffer A, and MBP-ArsD109 was eluted 
with Buffer B (50 mM MOPS, pH 7.5, 0.5 M NaCl, 5 mM DTT, 10mM maltose and 10 
mM 2-mercaptoethanol), followed by addition of 0.25 mM EDTA and 5 mM DTT to each 
fraction. MBP-ArsD109 containing fractions were identified by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE), pooled, concentrated by Amicon 
Ultra-15 Centrifugal Filter Unit with Ultracel-10 membrane (Millipore), mixed with 10% 
glycerol, aliquoted and stored at -80oC until used. ArsA with a six histidine tag at the C-
terminus was purified from cells of strain BL21(DE3) expressing pAlter-1-dAhB plasmid, 
as described (Zhou and Rosen, 1997). Basically similar procedure was used as 
purification of MBP-ArsD109, but with different buffer and column. Probond Ni-column 
(Invitrogen) was used. Buffer A(50 mM MOPS, pH 7.5, 0.5 M NaCl, 30 mM Imidazole  
and 10 mM 2-mercaptoethanol) and Buffer B(50 mM MOPS, pH 7.5, 0.5 M NaCl, 300 
mM Imidazole  and 10 mM 2-mercaptoethanol) were used. ArsD and its derivatives with 
a six histidine tag at the N-terminus were purified similarly. Purified proteins were stored 
at -80°C until use, and their concentrations were determined according to the method of 
Bradford (Bradford, 1976) or from the absorption at 280 nm (Gill and von Hippel, 1989). 
2.2.4 Circular dichroism measurements 
Circular dichroism (CD) spectra from 190 to 260 nm were acquired with a 
spectrometer from Olis Inc. (Bogart, GA) at 20 °C using a 0.2-cm path-length cell at 
1.75-nm intervals. Three scans were averaged for each spectrum. ArsDs were assayed 
at 10 μM in 10 mM potassium phosphate buffer, pH 7.5. 
2.2.5 X-ray absorption spectroscopy (XAS) 
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XAS samples were prepared in 50 mM MOPS, 0.5 M NaCl and 30% glycerol, pH 
7.5. For wild-type ArsD109, 4 mM protein was incubated with 3.2 mM sodium arsenite 
for 1 hr on ice, and unbound As(III) was removed with a Bio-Gel P-6 column. For C12G, 
C13G and C18G, 4mM protein was incubated with 1 mM As(III) for 1hr.  A higher 
protein:ligand ratio was used since unbound As(III) was not removed by gel filtration 
due to weak binding by the mutant proteins. Solution samples were loaded in Lucite 
cells, wrapped in Kapton tape and flash frozen in liquid nitrogen.  
XAS data were collected at the Stanford Synchrotron Radiation Laboratory 
(SSRL) on beamline 9-3, equipped with Si[220] double crystal monochromator equipped 
with a harmonic rejection mirror.  Samples were maintained at 10 K using Oxford 
Instruments continuous-flow liquid helium cryostats. Protein fluorescence excitation 
spectra were collected using a 30-element Ge solid-state array detector.  A germanium 
filter (0.6 mM in width) and solar slits were placed between the cryostat and detector to 
filter scattering fluorescence not associated with protein bound arsenic signals. XAS 
spectra were acquired in 5 eV steps in the pre-edge region (11,625-11,825 eV), 0.25 eV 
steps in the edge region (11,850-11,900 eV) and 0.05 Å-1 increments in the extended x-
ray absorption fine structure (EXAFS) region out to a k range of 13 Å-1.  The data were 
integrated from 2 to 20 s in a k-weighted manner in the EXAFS region for a total scan 
length of 45 min. X-ray energies were calibrated using an arsenic foil absorption 
spectrum collected simultaneously with the protein data. The first inflection point for the 
arsenic foil edge was assigned to 11,867 eV.  Each fluorescence channel of each scan 
was examined for spectral anomalies prior to averaging and spectra were closely 
monitored for photodegradation.  The data represent an average of 6 to 7 scans. 
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XAS data were processed using the Macintosh OS X version of the EXAFSPAK 
software suite (available on the World Wide Web) integrated with the Feff v7 software 
(Ankudinov and Rehr, 1997) for theoretical model generation.  Data reduction followed a 
previously published protocol for a spectral resolution in bond lengths of 0.13 Å 
(Lieberman et al., 2006).  EXAFS fitting analysis was performed on raw/unfiltered data. 
Protein EXAFS data were fit using single scattering Feff v7 theoretical models, 
calculated for carbon, oxygen, sulfur and copper coordination to simulate arsenic-ligand 
environments, with values for the scale factors (Sc) and E0 calibrated by fitting 
crystallographically characterized arsenic model compounds.  Criteria for judging the 
best-fit EXAFS simulations utilized both the lowest mean square deviation between data 
and fit, corrected for the number of degrees of freedom (F’), and reasonable Debye-
Waller factors (σ2 < 0.006 Å2). 
2.2.6 Fluorescence measurements 
Fluorescence measurements were conducted with a QuantaMaster™ UV VIS 
QM-4 Steady State Spectrofluorometer (Photon Technology International, Birmingham, 
NJ) at room temperature.  For time based measurements, the excitation wavelength 
was 295 nm, and the emission wavelength was 345 nm.  Emission scans were acquired 
between 310 and 390 nm.  As(III) or Sb(III) was added as sodium arsenite or potassium 
antimonyl tartrate, respectively, at the indicated concentrations to a cuvette containing 2 
ml of 1 μM ArsD in a buffer consisting of 50 mM MOPS-KOH, pH 7.5, 0.25 mM EDTA. 
GSH was added to the indicated concentrations. Additions were made from 
concentrated solutions, and fluorescence was corrected for dilution. To examine the 
effect of pH, buffers containing 50 mM sodium acetate, pH 4.0, 50 mM sodium acetate, 
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pH 5.0, 50 mM MES, pH 6.0, 50 mM MOPS, pH 7.0, 50 mM Tris, pH 8.0 or 50 mM 
CHES, pH 9.0, were used. 
2.2.7 ATPase activity assays 
ATPase activity was estimated using a couple assay (Vogel and Steinhart, 1976), 
as described (Hsu and Rosen, 1989). ArsA was added at a final concentration of 0.3 μM 
into an assay mixture containing 5 mM ATP, 1.25 mM phosphoenolpyruvate, 0.25 mM 
NADH, 10 units of pyruvate kinase and lactate dehydrogenase with or without the 
indicated concentrations of potassium antimonyl tartrate or sodium arsenite, in the 
buffer containing 50 mM MOPS-KOH, pH 7.5, 0.25 mM EDTA. ArsD was added at the 
indicated concentrations. The mixture was pre-warmed to 37°C, and the reaction was 
initiated by addition of 2.5 mM MgCl2 and measured at 340 nm. The linear steady state 
rate of ATP hydrolysis was used to calculate specific activity. The reaction volume was 
0.2 ml each in 96-well microplates, and the reactions were monitored by microplate 
reader SPECTRA max 340PC (Molecular Devices). GSH or DMSA was added as 
indicated. 
2.2.8 Metalloid transfer assays  
Transfer assays were performed as described (Lin et al., 2007b) except that 
purified MBP-ArsD109 was used in place of cytosol fractions containing MBP-ArsD109. 
A 0.5 ml amylose column pre-equilibrated with 4 ml of buffer consisting of  50 mM 
MOPS-KOH, 0.5 mM NaCl, pH 7.5 (column buffer) was used.  Purified MBP-ArsD109 
was dialyzed against column buffer supplemented with 5 mM β-mercaptoethanol and 
0.5 mM dithiolthreitol and loaded to the column, which was then washed with 1 ml of 
column buffer. Next 0.5 ml of 1 mM sodium arsenite was added to the column, which 
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was then washed with 4 ml of column buffer.  BSA or purified ArsA (0.5 ml of 20 μM of 
either protein) was applied to the columns with 5 mM MgATP, MgADP or MgATPγS, as 
indicated.  The column was eluted with 1 ml of column buffer supplemented with the 
appropriate nucleotide and then 2 ml of column buffer. Finally the column was eluted 
with 1.5 ml of 10 mM maltose. Ten fractions of 0.5 ml were collected and analyzed by 
sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis (PAGE) (Laemmli, 
1970). For assays conducted at 4ºC, everything was pre-cooled to 4ºC for 30 min.  The 
protein concentration of each fraction was determined according to the method of 
Bradford (Bradford, 1976). The arsenic concentration was quantified by inductively 
coupled plasma mass spectroscopy (ICP-MS).  
2.3 Results 
2.3.1 Cys12, Cys13 and Cys18 form a three-coordinate As(III) binding site in 
ArsD  
R773 ArsD has three cysteine pairs, Cys12-Cys13, Cys112-Cys113 and Cys119-
Cys120, plus an additional cysteine at residue 18.  However, only cysteine residues 12, 
13 and 18 are conserved in known homologues, and truncation of the last two vicinal 
pairs had no effect on ArsD chaperone activity, and this variant, with a N-terminal six-
histidine tag was used as the wild type ArsD109 for further analysis (Lin et al., 2007a). 
(It should be pointed out that six-histidine tags do not bind As(III) (Qin et al., 2007)).  
The nature of the binding site was investigated in structural detail using XAS using wild 
type and mutant ArsD109s lacking individual cysteine residues (C12G, C13G and 
C18G). XANES analysis indicated arsenic in both the wild type and mutant proteins is 
As(III) (Figure 2-1). The observed value for the first inflection point energy is 11868 eV, 
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consistent with observed values for As(III) in protein and model systems (Ramirez-Solis 
et al., 2004). XANES spectra for wild type ArsD109 are unique from those observed for 
the three mutant proteins, indicating the distinctive structural environment that 
coordinates As(III) in the wild type sample is different from that seen in the mutant 
samples. On the other hand, the structural environment of each mutant sample is 
closely related to the other mutant samples. 
The EXAFS fitting results are most consistent with trivalent arsenic being 
maintained in a 3-coordinate all-sulfur structural environment in wild type ArsD109 
(Figure 2-2). This environment is different in the mutants. The structural environment for 
the wild type protein is dominated by a symmetric three sulfur coordination environment 
to the As(III) at an average bond length of 2.24 Å. Addition of a small oxygen/nitrogen 
scattering contribution to the As-S3 fits for the wild type suggests a possible low 
percentage partial dissociation of the bound metalloid (Table 2-3). There was no sulfur 
ligation in any of the three cysteine mutants. EXAFS analysis of C18G suggests an 
average nearest neighbor coordination environment constructed of three As-O 
interactions at 1.79 Å.  In the remaining two mutants, the data are best fit with two 
independent As-O/N environments constructed of two oxygen ligands at 1.79 Å and a 
third oxygen/nitrogen ligand interaction between 2.13 and 2.16 Å. The most likely 
explanation for these results is that As(III) is bound to the thiolates of Cys12, Cys13 and 
Cys18 in the wild type, but that, in the mutants, binding to the two remaining cysteines is 
weak, and most of the arsenic is present as As(OH)3 . 
2.3.2 Tryptophan fluorescence reports trivalent metalloid binding by ArsD 
Previous assays to quantify arsenic binding by wild type and mutant ArsDs used 
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ICP-MS (Lin et al., 2006; Lin et al., 2007a). To develop a real-time assay for arsenic 
binding, single tryptophan derivatives of ArsD109 were constructed. ArsD has two 
native tryptophan residues, Trp35 and Trp97. Trp35 does not respond to As(III), but the 
fluorescence of Trp97 is quenched when As(III) binds to the vicinal pair, Cys112-
Cys113 but not to the Cys12-Cys13-Cys18 As(III) binding site (Li et al., 2001; Li et al., 
2002).  A tryptophan-free derivative lacking the last two vicinal cysteine pairs was 
constructed (W35/97Y).  Two derivatives with single tryptophan residues near the As(III) 
binding site were then constructed by changing Thr15 or Val17 to tryptophan. 
Introduction of either tryptophan residue had no apparent effect on ArsD structure or 
function. The overall secondary structure of these two mutants, T15W and V17W, were 
similar to wild-type ArsD109, as determined by circular dichroism (Figure 2-3A), and 
both stimulated ArsA ATPase activity nearly as well as wild-type ArsD109 (Figure 2-3B; 
data not shown for V17W).  Tryptophan-free W35/97Y showed very low background 
fluorescence (Figure 2-4A). Both single tryptophan derivatives exhibited considerable 
intrinsic protein fluorescence compared with W35/97Y, with emission maxima of 
approximately 340 nm compared with an emission maximum of approximately 355 nm 
for free tryptophan in solution.  Denaturation of the proteins with guanidine red shifted 
the emission maxima to approximately 352 nm.  The fluorescence of either T15W or 
V17W was quenched approximately 50% by addition of high concentrations of As(III) or 
Sb(III) (Figure 2-4B). 
 In the absence of added thiols, the rate of fluorescence quenching, presumably 
proportional to the rate of As(III) binding, was very slow, requiring more than 0.5 hr to 
attain a steady-state level of fluorescence when 1 μM protein was mixed with 5 μM 
  
44
As(III) (Figure 2-5A). From the As(III) concentration dependence of fluorescence 
quenching, apparent binding constants for the two single tryptophan proteins could be 
calculated from the relationship kobs = koff + kon*[As(III)] (Tamerler et al., 2006), where 
kobs is the rate of quenching fitted with SigmaPlot 9.0 (Figure 2-5B).  For V17W, koff was 
calculated as (4 ± 2) x 10-4 s-1, and kon was calculated as (2 ± 0.06) x 10-4 s-1.μM-1. From 
the ratio koff/kon = kd, a binding affinity of 2 ± 1 μM was calculated. For T15W, koff was 
estimated as (3 ± 1) x 10-4 s-1, and kon as (2 ± 0.05) x 10-4 s-1.μM-1, and kd = 1.5 ± 0.5 
μM. Thus, the values for the two single tryptophan derivatives are in agreement. 
2.3.3 Effect of cysteine substitutions on As(III) binding 
Substitutions of the three cysteines in ArsD were previously result in loss of 
Sb(III) binding ability by gel filtration assays (Lin et al., 2007a).  As noted above, no 
sulfur ligation was observed with any of the three cysteines mutants in the EXAFS 
experiments. However, neither EXAFS nor binding assays by gel filtration are as 
sensitive as fluorescence assays and cannot measure low affinity binding. As(III) 
binding parameters were estimated from quenching of T15W fluorescence of each 
cysteine mutant (Figure 2-5B). C18G/T15W, which retains the Cys12 and Cys13 vicinal 
pair, has kon = (5 ± 0.1) x 10-5 s-1.μM-1, koff = (1.4 ± 0.1) x 10-3 s-1 and kd = 28 ± 3 μM. 
C12G/T15W, which retains Cys13 and Cys18, has kon = (5 ± 0.1) x 10-5 s-1.μM-1, koff = 
(2.4 ± 0.1) x 10-3 s-1 and kd = 48 ± 3 μM. C13G/T15W, which retains Cys12 and Cys18, 
has kon = (4 ± 0.2) x 10-5 s-1.μM-1, koff = (2.7 ± 0.1) x 10-3 s-1 and kd = 68 ± 6 μM. Thus, 
the affinity of each of the three cysteine mutants decreased by 20-fold or more 
compared with the parental protein containing Cys12, Cys13 and Cys18. 
2.3.4 Reduced glutathione increases the rate of binding of As(III) to ArsD but not 
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ArsA In vivo  
As(III) is nearly completely complexed with GSH (Delnomdedieu et al., 1994a). 
As GSH is the major intracellular thiol in E. coli, cytosolic As(III) would be expected to 
be primarily in the form of As(GS)3 (Apontoweil and Berends, 1975).  For that reason, 
the effect of 5 mM GSH on the rate of binding of 50 μM sodium arsenite to 1 μM V17W 
was examined over a pH range of 4.0 to 9.0 (Figure 2-6).  The rate of fluorescence 
quenching increased with increasing pH with or without GSH. In the absence of GSH, 
the rate of fluorescence quenching was about 10-fold faster at pH 9 than at pH 7. 
Addition of GSH accelerated the rate by 10-fold at pH 7.5, and the rate was too fast to 
measure accurately at pH 8 or higher.  The pH dependence in the absence of GSH 
indicates binding of As(III) by thiolates of the three ArsD cysteines but could also reflect 
dissociation of As(OH)3 to As(OH)2-1 (pKa of 9.23).  Acceleration by GSH is consistent 
with binding of As(III) by thiolates of GS-1 (pKa of 8.7), which is highly pH dependent 
(Yehiayan et al., 2009), consistent with intermolecular transfer of metalloid from As(GS)3 
to ArsD. 
 The effect of GSH was investigated in more detail. In the absence of GSH, 
fluorescence of V17W decreased very slowly when 50 μM sodium arsenite was added 
at pH 7.5 (Figure 2-7A).  Addition of 0.2 mM GSH had little effect, but 5 mM GSH 
increased the rate substantially.  Addition of 5 mM of either β-mercaptoethanol or L-
cysteine also increased the rate of quenching with As(III) (Figure 2-7B).  While ArsD 
might be able to accept As(III) from complexes with other monothiols, but only GSH is 
present intracellularly in concentrations high enough to be involved physiologically. In 
contrast, 2.5 μM potassium antimonyl tartrate rapidly quenched fluorescence in the 
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absence of added monothiols (Figure 2-7B), consistent with the fact that ArsD has 
higher affinity for Sb(III) than As(III) (Li et al., 2002). Addition of 5 mM tris(2-
carboxyethyl)phosphine (TCEP), which is a stronger reductant than GSH but is not a 
monothiol, did not increase the rate of quenching (Figure 2-7A), indicating that the effect 
of GSH is not simply to protect either ArsD or As(III) from oxidation. Since formation of 
As(GS)3 is slow at pH 7.5 (Yehiayan et al., 2009), 4 mM sodium arsenite was pre-
incubated with 16 mM GSH for 10 min to allow for formation of the complex.  When 
preformed As(GS)3 was added at 50 μM, the rate of quenching was too fast to quantify 
(Figure 2-7A), supporting our hypothesis that As(GS)3 is a direct donor of metalloid to 
ArsD. 
 To examine whether GSH also facilitates As(III) binding to ArsA, the stimulation 
of ArsA activity by As(III) was determined in the presence or absence of GSH (Figure 2-
8). ArsA exhibited an apparently affinity of around 0.6 mM for As(III) with or without 
GSH. These results indicate that ArsA accepts either free As(III) or from As(GS)3 with 
low affinity, but As(GS)3 does not replace ArsD as an intracellular metallochaperone for 
high affinity As(III) binding. 
To see the effect of glutathione on the cooperation of ArsD and ArsA, the change 
of apparent affinity of ArsA for As(III) by ArsD was determined in the absence and 
presence of 5 mM glutathione. 3 μM ArsD increases apparent affinity of ArsA to about 
34 μM in the absence of glutathione and 5 μM in the presence of glutathione (Figure 2-
9A). To study in more detail, the change of apparent affinity of ArsA for As(III) by 
different concentrations of ArsD was determined. 0.3 μM ArsA was used in the assay. In 
the absence of glutathione, when ArsD concentration was increased from 0.3 μM to 3 
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μM, the apparent affinity was increased from 0.6 mM to a plateau of 30 μM.  In the 
presence of 5mM glutathione, when ArsD concentration was increased from 0.3μM to 
3μM, the apparent affinity was increased from 0.6 mM to a plateau of 5 μM, six fold less 
comparing in the absence of glutathione (Figure 2-9B). From another aspect, in the 
presence of glutathione, less ArsD is required to stimulate ArsA ATPase activity to the 
same extent. To exclude the possibility that the effect of glutathione is due to prevention 
of ArsA and ArsD from oxidation, 5mM TCEP was added in the buffer and it show 
almost no effect on the cooperation of ArsA and ArsD (Figure 2-9B). These results 
suggests that glutathione increases the binding rate of As(III) to ArsD, therefore 
increasing the transferring rate of As(III) from ArsD to ArsA and stimulating ArsA 
ATPase activity at low concentration of As(III) when As(III) binding is the rate-limiting 
step in ArsA ATP hydrolysis cycle. 
2.3.5 ArsD transfers As(III) directly to ArsA  
From the results of yeast two-hybrid analysis, it is clear that ArsD and ArsA 
physically interact (Lin et al., 2006). How is As(III) transferred during this interaction?  
One possibility is that the metalloid dissociates from ArsD and re-associates with ArsA. 
A second possibility is that there is direct transfer from the thiols of ArsD to the thiols of 
ArsA in a step-wise fashion (Lin et al., 2007a), similar to the mechanism of copper 
transfer from the yeast Atx1p chaperone to the Ccc2p copper efflux pump (Pufahl et al., 
1997).   
Metabolic trapping is often applied to examine for channeling (Anderson, 1999; 
Kwok et al., 2006). To differentiate between channeling and a dissociation/re-
association mechanism, the As(III) chelator DMSA was added to the reaction. DMSA 
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has an apparent affinity of approximately 20 μM for As(III) (Spuches et al., 2005), which 
is between the ArsD and ArsA affinities.  Direct transfer of As(III) from ArsD to ArsA 
would be expected to be insensitive to DMSA.  In contrast, if As(III) dissociates from 
ArsD before binding to ArsA, an excess of DMSA should prevent transfer. Using the 
stimulation of ArsA ATPase by the ArsD-As(III) complex, the effect of DMSA was 
examined (Figure 2-10).  DMSA did not affect the basal activity of ArsA, but the As(III)-
stimulated rate of ArsA activity was inhibited by DMSA.  In that experiment ArsA + As(III) 
was titrated with DMSA, and the stimulated ATPase activity returned to basal level at 
higher concentrations of DMSA.  When ArsD was preincubated with As(III) and then 
added to ArsA, the rate of ATP hydrolysis was stimulated, reflecting the chaperone 
activity of ArsD.  Titration of that mixture with DMSA resulted in an initial decrease in 
activity as free As(III) was chelated, but the activity plateaued at a level corresponding 
to the activated rate.  Since ArsD has higher affinity for As(III) than DMSA, it is able to 
retain and transfer metalloid even at higher concentrations of DMSA.  These results are 
consistent with direct transfer of As(III) from ArsD to ArsA.   
2.3.6 Transfer of As(III) from ArsD to ArsA requires catalysis  
We have previously shown that ArsD transfers Sb(III) to ArsA in the presence of 
MgATP (Lin et al., 2007a).  Here transfer of As(III) from ArsD to ArsA was compared 
under catalytic and noncatalytic conditions. Purified MBP-ArsD109 was bound to an 
amylose column. Sufficient As(III) was added to the column to saturate ArsD, following 
which free As(III) was washed off.  Next either ArsA or BSA pre-incubated with 
nucleotides was passed through the column.  When ArsA pre-incubated with MgATP 
was passed through the column at room temperature, conditions under which ArsA 
  
49
hydrolyzes ATP, nearly all of the As(III) eluted in the ArsA-containing fractions, with 
almost none in the MBP-ArsD109-containing fractions (Figure 2-11A and B). In contrast, 
when BSA preincubated with MgATP was passed through the column, almost none of 
the As(III) eluted in the BSA-containing fractions, but eluted in the MBP-ArsD109-
containing fractions (Figure 2-11C).  
When MgADP was used instead of MgATP, As(III) eluted with MBP-ArsD109 and 
not with ArsA (Figure 2-11D).  Similarly, the MgATP-γ-S, a nonhydrolyzable nucleotide, 
did not promote transfer (Figure 2-11E).  When the reaction with MgATP and column 
elution were at 40 C, where ArsA hydrolyzes ATP very slowly, almost no As(III) eluted 
with ArsA but remained bound to MBP-ArsD109 (Figure 2-11F). These data 
demonstrate that ATP hydrolysis is required for As(III) transfer from ArsD to ArsA. 
2.4 Discussion 
 In vivo results quite clearly demonstrate that ArsD is an As(III)/Sb(III) chaperone 
that transfers metalloid to the ArsA ATPase (Lin et al., 2006; Lin et al., 2007a), but the 
molecular details of the process are lacking.  In this study the questions of the nature of 
the metalloid binding site in ArsD and requirements for the transfer reaction were 
addressed. 
From genetic analysis and conservation of residues in homologues, it seemed 
likely that the metalloid binding site in ArsD involved the three conserved cysteines, 
residues 12, 13 and 18.  Here the EXAFS data with wild type ArsD unambiguously 
demonstrate that the binding site is a three-coordinate sulfur-containing site, similar in 
nature but not sequence to the ArsA As(III) binding site (Bhattacharjee et al., 1995) and 
the three convergently evolved sites of three different ArsR repressors (Ordóñez et al., 
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2008; Qin et al., 2007; Shi et al., 1996).  This suggests that a common type of As(III) 
binding site in proteins is composed of three cysteine residues, with similar As-S bond 
distances of 2.24 Å and probably similar geometries.   
 While EXAFS is useful for determining the environment surrounding the bound 
metalloid, a more complete analysis requires quantitative measurements of As(III) 
binding.  Previous assays using gel filtration yield stoichiometries, but it is difficult to 
extract more detailed information from analysis conducted after the reaction is complete.  
Changes in intrinsic protein fluorescence can provide real-time information about ligand 
binding or catalysis.  Full length ArsD has three vicinal cysteines pairs, Cys12-Cys13, 
Cys112-Cys113 and Cys119-Cys120, and two tryptophan residues, Trp35 and Trp97.  
Trp97 fluorescence reports binding of Sb(III) or As(III) to the vicinal Cys112-Cys113 pair 
(Li et al., 2001; Li et al., 2002).  However, only the N-terminal Cys12-Cys13 pair is 
involved in chaperone activity; the C-terminal pairs are dispensable and not present in 
the constructs used for this study. For that reason, the two endogenous tryptophan 
residues were altered by site-directed mutagenesis, and new tryptophan residues 
introduced singly at positions 15 and 17, near the Cys12-Cys13-Cys18 As(III) binding 
site. Fluorescence of either single tryptophan derivative was blue-shifted approximately 
14 nm compared with free tryptophan. The fluorescence was red-shifted and decreased 
by denaturation with guanidine. These results indicate that the two tryptophan residues 
are in a less aqueous environment compared with free tryptophan.  These two 
tryptophans are located between the three cysteines that form the As(III) binding site.  
Both single tryptophan derivates of ArsD exhibited substantial quenching of protein 
fluorescence upon addition of either As(III) or Sb(III), consistent with the region of ArsD 
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containing the metalloid binding site undergoing a conformational change when the site 
is filled. 
 However, the rate of quenching with As(III) was slower than might be expected 
for a simple binding reaction.  If in vivo binding to ArsD was slower than the transfer to 
ArsA, then free arsenite might accumulate in the cytosol, negating the value of a 
chaperone.  As(III) likely forms a As(GS)3 complex with cytosolic GSH, the major 
reduced thiol in E. coli, where it can accumulate to concentrations as high as 10 mM 
(Apontoweil and Berends, 1975; Fahey and Sundquist, 1991). However, ArsA accepts 
metalloid from As(GS)3 no faster than it binds free As(III), so, even though GSH might 
serve as an As(III) buffer, it does not aid in detoxification via the ArsAB pump.  In 
contrast, ArsD accepts metalloid from As(GS)3 faster than can be determined with our 
instrumentation. These considerations lead us to propose that the physiological donor to 
ArsD is As(GS)3 (Figure 2-12).  As arsenite enters E. coli cells via the aquaglyceroporin 
GlpF as As(OH)3, the high concentration of GSH would by mass action rapidly drive 
exchange of hydroxyls for thiols. 
 The next series of steps is proposed to involve the step-wise transfer of As(III) 
from ArsD thiolates to ArsA thiolates.  The lack of effect of the As(III) chelator DMSA on 
the transfer reaction indicates that transfer is direct channeling from one protein to the 
other, rather than dissociation from ArsD and re-association with ArsA. The transfer 
reaction itself apparently requires ArsA to be undergoing catalysis. As(III) is not 
transferred from ArsD to ArsA in the presence of MgADP or MgATP-γ-S, but only in the 
presence of MgATP, and then only at a temperature at which hydrolysis occurs.  During 
the catalytic cycle ArsA undergoes a series of conformational changes in which the A1 
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and A2 halves are open relative to each other to a tightly closed conformation in which 
the product MgADP is trapped (Zhou et al., 2000, 2001).  In our model, ArsD would 
interact with one of the transitional conformations, with transfer of As(III) integral to 
formation of the closed conformation.  Further details of the transfer reaction will require 
structural information about ArsD and the ArsD-ArsA complex. 
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CHAPTER 3   
Correlation between ArsD dimerization and metallochaperone function 
3.1 Introduction 
 In vivo results demonstrate that ArsD is an As(III)/Sb(III) chaperone that transfers 
metalloid to the ArsA ATPase (Lin et al., 2006). ArsD and ArsA interact with each other 
by yeast two-hybrid analysis. ArsD transfers As(III) to ArsA in the presence of Mg2+ and 
ATP. Channeling of arsenic from ArsD to ArsA protected As(III) from chelation by the 
chelator dimercaptosuccinic acid (DMSA). ArsA (Zhou et al., 2000) and ArsD (Ye et al., 
2010). Structures have been solved by crystallization. But the details of interaction 
between ArsD and ArsA are still unknown. Non-tagged wild-type ArsD has been shown 
to be a homodimer by Sephacryl S-200 chromatography (Chen and Rosen, 1997). ArsD 
is also a dimer in the crystal structure. In this section, the question, whether ArsD 
dimerization is required for its function is studied. 
 The residues in dimerization interface observed in the ArsD crystal structure 
were mutated by site-directed mutagenesis. The dimerization status of the mutants was 
analyzed by gel-filtration chromatography. The activity of the mutants was also 
examined. 
 In addition, we did random mutagenesis of the arsD gene by error-prone PCR 
induced with Mn2+ (Cadwell and Joyce, 1992). Then ArsD mutants that lose interaction 
with wild-type ArsD was selected by reverse yeast two-hybrid analysis. The yeast two-
hybrid system is a genetic system engineered to study protein-protein interactions 
(Fields and Song, 1989). Yeast two-hybrid analysis takes advantage of the properties of 
yeast transcriptional factor such as GAL4. GAL4 is a transcriptional activator required 
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for expression of genes encoding enzymes for utilizing galactose. It consists of two 
separate and essential domains. One is the N-terminal DNA binding domain (BD). The 
other is the C-terminal activation domain (AD). The BD binds to a small DNA element 
(UAS, upstream activation sequence), usually in the promoter region of the activated 
genes. The AD recruits the transcriptase to initiate transcription. By expressing a bait 
protein fused with BD and prey protein fused with AD separately from different 
plasmids, a functional GAL4 transcriptional activator can be reconstituted through their 
interaction. A reporter gene was engineered in the yeast chromosome as a marker for 
selection. When the two proteins interact, the reporter gene will be expressed. Usually 
the yeast two-hybrid system uses a nutritional synthetic gene such as his3, a histidine 
synthesis gene, as reporter gene. So only when two proteins interact with each other 
can the yeast cells grow on medium lacking histidine. New systems are also 
constructed using a toxic gene such as ura3 as a reporter gene. ura3 encodes orotidine 
5-phosphate decarboxylase. It can metabolize 5-FOA (5-fluoroorotic acid) to 5-
fluorouridine, an analog of uridine, inhibiting cell growth. Therefore it can be used to 
select for the mutants with weaker interaction or no interaction by growing the yeast 
cells on the plate with 5-FOA.  
3.2 Materials and Methods 
3.2.1 Strains, plasmids and media 
E. coli cells were grown in Luria-Bertani (LB) medium (Sambrook et al., 1989) at 
37°C.  Ampicillin (100 µg/ml) or kanamycin (40 µg/ml) was added as required. E. coli 
strain JM109 [recA1 supE44 endA1 hsdR17 gyrA96 relA1 thiΔ(lac-proAB) F’ (traD36 
proAB+ lacIq lacZΔM15)] was used for molecular cloning. E. coli strain BL21(DE3) [F- 
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ompT hsdSB (rB-mB-) gal dcm (DE3 [lacI lacUV5-T7 gene1 ind1 Sam7 nin5]) was used 
for protein expression and purification. ArsA with a C-terminal 6-histidine tag was 
expressed from plasmid pAlter-dAhB (Li and Rosen, 2000). N-terminal MBP-fused 
ArsD1-109 (henceforth designated MBP-ArsD109) was expressed from plasmid pMAL-
ArsD109 (Lin et al., 2007a). ArsD1-109 with an N-terminal six-histidine tag (henceforth 
designated as wild type His6-ArsD109) was expressed from plasmid pET28a-ArsD109. 
Site-directed mutagenesis was done on plasmid pET28a-ArsD109 to get the mutant 
ArsD109S68A/R87A/R96A. Plasmid pGBT9 and pACT2 were used as S. cerevisiae/E. coli 
shuttle vectors for yeast two-hybrid assay (Lin et al., 2007b).  S. cerevisiae strain 
AH109 (MATa, trp1-901, leu2-3, 112, ura3-52, his3-200, gal4∆, gal80∆, 
LYS2::GAL1UAS-GAL1TATA-HIS3, GAL2UAS-GAL2TATA-ADE2,URA3::MEL1UAS-MEL1TATA-
lacZ) (Clontech, Mountain View, CA) and MAV203 (MATα; leu2-3,112; trp1-901; 
his3Δ200; ade2-101; cyh2R; can1R; gal4Δ; gal80Δ; GAL1::lacZ; 
HIS3UASGAL1::HIS3@LYS2; SPAL10::URA)  (Invitrogen, Carlsbad, CA) were used for 
yeast two-hybrid assay. Yeast cells were grown in complete yeast extract-peptone-
dextrose (YPD) or minimal synthetic dextrose (SD) media with the appropriate 
supplements at 30°C (Adams et al., 1998). Growth in liquid culture was estimated from 
the absorbance at 600 nm. The strains and plasmids are listed in Table 3-1. 
3.2.2 DNA manipulation and mutagenesis 
Plasmid extraction, DNA restriction endonuclease analysis, ligation and other 
general molecular biological procedures were performed as described (Sambrook et al., 
1989).  Transformation of E. coli cells was carried out using a BIO-RAD MicroPluser 
(BIO-RAD, Hercules, CA). Transformation of Yeast cells was performed using Fast 
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Yeast Transformation™ kit from G-Biosciences (Maryland Heights, MO). DNA 
purification kits were obtained from QIAGEN (Valencia, CA).  Either a Qiaprep Spin 
Miniprep kit or a Qiaquick gel extraction kit (QIAGEN) was used to prepare plasmid 
DNA for restriction enzyme digestion, sequencing, and recovering DNA fragments from 
agarose gels. Zymoprep II™ Yeast Plasmid Miniprep (Zymo Research, Orange, CA) 
was used to extract plasmid from yeast cells. The sequence of new plasmid constructs 
was confirmed by DNA sequencing of the entire gene. Site-directed mutagenesis was 
performed using Quick-change Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA) 
and confirmed by sequencing.  DNA sequencing was performed using a CEQ2000 DNA 
sequencer (Beckman Coulter, Brea, CA).  The primers used are listed in Table 3-2. 
3.2.3 Protein expression and purification 
Cells bearing the indicated plasmids were grown in LB medium overnight at 37°C 
and then diluted 50-fold into 1 L of the same medium. Proteins were expressed by 
induction with 0.3 mM isopropyl-ß-D-thiogalactopyranoside at A600 of 0.6-0.8 for 3 hrs. 
MBP-ArsD109 was purified from E. coli strain BL21(DE3) bearing plasmid pMAL-
ArsD109 as described (Lin et al., 2006). ArsA with a six histidine tag at the C-terminus 
was purified from cells of strain BL21(DE3) expressing pAlter-1-dAhB plasmid, as 
described (Zhou and Rosen, 1997). ArsD and its derivatives with a six histidine tag at 
the N-terminus were purified similarly. Purified proteins were stored at -80°C until use, 
and their concentrations were determined according to the method of Bradford 
(Bradford, 1976) or from the absorption at 280 nm (Gill and von Hippel, 1989). 
3.2.4 Gel-filtration chromatography 
A 1.5cm diameter column filled with 165ml home-packed Superdex-75 (GE 
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Healthcare) gel-filtration column was used to analyze His6-ArsD109 truncation and 
ArsD109 derivatives on a Bio-rad Biological LP chromatography system. 1.5mg 
ovalbumin, 1.5mg carbonic anhydrase and 1.5mg ribonuclease were used as internal 
standard. 2mg His6-ArsD109 or His6-ArsD109 mutants and protein standards in 1ml 
buffer were loaded onto the column pre-equilibrated with column buffer (50mM MOPS, 
200mM NaCl, 5mM 2-mercaptoethanol and 2mM DTT, pH 7.5). A 1.5cm diameter 
column filled with 165ml home-packed Sephacryl-200 (GE Healthcare) gel-filtration 
column was used to analyze MBP-ArsD109 on a Bio-rad Biological LP chromatography 
system. 1.5mg aldolase, 1.5mg conalbumin, and 1.5mg ovalbumine were used as 
internal standard. 2.4mg MBP-ArsD109 and protein standards in 1ml buffer were loaded 
onto the column pre-equilibrated with same column buffer as above. Then the column 
was washed with 200ml of column buffer. Elutions were collected as 1.5ml each 
fraction. Fractions were analyzed by 16% SDS-PAGE for His6-ArsD109 and 12% SDS-
PAGE for MBP-ArsD109. Standard proteins are from Gel Filtration LMW Calibration Kit 
and Gel Filtration HMW Calibration Kit (GE Healthcare). 
3.2.5 ATPase activity assays 
ATPase activity was estimated using a couple assay (Vogel and Steinhart, 1976), 
as described (Hsu and Rosen, 1989). ArsA was added at a final concentration of 0.3 μM 
into an assay mixture containing 5 mM ATP, 1.25 mM phosphoenolpyruvate, 0.25 mM 
NADH, 10 units of pyruvate kinase and lactate dehydrogenase with or without the 
indicated concentrations of potassium antimonyl tartrate or sodium arsenite, in the 
buffer containing 50 mM MOPS-KOH, pH 7.5, 0.25 mM EDTA. ArsD was added at the 
indicated concentrations. The mixture was pre-warmed to 37°C, and the reaction was 
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initiated by addition of 2.5 mM MgCl2 and measured at 340 nm. The linear steady state 
rate of ATP hydrolysis was used to calculate specific activity. The reaction volume was 
0.2 ml each in 96-well microplates, and the reactions were monitored by microplate 
reader SPECTRA max 340PC (Molecular Devices).  
3.2.6 Generation of a random mutated library of PCR fragments  
Random mutagenesis of ArsD was performed using ep-PCR (Cadwell and Joyce, 
1992) by employing biased nucleotide composition of the PCR buffer, high 
concentration of Mg2+ and addition of Mn2+. The ep-PCR reaction mixture (50 μl) 
contained 20 mM Tris-HCl (pH 8.4), 50 mM KCl, 7 mM MgCl2, 0.2 mM each of dATP 
and dGTP, 1 mM each of dCTP and dTTP, 25 pmol each of the oligonucleotide primers, 
80 ng of template DNA, 2.5 U of Taq DNA polymerase (Invitrogen). pGBT9-D plasmid 
DNA was used as template. Primer pGBT9-s (TAA AGA TGC CGT CAC AGA TAG ATT 
G) and pGBT9-a (ACC TGA CCT ACA GGA AAG AGT TAC T) were used as primer, 
and 0.5 mM Mn2+ was added. PCR condition was 1× 96 °C for 3 min, 30× 94 ° for 30 s, 
1×55 °C for 30 s, 1×72 °C for 100s, and, finally, 1× 72 °C for 10 min. The ep PCR 
product was analyzed by agarose gel, extracted from gel and quantified by absorption 
at 260nm.  
3.2.7  Yeast two-hybrid analysis 
Two yeast stains, AH109 (Fields and Song, 1989) and MAV203 (Vidal et al., 
1996), were used. Both are GAL4-based yeast two-hybrid system. Yeast cells are co-
transformed with ars gene-fused pGBT9-X (BD-X) and pACT2-Y (AD-Y) plasmids. 
pGBT9 was modified to pGBT9-k by inserting kanamycin resistant gene for easier 
selection of the mutants. Primers pET28a-3600-AatII (CTA TGA CGT CCA ACC CGG 
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TAA GAC ACG ACT TAT C) and pET28a-5300-AatII (CTA TGA CGT CCG CCC GCT 
CCT TTC GCT TTC TTC C) were used to amplify kanamycin resistant gene from 
pET28a by PCR. Then the PCR product was analyzed by agarose gel, extracted from 
gel and digested by AatII. pGBT9 was also digested with AatII. Then digested PCR 
fragment and vector are ligated and transformed into JM109. The cells were plated on 
the LB plate with kanamycin to select for the vector, pGBT9-k, which shows kanamycin 
resistance. For unknown reason, pGBT9-k loses ampicillin resistance.  
MAV203 was firstly used to select for ArsD mutants that lose the capability of 
dimerization with wild-type ArsD. The ep-PCR fragment was mixed with pGBT9-k vector 
linearized by EcoRI and BamHI, and co-transformed with pACT2-D into MAV203 and 
selected on the SD-L-W plate supplemented with 0.2% 5-FOA (5-Fluoroorotic Acid) 
(Fermentas, Burlington, Ontario). The PCR fragment will be ligated into the vector in 
vivo through homology recombination (Hua et al., 1997). The colonies were pooled and 
colony-PCR was done with primer pGBT-s and pGBT9-a. PCR product was purified by 
agarose gel-extraction, mixed with pGBT9-k vector linearized by EcoRI and BamHI, and 
co-transformed with pACT2-A into AH109 and selected on the SD-L-W-H plates lacking 
histidine. To determine protein-protein interaction by growth of series of dilutions, the 
transformed cells were cultured overnight in SD medium at 30°C and then washed, 
suspended and adjusted to an absorbance of 1 at A600nm in 20 mM Tris-HCl pH 7.5. 
Portions of the cell suspensions (1 μl) were inoculated in serial 10-fold dilutions on SD 
agar plates lacking histidine or with 3-AT at indicated concentration. The plates were 
incubated at 30°C for 3 days.   
3.2.8  Sequencing of ArsD mutant genes in yeast colonies  
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Each yeast colony was grown in corresponding liquid SD medium. The plasmids 
were isolated from yeast by Zymoprep II™ Yeast Plasmid Miniprep Kit (Zymo Research 
Cop. Orange, CA), transformed to E. coli JM109 and grown on LB plate with kanamycin. 
Then the plasmids were extracted from E. coli JM109 and sequenced with the GAL4-BD 
sequencing primer (GAG TAG TAA CAA AGG TCA A).  
3.3 Results  
3.3.1 Dimerization equilibria of MBP-ArsD109 and His6-ArsD109  
Non-tagged wild-type ArsD has been shown to be a homodimer by Sephacryl S-
200 chromatography (Chen and Rosen, 1997). In my studies, both N-terminal MBP 
(maltose binding protein) tagged ArsD and N-terminal six-histidine-tagged ArsD were 
used. Both MBP-ArsD109 and His6-ArsD109 could stimulate ArsA ATPase activity. 
ArsA exhibits apparent affinity for As(III) of approximately 0.5 mM. Both MBP-ArsD109 
and His6-ArsD109 increased ArsA the apparent affinity for As(III) to around 10 μM 
(Figure 3-1). However, these two different ArsD derivatives showed different 
dimerization equilibria by gel-filtration chromatography. The apparent molecule weight 
of MBP-ArsD109 monomer is 56 kDa. It elutes out between standard conalbumin (75 
kDa) and ovalbumin (43 kDa) and is more likely a monomer (Figure 3-2A). The 
molecule weight of His6-ArsD109 is predicted to be 16 kDa for a monomer and 32 kDa 
for a dimer. It elutes out before standard carbonic anhydrase (29 kDa) and so is more 
likely a dimer (Figure 3-2B). Since dimerization is concentration dependent, both MBP-
ArsD109 and His6-ArsD109 could be in equilibrium between monomer and dimer. This 
leads to the question whether ArsD interacts with ArsA as a dimer or a monomer. It is 
also possible that both dimer and monomer are able to interact with ArsA. 
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3.3.2 Mutations at the putative dimerization interface shift ArsD to a monomer 
We attempted to make monomeric ArsD by mutating residues located at the 
major dimerization interface observed in the crystal structure to test whether it is still 
active. Whether the crystallographic ArsD dimer represents the solution dimer is not 
know, but the observed dimer has an extensive interface between two subunits mainly 
contributed by the 4th β-sheet and 3rd and 4th α-helix. In the crystallographic dimer, a 
total surface area of 1,338 Å2 is buried between the two ArsD monomers. This 
represents 11.5% of the total solvent-accessible surface. The dimer is mainly held 
together by hydrogen bonds. Notably, there are at least 10 hydrogen bonds, and the 
donors from one monomer and the acceptor from the other are less than 3.2 Å apart. 
The hydrogen bond and salt bridge was shown in Figure 3-3. The amide and carbonyl 
groups of Ala85 from one monomer make hydrogen bonds to the carbonyl and amide of 
Ala85 from the other monomer, respectively. The hydroxyl of the Ser68 side chain from 
one monomer is hydrogen bonded to the carbonyl of Val83 from the other monomer. 
The carbonyl of Gly86 from one monomer makes hydrogen bonds to the side chain 
amides of Arg96 from the other monomer. The carbonyl of Gly86 from one monomer 
also makes hydrogen bonds to the side chain amides of Arg87 from the other monomer. 
Arg96 and Glu71 form salt-bridge.  
The side chains of Ser68, Arg87 and Arg96 are predicted to contribute hydrogen 
bonds and a salt bridge. A triple mutant was made by mutating these three residues to 
alanines. Eight hydrogen bonds should be eliminated if no new bonds are formed. This 
triple mutant His6-ArsD109S68A/R87A/R96A is predicted to have molecular weight of 16 kDa 
for a monomer and 32 kDa for a dimer, similar to the wild-type His6-ArsD109. In gel-
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filtration chromatography, this mutant elutes after carbonic anhydrase (29 KDa) (Figure 
3-4A) and so is most likely in an equilibrium between dimer and monomer, compared 
with wild-type His6-ArsD109, which elutes before carbonic anhydrase (Figure 3-2B). 
Thus the dimerization equilibrium of this mutant is shifted toward the monomer. This 
suggests that Ser68, Arg87 and Arg96 are involved in dimerization in the solution, and 
that the dimer interface in the crystal structure is similar to that in solution. 
We further mutated four other residues, Glu81, Thr82, Val83 and Met84 to 
alanine residues, creating His6-ArsD109S68A/R87A/R96A/E81A/T82A/V83A/M84A. These seven 
mutations totally changed the 4th β-sheet, which is predicted to be involved in 
dimerization. In gel-filtration chromatography, this mutant elutes between carbonic 
anhydrase (29 kDa) and ribonuclease (13 kDa), suggesting that it is in equilibrium 
between monomer and dimer (Figure 3-4B). However, it does not totally correspond to a 
monomer size, making interpretation difficult.  
The mutant ArsD109S68A/R87A/R96A/E81A/T82A/V83A/M84A stimulated ArsA ATPase 
activity as well as the wild type. Both of wild type His6-ArsD109 and this mutant 
increased the apparent affinity of ArsA for As(III) to around 10 μM (Figure 3-4C), 
suggesting that dimerization may be not required for the ArsD metallochaperone 
function. However, since the mutants are in monomer-dimer equilibrium, this conclusion 
is not firm. 
3.3.3 Generating an ArsD mutant with weaker dimerization 
Since we were unable to change ArsD entirely to a monomeric form by site-
directed mutagenesis, we use yeast random mutagenesis coupled with the yeast two-
hybrid system to select for ArsD mutants that show weaker dimerization. Yeast strain 
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MAV203 has ura3 reporter gene that encodes an enzyme metabolizing 5-FOA (5-
fluoroorotic acid) to 5-fluorouridine, an analog of uridine, inhibiting cell growth. Therefore 
MAV203 can be used to select for mutants with weaker interaction or no interaction as a 
result of ability to grow on plates with 5-FOA (Vidal et al., 1996). ArsD have been shown 
to dimerize by GAL4 yeast two-hybrid analysis with yeast strain AH109 (Lin et al., 
2007b). We confirmed that ArsD also dimerizes in MAV203 and determined that 
MAV203 co-transformed with pACT2-D (encoding wild type AD-ArsD) and pGBT9-D 
(encoding wild type BD-ArsD) cannot grow on SD-L-W plates with 0.2 % 5-FOA. So we 
used 0.2 % 5-FOA to select for ArsD mutants that cannot interact with wild type ArsD or 
interacts more weakly.  
 Using a pair of primers homologous to regions on pGBT9-D (encoding BD-ArsD) 
flanking the inserted arsD gene, error-prone PCR was performed on ArsD as described 
under ‘Materials and Methods’. The purified PCR product was mixed with pGBT9-k 
vector linearized by EcoRI and BamHI, and co-transformed with pACT2-D (encoding 
wild type AD-ArsD) into MAV203 and selected on SD-L-W plates with 0.2 % 5-FOA. 240 
colonies could grow on 5-FOA plates, 8% of the 3000 clones that grew on plates without 
5-FOA. Presumably these colonies might contain not only ArsD mutants interacting 
more weakly with wild type ArsD, but also truncated ArsD mutants, non folding ArsD 
mutants, or even empty pGBT9 vector. Since ArsD interacts with ArsA in yeast strain 
AH109 (Lin et al., 2007b), we further screened the mutants for their ability to still interact 
with ArsA. If they retained the ability to interact with ArsA, they should fold normally. We 
pooled the resulting 240 colonies and used the same primer, homologous to regions on 
pGBT9-D flanking the inserted arsD gene for colony PCR. Then the purified PCR 
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products were mixed with vector plasmid pGBT9-k linearized by EcoRI and BamHI. The 
mixture was co-transformed with pACT2-A (encoding AD-ArsA) into AH109, and 
colonies were selected on SD-L-W-H plates. 55 colonies grew on SD-L-W-H plates, 
0.8% compared with 6500 colonies on the SD-L-W plates. 24 colonies were picked and 
sequenced. Finally, we isolated two ArsD mutants that showed no interaction with wild 
type ArsD but retained interaction with ArsA (Figure 3-5A). These two mutants are 
ArsDL36H, I43F,G86E and ArsDG86E.  
Only the G86E mutation was found in both mutants. Gly86 sits in the dimerization 
interface (Figure 3-3C), suggesting this mutant might be a monomer. His6-ArsD109G86E 
was constructed by site-directed mutagenesis. The protein was expressed, purified and 
analyzed by gel-filtration chromatography. His6-ArsD109G86E eluted between carbonic 
anhydrase (29 KDa) and ribonuclease (13 KDa), suggesting an equilibrium between 
monomer and dimer (Figure 3-5B). Compared with wild-type His6-ArsD109, which 
elutes before carbonic anhydrase (Figure 3-2B), mutant His6-ArsD109G86E was shifted 
toward monomer, consistent with yeast two-hybrid analysis.  
The ability of mutant ArsD109G86E to stimulate ArsA ATPase activity was 
examined. His6-ArsD109G86E increased the apparent affinity of ArsA for As(III) to around 
10 μM (Figure 3-6), again suggesting dimerization may be not required for the ArsD 
metallochaperone function. 
3.4 Discussion 
In vivo results demonstrate that ArsD is an As(III)/Sb(III) chaperone that transfers 
metalloid to the ArsA ATPase (Lin et al., 2006; Lin et al., 2007a), but the molecular 
details of the process are lacking. Structural information about ArsD and the ArsD-ArsA 
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complex is needed to understand the details. ArsD has been shown to be a dimer in 
crystal structure. In this study the correlation between ArsD dimerization and 
metallochaperone function was studied.  
Non-tagged wild-type E. coli R773 ArsD has been shown to be a homodimer by 
Sephacryl S-200 chromatography (Chen and Rosen, 1997). ArsD is also a dimer in the 
crystal structure (Ye et al., 2010). ArsD constructs with either an N-terminal maltose 
binding protein (MBP) tag or an N-terminal His6 tag were used in this study. They were 
both active but behaved differently in gel-filtration chromatography. The monomer-dimer 
equilibrium of MBP-ArsD109 is toward monomer, while the equilibrium of His6-ArsD109 
is toward dimer.  These results could mean that either monomer or dimer of ArsD 
interact with ArsA, so further analysis was required. 
The crystallographic dimerization interface of ArsD involves a series of hydrogen 
bonds and one salt bridge, with the side chains of Ser68, Arg87 and Arg96 participating. 
As a consequence of mutating these residues to alanines, there was a shift in the 
equilibrium toward the monomer direction, but each mutant was still active in terms of 
metallochaperone activity. Using the yeast two-hybrid assay to select and screen 
mutants with reduced interaction with wild-type ArsD but retaining interaction with ArsA, 
the mutation G86E was found to decrease ArsD dimerization. Gly86 is located in the 
dimerization interface in the crystal structure. Gel-filtration chromatography confirmed 
that the equilibrium of His6-ArsD109G86E is shifted toward monomer direction, and this 
mutant retains ability to stimulate ArsA ATPase activity. All these results suggest that 
the dimerization region observed in the crystal structure also exists in solution, and that 
dimerization is not strictly required for ArsD metallochaperone function. 
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Recently the crystal structure of another ArsD homolog from Bacteroides 
vulgatus ATCC 8482 was deposited in the Protein Data Base (pdb: 3KTB; Kim, 
Y.,   Tesar, C.,   Feldmann, B.,   Joachimiak, A., Midwest Center for Structural 
Genomics (MCSG), unpublished). E. coli R773 ArsD is clearly a dimer (Figure 3-7A). 
However, Bacteroides vulgatus ATCC 8482 ArsD has four molecules in the 
crystallographic unit (Figure 3-7C).  In all four molecules, Cys13 and Cys18 form intra-
subunit disulfide bonds. Each two of the subunits form an inter-subunit disulfide bond 
with Cys12 from each subunit. Then two dimers form a tetramer noncovalently. 3KTB 
and R773 ArsDs can be superimposed with an RMSD of 1.0 Å (Figure 3-7B). 
 Although Bacteroides vulgatus ATCC 8482 ArsD is a tetramer in crystal 
structure, it is not known the aggregation status in the solution. But the structure 
definitely suggests different subunit contact positions. The cysteine residues position of 
Bacteroides vulgatus ATCC 8482 ArsD is very consistent with our previous result of 
cysteine crosslinking by dibromobimane that Cys12, Cys13 and Cys18 from one subunit 
are close to the cysteine residues from another subunit (Lin et al., 2007a). So it is also 
possible R773 ArsD may have more than one site of contact between subunits, one at 
the interface shown in R773 ArsD crystal structure and another one is close to the 
cysteines. This may be one reason that no mutant is totally monomeric ArsD. 
 Very recently a new ArsD mutant, P52L, which exhibits increased affinity for wild 
type ArsD was isolated using random mutagenesis and a modified yeast two-hybrid 
assay (unpublished data). In the standard assay cells of histidine-requiring yeast are 
screened for interaction between proteins by the ability to grow in the absence of 
histidine.  3-Aminotriazole (3-AT) is a HIS3 competitive inhibitor that prevents growth. 
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The two proteins fused to AD and BD should interact stronger to support the yeast cell 
growth on the plates with 3-AT. Yeast cells co-transformed with BD-ArsD P52L (mutant 
ArsD fused to BD) and AD-ArsD (wild-type ArsD fused to AD) grow in the presence of 
60 mM 3-AT (Figure 3-8). Interestingly, the yeast two-hybrid results suggest that P52L 
loses interaction with ArsA (Figure 3-8). This may indicate that there is another 
dimerization interface that involves Pro52 (Figure 3-9A and B). The crystal structure 
suggests that a hydrophobic patch may be involved in interaction between subunits in 
neighboring asymmetric units, including Leu48, Phe52, Met53, Phe55, Val56, Val61, 
Ile66 and Ala70, which may form an extensive hydrophobic interface (Figure 3-9C and 
D). Residues Leu48, Pro52, Met53 and Val56 are close to an adjacent subunit, 
contributing to this crystallographic dimerization interface. Although the side chains of 
residues Phe55, Val61 and Ile66 point inward, they are less than 5Å from corresponding 
residues in the adjacent subunit, close enough to form an intra-subunit hydrophobic 
core. They may be important for maintaining the angles between the α2 and α3 helixes 
and may contribute to dimerization as well (Figure 3-9E). This hypothesis can explain 
why mutations in the previous dimerization interface do not result in strict monomer. 
This idea will be tested by future students in the lab.   
 In addition, ultra-centrifugation will be used to analyze the aggregation status of 
ArsD in the solution and to obtain the associating constant of ArsD. In summary, it is still 
unclear whether ArsD is a monomer or dimer when it interacts with ArsA.  
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CHAPTER 4 
Mapping ArsA-ArsD interaction interface by genetic analysis 
4.1 Introduction 
 ArsD is an As(III)/Sb(III) chaperone that transfers metalloid to the ArsA ATPase 
(Lin et al., 2006). ArsD transfers As(III) to ArsA in the presence of Mg2+ and ATP. 
Correspondingly, ArsD can be crosslinked with ArsA in the presence of Mg2+ and ATP, 
by the homofunctional cysteine crosslinker dibromobimane. ArsA structure has been 
solved by crystallization (Zhou et al., 2000). Cys113, Cys172 and Cys422 are close to 
each other and involved in metal binding (Ruan et al., 2006, 2008). ArsD structure has 
been recently solved (Ye et al., 2010). Though the metal binding site is missing in the 
structure, biochemical results suggest that Cys12, Cys13 and Cys18 form a three-sulfur 
coordinated metal binding site important for transferring As(III) to ArsA (Lin et al., 
2007a). According to this, we proposed a model for the metal transfer similar as the 
model shown in Figure 2-12 (Lin et al., 2007a), that ArsA and ArsD interact at their 
metal binding sites, then As(III) is transferred through ligand-exchange between 
cysteine residues of ArsA and ArsD. Consistent with this model, As(III) is protected from 
sequestration by As(III) chelator, DMSA, during transfer from ArsD to ArsA, suggests 
that ArsA-ArsD interaction forms a channel for As(III) transferring from MBS of ArsD to 
MBS of ArsA. However, a detail of interaction between ArsD and ArsA is still unknown.  
Copper chaperone has been found from prokaryotic cells to eukaryotic cells. 
They are most well studied metallochaperone protein. The study of interaction between 
copper chaperone proteins and their targets are summarized in Table 4-1. So far, no co-
crystallization of the wild-type chaperone proteins and their targets has been successful. 
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Through gel-filtration, Cu(I)-CopZ transfer Cu(I) to CopY. But these two protein do not 
come off the gel-filtration column as a complex (Cobine et al., 1999). Similar to this, 
ArsD transfers As(III) to ArsA but they do not form stable complex. The interaction 
between HAH1, and the second or the fifth soluble domains of ATP7A (MNK2 and 
MNK5, respectively), was investigated in solution using heteronuclear NMR. No stable 
adduct is formed between either of the MNK domains and HAH1 (Banci et al., 2005). 
NMR titration shows the formation of an adduct by Cu(I)-HAH1 with WLN4 that is in fast 
exchange on the NMR time scale with the isolated protein species as confirmed by 15N 
relaxation data. A similar interaction is also observed between Cu(I)-HAH1 and WLN2; 
however, the relative amount of the adduct in the protein mixture is lower. In both cases 
the interaction interface can not be mapped by NMR (Achila et al., 2006). All these 
results suggest that the interaction between copper chaperone proteins and their targets 
is weak and transient. Maybe this is a common nature for all metallochaperone proteins 
since their roles are to escort the metal to the target proteins but not stick to their target 
proteins. Unless we can stop the transfer process, the complex will not be stable. One 
example is the complex structure of yeast copper chaperone yCCS and its partner 
protein, superoxide dismutase (SOD1). His48, one of the ligand for copper was mutated 
to Phe in SOD1; in this mutant transfer could not be completed. yCCS and this mutant 
SOD1 form stable complex (Lamb et al., 2000) and can be co-crystallized (Lamb et al., 
2001).  
 Another complex structure was characterized by combination of NMR and in 
silico modeling. The study was conducted with Atx1 and the first MBD of Ccc2. By 
following the 15N and 1H chemical shifts, a new species was detected. This species is in 
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fast exchange with the parent species on the NMR time scale. Nuclear relaxation data 
are consistent with the formation of an adduct (Arnesano et al., 2001). Based on NMR 
chemical shift mapping information, a structure model of the transient complex was 
proposed through in silico docking. The model shows that the interaction is mainly of an 
electrostatic nature with hydrogen bonds stabilizing the complex (Arnesano et al., 
2004).    
 Crystallization and NMR are two major tools to get the details of structural 
information. Dr. Abdul Ajees Abdul Salam in our laboratory is trying to get the crystal 
structure of ArsA-ArsD complex, but with no success so far. Dr. Jun Ye and I tried NMR 
study on ArsD in the hope of mapping interaction interface by following the 15N and 1H 
chemical shifts. However, the inhomogeneous nature of ArsD aggregation state at high 
concentration such as 1 mM required for NMR study has delayed complete assignment. 
 Yeast two-hybrid has been used to show interaction between Atx1 and the N-
terminal MBD of Ccc2 (Pufahl et al., 1997), between Atx1 and copper amine oxidase 
Cao1 (Peter et al., 2008),  between HAH1 and the 2nd or 4th MBD of ATP7B (van 
Dongen et al., 2004), and also between HAH1 and 2nd-6th MBD of ATP7A (Larin et al., 
1999).    
 The yeast two-hybrid system is a genetic system engineered to study protein-
protein interaction (Fields and Song, 1989). It has been widely used to build protein-
protein interaction networks (Bruckner et al., 2009). Yeast two-hybrid analysis takes 
advantage of the properties of yeast transcriptional factor such as GAL4. GAL4 is a 
transcriptional activator required for expression of genes encoding enzymes for utilizing 
galactose. It consists of two separate and essential domains. One is the N-terminal 
  
71
DNA binding domain (BD). The other is the C-terminal activation domain (AD). DNA 
binding domain (BD) binds to a small DNA element (UAS, upstream activation 
sequence), usually in the promoter region of the activated genes. The activation domain 
(AD) recruits the transcriptase to initiate the transcription. By expressing bait protein 
fused with BD and prey protein fused with AD separately from different plasmids, only 
when bait protein and prey protein interact with each other, a functional GAL4 
transcriptional activator can be reconstituted. Usually a reporter gene was engineered in 
the yeast chromosome as a marker for selection. When two proteins interact, the 
reporter gene will be expressed. Normal yeast two-hybrid analysis uses nutrition 
synthetic genes such as his3, a histidine synthesis gene, as a reporter. So only when 
two proteins interact with each other, can the yeast cells grow on media lacking 
histidine. New systems have also been devised using a toxic gene such as ura3 as a 
reporter gene. ura3 encodes orotidine 5-phosphate decarboxylase. It can metabolize 5-
FOA (5-fluoroorotic acid) to 5-fluorouridine, an analog of uridine, inhibiting cell growth. 
Therefore it can be used to select for the mutants with weaker interaction or no 
interaction by growing the yeast cells on the plate with 5-FOA. This is also called 
reverse yeast two-hybrid analysis (Vidal et al., 1996). Mutations interfering with 
interaction can give information about the protein-protein interaction interface. The 
normal yeast two-hybrid analysis has been used to select for the mutants retaining the 
interaction. The absence of interference of these mutation points was used to map the 
protein-protein interaction interface (Dhayalan et al., 2008).  
 Using a yeast two-hybrid system based on the GAL4 transcriptional factor, ArsD 
and ArsA were shown to interact with each other (Lin et al., 2006). Plasmid pACT2 was 
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used to express ArsD or ArsA fused with GAL4 activation domain (GAL4-AD). Plasmid 
pGBT9 was used to express ArsD or ArsA fused with GAL4 DNA binding domain 
(GAL4-BD). Yeast strain AH109 with his3 as reporter gene was used to show ArsD-
ArsA interaction. his3 encodes imidazole glycerol-phosphate dehydratase, catalyzing 
the sixth step in histidine biosynthesis. ArsD-ArsA interaction is indicated by cell growth 
on the plate lacking histidine.  
 Histidine synthesis by HIS3 enzyme is competitively inhibited by 3-AT (3-amino-
1,2,4-triazole) (Klopotowski and Wiater, 1965). If 3-AT was added to the medium, the 
yeast cells need to synthesize more HIS3 to grow normally. 3-AT has been used in the 
yeast three-hybrid system to select RNA with higher affinity to the protein (Cassiday and 
Maher, 2003; Hook et al., 2005).   
 We did random mutagenesis by error-prone PCR induced with Mn2+ on both 
ArsA and ArsD (Cadwell and Joyce, 1992). Then we selected for mutants that lose 
interaction using reverse yeast two-hybrid analysis. 3-AT was used with the yeast two-
hybrid strain AH109 using his3 as a report gene to select for mutants showing stronger 
interaction. In addition, we also did site-directed mutagenesis on lysine residues of ArsD 
and obtained mutants losing function. All these mutants will give us information about 
ArsA-ArsD interaction interface. 
4.2 Materials and Methods 
4.2.1  Reagents 
3-AT (3-amino-1,2,4-triazole) was purchased from MP Biomedicals (Solon, OH). 
5-FOA (5-Fluoroorotic Acid) was purchased from Fermentas (Burlington, Ontario). 
Yeast minimal SD base, amino acid Drop-out supplements, -Leu/-Trp and -Leu/-Trp/-His 
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were purchased from Clontech (Mountain view, CA). Sulfo-NHS Acetate 
(Sulfosuccinimidyl Acetate) was purchased from Thermo Scientific (Rockford, IL). 
Unless otherwise mentioned, all other chemicals were obtained from Sigma. 
4.2.2 Strains, plasmids and media 
E. coli strain JM109 [rcA1 supE44 endA1 hsdR17 gyrA96 relA1 thiΔ(lac-proAB) 
F’ (traD36 proAB+ lacIq lacZΔM15)] was used for molecular cloning. E. coli strain 
BL21(DE3) [hsdS gal(ΔcIts857 ind1 Sam7 nin5 lacUV5-T7 gene1)] was used for protein 
expression and purification. ArsA with C-terminal His6 tag was cloned in the expression 
vector pAlter-1 as pAlter-dAhB (Li and Rosen, 2000). Six histidines tagged ArsD1-109 
truncation was cloned in the expression vector pET28a as pET28a-ArsD109 (Chapter 2). 
E. coli cells were grown in Luria-Bertani (LB) medium (Sambrook et al., 1989) at 37°C.  
Ampicillin (100 µg/ml), kanamycin (40 µg/ml) and 0.3 mM isopropyl-ß-D-
thiogalactopyranoside were added as required. Plasmids pGBT9 and pACT2 were used 
as S. cerevisiae/E. coli shuttle vectors for yeast two-hybrid assay (Lin et al., 2007b).  S. 
cerevisiae strains AH109 (MATa, trp1-901, leu2-3, 112, ura3-52, his3-200, gal4∆, 
gal80∆, LYS2::GAL1UAS-GAL1TATA-HIS3, GAL2UAS-GAL2TATA-ADE2,URA3::MEL1UAS-
MEL1TATA-lacZ) (Clontech, Mountain View, CA) and MAV203 (MATα; leu2-3,112; trp1-
901; his3Δ200; ade2-101; cyh2R; can1R; gal4Δ; gal80Δ; GAL1::lacZ; 
HIS3UASGAL1::HIS3@LYS2; SPAL10::URA)  (Invitrogen, Carlsbad, CA) were used for 
yeast two-hybrid assay. Yeast cells were grown in complete yeast extract-peptone-
dextrose (YPD) or minimal synthetic dextrose (SD) media with the appropriate 
supplements at 30°C (Adams et al., 1998). Growth in liquid culture was estimated from 
the absorbance at 600 nm. The strains and plasmids are listed in Table 4-2. 
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4.2.3 DNA manipulation and mutagenesis 
Plasmid extraction, DNA restriction endonuclease analysis, ligation and other 
general molecular biological procedures were performed as described (Sambrook et al., 
1989).  Transformation of E. coli cells was carried out using a BIO-RAD MicroPluser 
(BIO-RAD, Hercules, CA). Transformation of Yeast cells was performed using Fast 
Yeast Transformation™ kit from G-Biosciences (Maryland Heights, MO). DNA 
purification kits were obtained from QIAGEN (Valencia, CA).  Either a Qiaprep Spin 
Miniprep kit or a Qiaquick gel extraction kit (QIAGEN) was used to prepare plasmid 
DNA for restriction enzyme digestion, sequencing, and recovering DNA fragments from 
agarose gels. Zymoprep II™ Yeast Plasmid Miniprep (Zymo Research, Orange, CA) 
was used to extract plasmid from yeast cells. The sequence of new plasmid constructs 
was confirmed by DNA sequencing of the entire gene. Site-directed mutagenesis was 
performed using Quick-change Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA) 
and confirmed by sequencing.  DNA sequencing was performed using a CEQ2000 DNA 
sequencer (Beckman Coulter, Brea, CA).  The primers used are listed in Table 4-3. 
4.2.4 Generation of a random mutated library of PCR fragments  
Random mutagenesis of ArsA or ArsD was performed using ep-PCR (Cadwell 
and Joyce, 1992) by employing biased nucleotide composition of the PCR buffer, high 
concentration of Mg2+ and addition of Mn2+. The ep-PCR reaction mixture (50 μl) 
contained 20 mM Tris–HCl (pH 8.4), 50 mM KCl, 7 mM MgCl2, 0.2 mM each of dATP 
and dGTP, 1 mM each of dCTP and dTTP, 25 pmol each of the oligonucleotide primers, 
80 ng of template DNA, 2.5 U of Taq DNA polymerase (Invitrogen).  
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 For ArsA, pACT2-A plasmid DNA was used as template, and pACT2-s (CTA TTC 
GAT GAT GAA GAT ACC CCA CCA AAC CC) and pACT2-a (AGG TTA CAT GGC 
CAA GAT TGA AAC TTA GAG GAG) were used as primer, 0.1mM Mn2+ was added. 
PCR condition was 1× 96 °C for 3 min, 30× 94 ° for 30 s, 1× 55 °C for 30 s, 1× 72 °C for 
4 min, and, finally, 1× 72 °C for 10 min. For ArsD, pGBT9-D plasmid DNA was used as 
template, and pGBT9-s (TAA AGA TGC CGT CAC AGA TAG ATT G) and pGBT9-a 
(ACC TGA CCT ACA GGA AAG AGT TAC T) were used as primer. 0.5mM Mn2+ was 
added. PCR condition was similar to the condition for ArsA, only extension time at 72°C 
is changed to 100 s. The ep PCR product was analyzed by agarose gel, extracted from 
gel and quantified by absorption at 260nm. 
4.2.5  Yeast two-hybrid analysis 
Two yeast stains, AH109 (Fields and Song, 1989) and MAV203 (Vidal et al., 
1996), were used. Both are GAL4-based yeast two-hybrid system. AH109 was used to 
analyze protein-protein interaction or select the mutants that retaining capability of 
interaction or showing stronger interaction in the presence of 3-AT (3-amino-1,2,4-
triazole) (Sigma-Aldrich, St. Louis, MO). MAV203 was used to select for the mutants 
that lose the capability of interaction through counter-selection in the presence of 5-FOA 
(5-Fluoroorotic Acid) (Fermentas, Burlington, Ontario). Yeast cells are co-transformed 
with ars gene-fused pGBT9-X (BD-X) and pACT2-Y (AD-Y) plasmids. To determine 
protein-protein interaction by growth of series of dilutions, the transformed cells were 
cultured overnight in SD medium at 30°C and then washed, suspended and adjusted to 
an absorbance of 1 at A600nm in 20 mM Tris-HCl pH 7.5. Portions of the cell suspensions 
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(1 μl) were inoculated in serial 10-fold dilutions on SD agar plates lacking histidine or 
with 3-AT at indicated concentration. The plates were incubated at 30°C for 3 days.   
 pGBT9 was modified to pGBT9-k as in Chapter 2. To select for ArsD mutants, 
the ep-PCR fragment was mixed with pGBT9-k vector linearized by EcorI and BamHI, 
and co-transformed with pACT2-A or pACT2-D into yeast-strains and selected on the 
indicated plates. The PCR fragment will be ligated into the vector in vivo through 
homology recombination (Hua et al., 1997). To select for ArsA mutants, the ep-PCR 
fragment was mixed with pACT2 vector linearized by EcorI EcoRI and BamHI, and co-
transformed with pGBT9-k-D into yeast-strains and selected on the indicated plates. 
4.2.6  Sequencing of ArsD and ArsA mutant genes in yeast colonies  
Each yeast colony was grown in corresponding liquid SD medium. The plasmids 
were isolated from yeast by Zymoprep II™ Yeast Plasmid Miniprep Kit (Zymo Research 
Cop. Orange, CA), transformed to E. coli JM109 and grown on LB plate with ampicillin 
for ArsA and kanamycin for ArsD. Then the plasmids were extracted from E. coli JM109 
and sequenced as the following. For ArsD, mutant genes on pGBT9-k vector were 
sequenced with the GAL4-BD sequencing primer (GAG TAG TAA CAA AGG TCA A). 
For ArsA, mutant genes on pACT2 vector were sequenced with five sets of primers 
(GAL4-AD sequencing primer: AAT ACC ACT ACA ATG GAT; ArsA-100-s:  GTC CTG 
CCT GAT GAC GTT GTT TCC A; ArsA-220-s: GTC GCC CGG ACT CAT CTG GAA 
CTT G; ArsA-420-s: AAG AGG ACT TAC GCT CAC CTT GCA C; ArsA-480-a: CGT 
GAC CAG TAA CAC TTT AGT GCG). 
4.2.7 Protein expression and purification 
Cells bearing the indicated plasmids were grown in LB medium overnight at 37°C 
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and then diluted 50-fold into 1 L of the same medium. Proteins were expressed by 
induction with 0.3 mM isopropyl-ß-D-thiogalactopyranoside at A600 of 0.6-0.8 for 3 hrs. 
ArsA with a six histidine tag at the C-terminus was purified from cells of strain 
BL21(DE3) expressing pAlter-1-dAhB plasmid, as described (Zhou and Rosen, 1997). 
Cells were harvested by centrifugation and washed once with a buffer containing 50 mM 
MOPS, pH 7.5, 0.5 M NaCl, 30 mM Imidazole and 10 mM 2-mercaptoethanol (Buffer A). 
The cells were suspended in 5 ml of Buffer A per gram of wet cells and lysed by a single 
passage through a French press at 20,000 psi.  Diisopropyl fluorophosphate (DIFP) 
(Sigma) was added at 2.5 μl/g wet cells immediately following French press. Unbroken 
cells and membranes were removed by centrifugation at 150,000 x g for 1 hr at 4oC. 
The supernatant was loaded to 10 ml Probond Ni-column (Invitrogen) pre-equilibrated 
with Buffer A.  Unbound proteins were washed by 60 ml of buffer A, and ArsA was 
eluted with imidazole gradient generated by Buffer A and Buffer B(50 mM MOPS, pH 
7.5, 0.5 M NaCl, 300 mM Imidazole and 10 mM 2-mercaptoethanol), followed by 
addition of 0.25 mM EDTA and 5 mM DTT to each fraction. ArsA containing fractions 
were identified by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE), pooled, concentrated by Amicon Ultra-15 Centrifugal Filter Unit with Ultracel-10 
membrane (Millipore), mixed with 10% glycerol, aliquoted and stored at -80oC until used. 
ArsD and its derivatives with a six histidine tag at the N-terminus were purified similarly. 
Purified proteins were stored at -80°C until use, and their concentrations were 
determined according to the method of Bradford (Bradford, 1976) or from the absorption 
at 280 nm (Gill and von Hippel, 1989). 
4.2.8 ATPase activity assays 
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ATPase activity was estimated using a couple assay (Vogel and Steinhart, 1976), 
as described (Hsu and Rosen, 1989). ArsA was added at a final concentration of 0.3 μM 
into an assay mixture containing 5 mM ATP, 1.25 mM phosphoenolpyruvate, 0.25 mM 
NADH, 10 units of pyruvate kinase and lactate dehydrogenase with or without the 
indicated concentrations of sodium arsenite, in the buffer containing 50 mM MOPS-KOH, 
pH 7.5, 0.25 mM EDTA. ArsD was added at the indicated concentrations. The mixture 
was pre-warmed to 37°C, and the reaction was initiated by addition of 2.5 mM MgCl2 
and measured at 340 nm. The linear steady state rate of ATP hydrolysis was used to 
calculate specific activity. The reaction volume was 0.2 ml each in 96-well microplates, 
and the reactions were monitored by microplate reader SPECTRA max 340PC 
(Molecular Devices).  
4.2.9 Acetylation of lysine by Sulfo-NHS acetate 
The Buffer of purified ArsD or ArsD derivatives was exchanged with a buffer 
containing 50 mM MOPS-KOH, 200mM NaCl, pH 7.8, 0.25 mM EDTA, 5mM TCEP and 
5mM DTT. Dissolve Sulfo-NHS acetate in pure water to 100mM. Dilute protein to 1 mM 
concentration. Add Sulfo-NHS acetate at 10 fold concentration of free amine in the 
protein solution. It is like mixing 1 ml of 1 M protein solution with 0.7 ml of 100 mM 
Sulfo-NHS acetate for ArsD109 or 0.3 ml of 100 mM Sulfo-NHS acetate for 
ArsD109K2/104A-K37/62R and ArsD109K2/104A-K60/90A. Mixture was incubated for 60 min at 
room temperature. 200 ul of 0.5 M Tris pH 6.8 was added to quench the reaction for 20 
min. Then protein was diluted with 10ml buffer of 50 mM MOPS-KOH, pH 7.5, 200 mM 
NaCl, 0.25 mM EDTA, 5 mM TCEP and 5 mM DTT and concentrated to 1ml with 
Amicon Ultra-15 Centrifugal Filter Unit. Repeat dilution with buffer and concentrating for 
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three more times to totally change protein buffer. Finally protein was concentrated, 
mixed with 10% glycerol, aliquoted and stored at -80oC until used. 
4.2.10 Metalloid binding assay  
The buffer of purified ArsD was exchanged with a buffer containing 50 mM 
MOPS-KOH, pH 7.5, 0.25 mM EDTA (ATPase assay buffer), using a Bio-Gel P-6 Micro 
Bio-Spin column (Bio-Rad, Hercules, CA).  Purified protein (100 μM) was incubated at 
4oC with 300 μM potassium antimonyl tartrate. After 1 h, each sample was passed 
through a Bio-Gel P-6 column pre-exchanged with the ATPase assay buffer. ArsA 
protein concentration in the flow through was quantified from the absorption at 280 nm 
(Gill and von Hippel, 1989) or according to the method of Bradford (Bradford, 1976). 
Flow through were diluted with 2% HNO3, and the quantity of metalloid was measured 
by inductively coupled mass spectrometry (ICP-MS) with a PerkinElmer ELAN 9000.  
Antimony standard solutions in the range of 1-20 ppb in 2% HNO3 were obtained from 
Ultra Scientific, Inc. (North Kingstown, RI). From the ratio of antimony concentration and 
protein concentration in the flow through, the binding molar ratio is calculated. 
4.3 Results 
4.3.1 ArsD mutants showing stronger interaction with ArsA 
AH109 uses his3 as the reporter gene. his3 will be transcribed when two proteins 
interact with each other. Histidine synthesis by HIS3 enzyme is competitively inhibited 
by 3-AT (3-amino-1,2,4-triazole) (Klopotowski and Wiater, 1965). If 3-AT was added to 
the medium, the yeast cells need to synthesize more HIS3 to grow normally. Here 3-AT 
was used in yeast two-hybrid analysis to qualitatively distinguish interaction strength 
between two proteins and select for stronger interaction mutants. Using a pair of primer 
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homologous to regions on pGBT9-D flanking the inserted arsD gene, error-prone PCR 
was done on ArsD in the presence of Mn2+. The purified ep-PCR product was mixed 
with pGBT9-k vector linearized by EcoRI and BamHI, co-transformed with pACT2-D into 
AH109 and selected on SD-L-W-H plates with 10 mM 3-AT. The PCR fragment was 
ligated into the vector in vivo through homology recombination (Hua et al., 1997). 
Around 30 colonies grew on SD-L-W-H plates with 10 mM 3-AT. We sequenced the 
ArsD gene in each colony. Some contained a single mutation, while others contained 
multiple mutations. Some mutations occurred only once, but mutations such as S14R, 
T20I, Q24L, D28V and Q34R were found in many mutants. These mutations were 
reintroduced by site-directed mutagenesis as single mutation and tested to see whether 
they increased the strength of interaction with ArsA, as shown in Figure 4-1 (only 
mutants with stronger interaction are shown).   
ArsDs with any of nine mutations at eight positions, including two at Asp 28, 
D28V and D28V, exhibit stronger interaction with ArsA (Figure 4-1). AH109 yeast cells 
co-transformed with pGBT9-k-D (encoding the GAL4 DNA binding domain fused with 
wild-type ArsD, BD-ArsD) and pACT2-A (encoding the GAL4 activation domain fused 
with wild-type ArsA, AD-ArsA) do not grow on SD-L-W-H plates with 10 mM 3-AT, while 
AH109 yeast cell co-transformed with pGBT9-k-DS14R (encoding BD-ArsDS14R) and 
pACT2-A grows normally on plates with 30mM 3-AT, and the mutation has no effect on 
dimerization with wild-type ArsD when co-transformed with pACT2-D (encoding wild-
type AD-ArsD) (Figure 4-1, right panel). ArsD mutants, T20I, Q24L, D28V, D28T, T31A, 
Q34R and V61A behave similarly as the S14R mutant. Mutant Q38R only slightly 
increases the strength of interaction with ArsA, as shown that cells grow on plates 
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containing 10 mM 3-AT but not on plates containing 30 mM 3-AT. Ser 14 and Thr 20 are 
in the loop containing the metal binding site formed by three cysteine residues Cys12, 
Cys13 and Cys18. Four residues, Gln24, Asp28, Thr31 and Gln34, are located on the 
same face of the first α-helix (Figure 4-7A). Q38R shows a slight effect on the 
interaction with ArsA and is located just following the above four residues on the same 
α-helix. These results suggest that a strip formed by these 5 residues on this α-helix 
may be involved in direct contact of ArsD with ArsA.  
4.3.2  Lys37 and Lys62 are involved in interaction with ArsA 
One unsuccessful approach had been to attempt to crosslink the ArsD dimer 
using amine-specific homofunctional crosslinker.  As part of that, we made series of 
ArsD lysine mutants to reduce nonspecific crosslinking. ArsD has 6 lysine residues, 
Lys2, Lys 37, Lys60, Lys62, Lys90 and Lys104. One of the mutants, ArsD109K2/104A-
K37/62A, was not able to stimulate ArsA ATPase activity (Figure 4-2A), suggesting that 
one or more of those four lysine residues might be involved in ArsD metallochaperone 
function, shown as increasing the apparent affinity of ArsA for As(III) in this assay. To 
identify which lysine residue(s) is (are) involved, we examined more ArsD mutants 
carrying fewer lysine mutations.  ArsD109K2/104A stimulates ArsA ATPase activity as well 
as the parental ArsD109. ArsD109 increases ArsA apparent affinity for As(III) from 535 
μM to 15 μM, and ArsDK2/104A increases to 8 μM. However, ArsD109K37A and 
ArsD109K62A individually only increase ArsA apparent affinity for As(III) to 126 μM and 
289 μM respectively, suggesting that Lys37 and Lys62 together, but not Lys2 and 
Lys104, may play roles during arsenic transfer from ArsD to ArsA. Thus, it appears that 
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the two mutations at Lys37 and Lys62 are synergistic in their effect on ArsD 
metallochaperone function. 
We further examined lysine residues Lys60 and Lys90 to see whether they are 
involved in the arsenic transfer. By mutating both of them to alanine, ArsD109K2/104A-
K60/90A increases ArsA apparent affinity for As(III) to 21 μM (Figure 4-2B), almost same 
as wild-type ArsD109, indicating that neither Lys60 nor Lys90 are required for arsenic 
transfer from ArsD to ArsA.   
To examine the requirement for a positive charge, Lys37 and Lys62 were 
changed to arginine. ArsD109K2/104A-K37/62R increases the apparent affinity of ArsA for 
As(III) to 15 μM, similar to ArsD109 (Figure 4-2B). Compared with ArsD109K2/104A-K37/62A, 
which loses ability to stimulate ArsA ATPase activity, arginine mutant ArsD109K2/104A-
K37/62R is still active, suggesting that a positive charge may be required for ArsD 
metallochaperone function. This was further supported by chemical modification of 
lysine residues with Sulfo-NHS acetate (sulfosuccinimidyl acetate), which acetylates 
amine group and neutralizes the positive charge.  ArsD109 increases the apparent 
affinity of ArsA for As(III) from 521 μM to 12 μM before acetylation, and 204 μM after 
acetylation, consistent with the involvement of lysine residues in metallochaperone 
activity. Acetylation decreases wild-type activity dramatically although not completely, 
which might be due to partial acetylation (Figure 4-3). Mutant ArsD109K2/104A-K60/90A, with 
only lysine residues Lys37 and Lys62 remaining, increases the apparent affinity of ArsA 
for As(III) to 26 μM before acetylation, and 283 μM after acetylation. This suggests that 
acetylation of Lys37 and Lys62 causes loss of ArsD metallochaperone function. Mutant 
ArsD109K2/104A-K37/62R, with only lysine residues Lys60 and Lys90 left, increases ArsA 
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apparent affinity for As(III) to 12 μM before acetylation, and 7 μM after acetylation. This 
is consistent with the result above that Lys 60 and Lys 90 are not required for 
stimulating ArsA ATPase activity. It also indicates that acetylation has no effect on other 
non-lysine residues. It is not surprised that acetylation has no effect on ArsD109K2/104A-
K37/62R, in which Lys37 and Lys62 were mutated to arginine, since acetylation by Sulfo-
NHS does not change the positive charge of arginine residues. All of these results 
suggest that Lys37 and Lys62 are involved for the ArsD metallochaperone function and 
that a positive charge at these positions is important. 
The antimony binding capability of the mutant ArsD109K2/104A-K37/62A was 
measured by gel-filtration and ICP-MS quantification. As expected, the parental 
ArsD109 binds approximately one Sb(III) per monomer (Lin et al., 2007a). 
ArsD109C12/13S-C18A, with no metalloid binding site, binds only a background level of 
Sb(III) (Lin et al., 2007a). ArsD109K2/104A-K37/62A binds Sb(III) as well as ArsD109, about 
one Sb(III) per monomer (Figure 4-4A). Interaction between ArsD lysine mutants and 
ArsA was investigated using yeast two-hybrid analysis. All of the mutants interact with 
wild-type ArsD, suggesting these mutants fold and dimerize (Figure 4-4B). This is also 
supported by the fact that these mutants can be overexpressed in E. coli and purified 
from the cytosolic soluble fraction. ArsDK2/104A-K37/62A does not interact with ArsA, while 
ArsDK2/104A-K37/62R and ArsDK2/104A-K60/90A interacts with ArsA as well as wild-type ArsD. 
This is consistent with above results that ArsD109K2/104A-K37/62A does not stimulate ArsA 
ATPase activity, but ArsD109K2/104A-K37/62R and ArsD109K2/104A-K60/90A do stimulate. K37A 
and K62A mutations were separated, and their individual effects on ArsA interaction 
was examined by yeast two-hybrid analysis. ArsD109K2/104A-K37A interacts with ArsA 
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poorly compared with wild-type ArsD, while ArsD109K2/104A-K62A interacts with ArsA 
almost same as wild-type, indicating that Lys37 may be more important than Lys62 in 
terms of interaction with ArsA. 
All these results suggest that mutating Lys37 and Lys62 to alanine does not 
affect metal binding ability of ArsD but causes loss of interaction with ArsA, leading to 
inability of transfer As(III) to ArsA and to stimulate ArsA ATPase activity. In the crystal 
structure, Lys37 is in the same first α-helix as residues Gln24, Asp28, Thr31, Gln34 and 
Gln38 (Fig. 4-7A). This is consistent with our hypothesis that this helix is involved in 
interaction with ArsA. On the other hand Lys62 is adjacent to Val61, located in the third 
α-helix, which is on the other side of the ArsD structure compared with the first α-helix 
(Figure 4-7A). The above results show that a V61A mutant interacts more strongly with 
ArsA, suggesting that the third α-helix, in which Val61 and Lys62 are located, may be 
another point of interaction with ArsA.  
4.3.3  ArsD mutants showing weaker interaction with ArsA 
Yeast strain MAV203 has the reporter gene ura3, which encodes an enzyme that 
metabolizes 5-FOA (5-fluoroorotic acid) to 5-fluorouridine, a toxic analogue of uridine 
that inhibits cell growth. Therefore MAV203 can be used to select for mutants with 
weaker or no interaction by selecting for growth on plates with 5-FOA (Vidal et al., 1996). 
ArsA and ArsD have been shown to interact with each other in GAL4 yeast two-hybrid 
system AH109 (Lin et al., 2007b). We confirmed that ArsA and ArsD also interact with 
each other in strain MAV203 and determined that MAV203 co-transformed with pACT2-
A (encoding AD-ArsA) and pGBT9-D (encoding wild-type BD-ArsD) cannot grow on SD-
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L-W plates with 0.2 % 5-FOA. So we use 0.2 % 5-FOA to select for ArsD mutants that 
cannot interact with ArsA or interact more weakly.  
 Using a pair of primer homologous to regions on pGBT9-D (encoding BD-ArsD) 
flanking the inserted arsD gene, error-prone PCR was done as described under 
‘Materials and Methods’. The purified PCR product was mixed with pGBT9-k vector 
linearized by EcoRI and BamHI, and co-transformed with pACT2-A (encoding AD-ArsA) 
into MAV203 and selected on SD-L-W plates with 0.2 % 5-FOA. 70 colonies were 
isolated from 5-FOA plates, 7% of the 1000 clones on plates without 5-FOA. Of these 
mutants, some will be ArsD mutants that interact more weakly with ArsA, but others 
may be prematurely chain terminating ArsD mutants, unfolded ArsD mutants, or even 
empty pGBT9 vector. Since ArsD forms a dimer in yeast two-hybrid AH109 (Lin et al., 
2007b), we further screened for those mutants that could still dimerize with wild-type 
ArsD, with the assumption that these should fold normally. We pooled all 70 colonies, 
and used the same primer, homologous to regions on pGBT9-D flanking the inserted 
arsD gene, for colony PCR. The purified PCR products were mixed with plasmid 
pGBT9-k that had been linearized with EcoRI and BamHI, co-transformed with plasmid 
pACT2-D (encoding AD-ArsD) into AH109 and selected on SD-L-W-H plates. 300 
colonies grew on SD-L-W-H plates, 7% of the 4000 colonies that grew on SD-L-W 
plates. 30 colonies were purified and sequenced. Finally we isolated 5 ArsD mutants 
showing weaker or no interaction with ArsA but still dimerizing with wild-type ArsD 
(Figure 4-5A). These mutants are ArsDV17A, ArsDV22A, ArsDV27D, ArsDQ51H, and ArsDF55L. 
Residues Val17 and Val22 are in the loop containing the metalloid binding site (Cys12, 
Cys13 and Cys18). Val27 is in the first α-helix, in which residues Gln24, Asp28, Thr31, 
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Gln34, Lys37 and Gln38 have been shown above to be important for the interaction with 
ArsA (Figure 4-7A). This supports our hypothesis that this first α-helix is involved in the 
interaction with ArsA. 
4.3.4  ArsA mutants restoring interaction with ArsD mutants 
To select for mutants that restored the ability of ArsD mutants to interact with 
ArsA, we used random mutagenesis of ArsA in plasmid pACT2-A. Using a pair of primer 
homologous to regions on pACT2 flanking the multiple cloning sites, error-prone PCR 
was done on ArsA, as described under ‘Materials and Methods’. The purified PCR 
product was mixed with the plasmid pACT2 linearized with EcoRI and BamHI, co-
transformed with ArsD mutants in the plasmid pGBT9-k into strain AH109 and selected 
on SD-L-W-H plates. Five ArsA mutants, ArsAP9L,L74H,D121G,F123L,E425A, ArsAD121E, 
ArsAG111C,E400V,L530H,Q557L, ArsAL179R,H219L, and ArsAA29S,R88G,D121N,V215A,T401A, restored 
interaction with ArsDV22A but also retained ability of interaction with wild-type ArsD 
(Figure 4-5B). Three ArsA mutants, ArsAD121E, ArsAE425K,L564H, and ArsAD417N, restored 
interaction with ArsDF55L (Figure 4-5C).  Six ArsA mutants, ArsAL152R,F162L,D513Y,S560C, 
ArsAD121E,L207P, ArsAI65T,Q84L,D121E,H453L, ArsAV101A,R151H,S570T, ArsAT149A,I150H,E438D, and 
ArsAD121G,E405V,E415V,H558R, restored interaction with ArsDQ51H (Figure 4-5D). All of the 
ArsA mutants retained the ability to interact with wild-type ArsD, and one mutant 
ArsAD121E, restored interaction with both ArsDV22A and ArsDF55L. This suggests that the 
compensation of mutation on ArsA is not specific for the particular mutation in ArsD but 
increase interactions from another site in ArsD, since an extensive interaction interface 
was identified on ArsD.  
4.3.5  ArsA mutants showing stronger interaction with ArsD 
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Using a pair of primer homologous to regions on pACT2 flanking the multiple 
cloning sites, error-prone PCR was done on ArsA. The purified PCR product was mixed 
with vector pACT2 linearized by EcoRI and BamHI, co-transformed with pGBT9-D into 
AH109 and selected on SD-L-W-H plates with 20 mM 3-AT. Six ArsA mutants show 
stronger interaction with wild-type ArsD (Figure 4-6). AH109 yeast cells co-transformed 
with pACT2-A or other ArsA mutants and pGBT9-k-D (encoding wild-type ArsD) were 
spotted on SD-L-W-H plates with different concentrations of 3-AT. Cells with wild-type 
ArsA cannot grow on plates with 10 mM 3-AT. ArsAI117M,E425G and ArsAH368L,E425k confer 
resistance to 60 mM 3-AT, and both have Glu425 mutation. ArsAF120L,L193S and 
ArsAF54L,F120L,H219R,E254V,F443L,K475R,A533T confer resistance to 120 mM 3-AT, and both have 
mutations at Phe120. ArsAD121E and ArsAD121N confer resistance to 30 mM 3-AT, and 
both have mutation at Asp121 position. These results suggest that ArsA residues 
Glu425, Phe120 and Asp121 may be involved in interaction with ArsD. 
 Another Asp121 mutant, ArsAD121G,E405V,E415V,H558R, which was isolated as 
complementing mutation Q51H in ArsD, also confers resistance to 60 mM 3-AT. 
ArsAP9L,L74H,D121G,F123L,E425A was isolated by ability to complement mutation V22A in ArsD. 
This multiple mutant contains changes at Asp121 and Glu425 and confers resistance to 
90 mM 3-AT (Figure 4-6). 
4.4 Discussion 
ArsD transfers As(III) to ArsA in the presence of Mg2+ and ATP (Lin et al., 2006). 
In vitro experiments suggest that ArsD and ArsA interact through their metal binding 
sites. ArsA and ArsD crystal structures have been solved individually, but the details of 
their interactions are still unknown. In this study, yeast forward and reverse two-hybrid 
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selections were used to isolate mutants with stronger or weaker interactions, providing 
information about the physical interface between ArsA and ArsD.  Totally 16 mutations 
in ArsD were identified to affect ArsA-ArsD interaction (Table 4-4).  
Using 3-AT and strain AH109 with his3 as report gene, nine ArsD mutants were 
found to increase the strength of interaction with ArsA. They include ArsDS14R, ArsDT20I, 
ArsDQ24L, ArsDD28V, ArsDD28T, ArsDT31A, ArsDQ34R, ArsDQ38R and ArsDV61A. Using reverse 
yeast two-hybrid selection, five ArsD mutants were isolated that show loss of or weaker 
interaction with ArsA. These mutants still dimerize with wild-type ArsD, indicating that 
the mutations do not cause protein misfolding. These five mutants are ArsDV17A, 
ArsDV22A, ArsDV27D, ArsDQ51H and ArsDF55L.  
Through site-directed mutagenesis, Lys37 and Lys62 were found to be significant 
for ArsD metallochaperone function. If mutated Lys37 or Lys62 to alanine individually, 
the resulting ArsD proteins partially lose the ability to stimulate ArsA ATPase activity. If 
mutated to alanine together, the resulting protein was unable to stimulate ArsA, 
suggesting a synergistic effect of these two lysines. However, if mutated to arginines, 
the resulting protein is still active, indicating that a requirement for positively charged 
residues. The effect of acetylation of lysine residues with Sulfo-NHS acetate further 
supported the requirement for positive charge. When both Lys37 and Lys62 were 
mutated to alanines, the resulting protein retains the ability to bind antimony but loses 
interaction with ArsA in yeast two-hybrid analysis. 
In total, 16 mutations of 15 amino residues show either stronger or weaker 
interactions with ArsA. They are at amino acid residues, Ser14, Val17, Thr20, Val22, 
Gln24, Val27, Asp28, Thr31, Gln34, Lys37, Gln38, Gln51, Phe55, Val61 and Lys62 
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(Table 4-4). These residues were mapped on the structure of ArsD (Figure 4-7). The 
ArsD monomer has a thioredoxin fold of four β-strands flanked by four α-helices.  
Residues 12 to 22 are mostly disordered in this structure. To show all the mutations, an 
ArsD structural model with residues 12 to 22 inserted was constructed by homology 
modeling (Ye et al., 2010). ArsD helices α1 and α4 are on one side of the ß-strands; α2 
and α3 are on the other side. α2 is almost perpendicular to α3, with only one residue 
between them. ß1 is between ß2 and ß3, parallel to ß2 and anti-parallel to ß3. ß3 and 
ß4 form a ß-hairpin. Residues 70 to 72 form a short 310 helix.  
Four residues, Ser14, Val17, Thr20 and Val22, are in the same loop as Cys12-
Cys13-Cys18. This is consistent with our model that the region near metal binding site 
is involved in direct contact with ArsA. Seven residues, Gln24, Val27, Asp28, Thr31, 
Gln34, Lys37 and Gln38, are in helix α1 just following the loop containing the metal 
binding site. They are aligned on one side of the helix and solvent exposed, suggesting 
that this surface is directly involved in interaction, or, alternatively, that the helix helps to 
position the metalloid binding loop in correct orientation to interact with ArsA. Another 
four residues Gln51, Phe55, Val61 and Lys62, are on helices α2 and α3. This region 
could also be involved in interaction with ArsA or, again, may also serve to position the 
loop for interaction with ArsA.   
Metallated ArsD interacts with and transfers As(III) to ArsA during catalysis, when 
the ATPase cycles between open to closed conformations (Lin et al., 2007a; Ruan et 
al., 2006). The x-ray crystal structure of ArsA has been solved in the closed form (Zhou 
et al., 2000, 2001). A yeast homologue termed Arr4p or Get3 (Auld et al., 2006) is 
involved in targeting tail-anchored proteins in the endoplasmic reticulum (Bozkurt et al., 
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2009). Recently crystal structures of Get3 were solved in the open (nucleotide free) and 
closed (ADP-AlF4-) conformations (Mateja et al., 2009). ArsA has two homologous 
halves, A1 and A2, each with a nucleotide binding domain (NBD) connected by a short 
linker, while Get3 is a dimer of two identical monomers, each homologous to either A1 
or A2. In the open Get3 conformation there is a large conformational change, and the 
two monomers are separated by approximately 37º rotation of one subunit towards the 
other relative to their orientation in the closed form, which is more compact.  The ADP-
AlF4- closed ArsA structure can be superimposed with Get3 closed structure with an 
RMSD of 3.4 Å for 420 Cα atoms (Figure 4-9A). ArsA NBD1 (residue 1-297)  and NBD2 
(298-583) can be superimposed with the two monomers in the Get3 open structure, with 
RMSD of 2.3 Å and 3.0 Å, respectively (Figure 4-9B).  An open model of the ArsA 
structure based on the open Get3 structure was generated for analysis of ArsA-ArsD 
interactions and docking studies (Figure 4-9C) (Ye et al., 2010).  
The open ArsA and metallated ArsD models were docked by using the fully 
automated, web-based program ClusPro Version 2.0 with balanced coefficients and 
default parameters (Ye et al., 2010).  The ClusPro docking server yielded several top-
scoring solutions.  One of the solutions with relative good score was consistent with 
biochemical analysis indicating that the three cysteines of ArsD and the three cysteines 
of ArsA must be in proximity for transfer (Figure 4-10). According to this model, most 
likely ArsA and ArsD interact with each other at multiple points. It is consistent with 
yeast two-hybrid results that the loop containing Cys12-Cys13-Cys18 metal binding site 
and helix α1 are directly involved in protein contact.  
  
91
Six ArsA mutants, ArsAI117M,E425G, ArsAH368L,E425k, ArsAF120L,L193S, 
ArsAF54L,F120L,H219R,E254V,F443L,K475R,A533T, ArsAD121E and ArsAD121N, show stronger 
interaction with wild-type ArsD. Mutations at Glu425, Phe120 and Asp121 occurred 
twice in different mutants, and they are spatially closing to ArsA MBS (metalloid binding 
site) (Figure 4-8). These mutations might change the local conformation of the MBS to 
increase the strength of interaction with ArsD, or they are possibly located in the 
interaction interface. Whichever it is, that all these mutations are located close to the 
ArsA MBS supports the model that ArsA and ArsD interacts at their metal binding sites.    
ArsA mutants were isolated that restore interaction with ArsDV22A, ArsDQ51H or 
ArsDF55L.  One common feature of all ArsA complementary mutants is that they all have 
one mutation spatially closing to the ArsA MBS, while most other mutations are 
scattered around all over the protein. The mutations near the MBS could slightly change 
the local conformation of MBS and restore the interaction with ArsD mutants. Among all 
14 ArsA mutants, seven contain mutations at Asp121, and two have mutations at 
Glu425. These two positions were shown to increase the interaction strength when they 
are mutated. These results suggest that restoration of interaction with ArsD mutants is 
not site-specific, but more likely ArsD and ArsA have multi-point contact sites, 
considering the extensive interaction interface on ArsD was identified. The loss of 
interaction at one point can be compensated by stronger interaction at another site.  
Currently, the effect of mutation F120L, D121E, D121G, E425K and E425A on 
ArsA and on ArsA-ArsD interaction is being studied. By changing these residues to 
other residues, more mutants will be constructed and studied. These ArsA mutants 
could be useful for co-crystallization with ArsD since they show stronger interaction with 
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ArsD. Probably these mutants could lock ArsA to the open conformation therefore 
interacting with ArsD better. All ArsD mutants showing stronger interaction with ArsA in 
yeast two-hybrid analysis will also be tried to co-crystallize with ArsA.  
In addition, methods quantitatively measuring ArsA-ArsD interaction will be very 
helpful to understand not only the effect of the mutations but also the basic mechanism 
of arsenic transfer. Some preliminary work using SPR (surface plasmon resonance) has 
been done. By immobilizing ArsD on the chip and flowing ArsA solution through the 
surface, ArsA-ArsD interaction could be watched. The result until now looks promising 
but stricter negative control is needed. ArsD109K2/104A-K37/62A could be a good negative 
control. This mutant has been shown not to stimulate ArsA ATPase activity and not to 
interact with ArsA in yeast two-hybrid analysis. Single molecule fluorescence resonance 
energy transfer could also be used to study ArsA-ArsD interaction. It has been 
successfully used to study transient interaction between copper chaperone HAH1 and 
Wilson disease protein (Benitez et al., 2008). This method has advantage not only to 
study ArsA-ArsD interaction in simulated pre-hydrolysis state, intermediate or post-
hydrolysis state but also to watch interaction change between single ArsA-ArsD 
molecule pair during ATP hydrolysis. 
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Table 2-1 
Strains and plasmids used in CHAPTER 2 
Strains/Plasmids Genotype/description Reference 
Strains   
JM109 endA1, recA1, gyrA96, thi, hsdR17 (rk-, 
mk+), relA1, supE44, λ-, Δ(lac-proAB), [F’, 
traD36, proAB, lacIqZΔM15] 
(Sambrook et al., 
1989) 
BL21(DE3)  [F- ompT hsdSB (rB-mB-) gal dcm (DE3 [lacI 
lacUV5-T7 gene1 ind1 Sam7 nin5]) 
(Sambrook et al., 
1989) 
Plasmids   
pAlter-dAhB Six histidine codons added to the 3’-end of 
arsA gene (Apr) 
(Li and Rosen, 
2000) 
pMAL-ArsD109 arsD1-109 truncation was fused to the C-
terminal of MBP (Apr) 
(Lin et al., 
2007a) 
pET28a For expression of his-tagged protein 
controlled by T7 promoter (Kanar) 
Novagen 
pET28a-ArsD109 arsD1-109 truncation was inserted into 
pET28a through EcoRI and SalI sites 
(Kanar) 
This study 
pET28a-ArsD109 
W35/97Y 
Trp35 and Trp97 were mutated to Tyr by 
site directed mutagenesis on pET28a-
ArsD109 (Kanar) 
This study 
pET28a-ArsD109 
T15W 
Thr15 was mutated to Trp by site directed 
mutagenesis on pET28a-ArsD109 W35/97Y 
(Kanar) 
This study 
pET28a-ArsD109 
V17W 
Val17 was mutated to Trp by site directed 
mutagenesis on pET28a-ArsD109 W35/97Y 
(Kanar) 
This study 
pET28a-ArsD109 
C12G  
Cys12 was mutated to Gly by site directed 
mutagenesis on pET28a-ArsD109 (Kanar) 
This study 
94 
 
Table 2-1 
Strains and plasmids used in CHAPTER 2 (continued) 
Strains/Plasmids Genotype/description Reference 
Plasmids   
pET28a-ArsD109 
C13G  
Cys13 was mutated to Gly by site directed 
mutagenesis on pET28a-ArsD109 (Kanar) 
This study 
pET28a-ArsD109 
C18G  
Cys18 was mutated to Gly by site directed 
mutagenesis on pET28a-ArsD109 (Kanar) 
This study 
pET28a-ArsD109 
C12G,T15W 
Cys12 was mutated to Gly by site directed 
mutagenesis on pET28a-ArsD109 T15W 
(Kanar) 
This study 
pET28a-ArsD109 
C13G,T15W 
Cys13 was mutated to Gly by site directed 
mutagenesis on pET28a-ArsD109 T15W 
(Kanar) 
This study 
pET28a-ArsD109 
C18G,T15W 
Cys18 was mutated to Gly by site directed 
mutagenesis on pET28a-ArsD109 T15W 
(Kanar) 
This study 
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Table 2-2 
Oligonucleotide primers used in CHAPTER 2 
Primer Sequence (5’–3’) Target / Direction 
T7 promoter 
sequencing primer 
TAATACGACTCACTATAGGG pET28a forward sequencing 
primer 
T7 terminator 
sequencing primer 
GCTAGTTATTGCTCAGCGG pET28a reverse sequencing 
primer 
ArsD-T15W-s GCGATGTGTTGCAGCTGGGGC
GTCTGCGGTACAG 
Mutate ArsD Thr15 to Trp, 
sense 
ArsD-T15W-a CTGTACCGCAGACGCCCCAGC
TGCAACACATCGC 
Mutate ArsD Thr15 to Trp, 
antisense 
ArsD-V17W-s GTGTTGCAGCACCGGCTGGTG
CGGTACAGATGTTG 
Mutate ArsD Val17 to Trp, 
sense 
ArsD-V17W-a CAACATCTGTACCGCACCAGCC
GGTGCTGCAACAC 
Mutate ArsD Val17 to Trp, 
antisense 
ArsD-C12G-s GGTATTTGACCCGGCGATGGGT
TGCAGCACCGGCGTC 
Mutate ArsD Cys12 to Gly, 
sense 
ArsD-C12G-a GACGCCGGTGCTGCAACCCAT
CGCCGGGTCAAATACC 
Mutate ArsD Cys12 to Gly, 
antisense 
ArsD-C13G-s GTATTTGACCCGGCGATGTGTG
GCAGCACCGGCGTCTGC 
Mutate ArsD Cys13 to Gly, 
sense 
ArsD-C13G-a GCAGACGCCGGTGCTGCCACA
CATCGCCGGGTCAAATAC 
Mutate ArsD Cys13 to Gly, 
antisense 
ArsD-C18G-s GTTGCAGCACCGGCGTCGGCG
GTACAGATGTTGATC 
Mutate ArsD Cys18 to Gly, 
sense 
ArsD-C18G-a GATCAACATCTGTACCGCCGAC
GCCGGTGCTGCAAC 
Mutate ArsD Cys18 to Gly, 
antisense 
ArsD-12G15W-s GGTATTTGACCCGGCGATGGGT
TGCAGCTGGGGCGTC 
Mutate ArsD Cys12 to Gly 
and Thr15 to Trp, sense 
ArsD-12G15W-a GACGCCCCAGCTGCAACCCAT
CGCCGGGTCAAATACC 
Mutate ArsD Cys12 to Gly 
and Thr15 to Trp, antisense 
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 Table 2-2 
Oligonucleotide primers used in CHAPTER 2 (continued) 
Primer Sequence (5’–3’) Target / Direction 
ArsD-13G15W-s GTATTTGACCCGGCGATGTGTG
GCAGCTGGGGCGTCTGC 
Mutate ArsD Cys13 to Gly 
and Thr15 to Trp, sense 
ArsD-13G15W-a GCAGACGCCCCAGCTGCCACA
CATCGCCGGGTCAAATAC 
Mutate ArsD Cys13 to Gly 
and Thr15 to Trp, antisense 
ArsD-18G15W-s GTTGCAGCTGGGGCGTCGGCG
GTACAGATGTTGATC 
Mutate ArsD Cys18 to Gly 
and Thr15 to Trp, sense 
ArsD-18G15W-a GATCAACATCTGTACCGCCGAC
GCCCCAGCTGCAAC 
Mutate ArsD Cys18 to Gly 
and Thr15 to Trp, antisense 
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Table 2-3 
Summary of the best-fit parameters from the ArsD1-109-As EXAFS fitting analysisa.  
Fits in bold are the best fit for each sample. 
 
Ligand Environmentb Ligand Environmentb 
 
Sample Atomc R(Å)d C.N.e Å 2 f Atomc R(Å)d C.N.e Å 2 f F’ g 
ArsD1-109,C18G O/N 1.79 3.0 5.53     0.58 
 S 2.5 1 12.6     4.6 
 O/N 1.79 2.0 3.2 O/N 2.28 1.0 16.5 0.96 
 O/N 1.79 2.0 3.2 S 2.48 0.5 10.2 0.93 
          
ArsD1-109,C13G O/N 1.79 2.0 3.0     0.79 
 S 1.97 1 3.02     1.98 
 O/N 1.79 2.5 4.37 O/N 2.13 1.0 3.63 0.67 
 O/N 1.79 2.0 4.8 S 1.96 1.0 8.8 0.66 
          
ArsD1-109,C12G O/N 1.79 2.0 4.50     1.6 
 S 2.5 1 20.4     4.1 
 O/N 1.79 2.0 4.86 O/N 2.16 1.5 4.16 1.58 
 O/N 1.79 2.0 4.87 S 2.41 1.0 24.3 1.56 
          
ArsD1-109 O/N 2.08 3 0.9     3.86 
 S 2.24 3 2.4     0.89 
 O/N 2.01 2 -4.1 O/N 2.13 1 -7.8 6.01 
 O/N 2.06 0.5 4.4 S 2.24 3 2.6 0.84 
 
a Data were fit over a k range of 1 to 13 Å-1.   
b Independent metal-ligand scattering environment 
c Scattering atoms: O (oxygen), N (nitrogen), S (sulfur) and C (carbon), Cu (Copper) 
d Average metal-ligand bond length from three independent samples 
e Average metal-ligand coordination number from three independent samples 
f Average Debye-Waller factor in Å2 x 103 from three independent samples 
g Number of degrees of freedom weighted mean square deviation between data and fit.
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Table 3-1 
Strains and plasmids used in CHAPTER 3 
Strains/Plasmids Genotype/description Reference 
E.coli strains 
JM109 endA1, recA1, gyrA96, thi, hsdR17 (rk-, mk+), 
relA1, supE44, λ-, Δ(lac-proAB), [F’, 
traD36, proAB, lacIqZΔM15] 
(Sambrook et al., 
1989) 
BL21(DE3)  [F- ompT hsdSB (rB-mB-) gal dcm (DE3 [lacI 
lacUV5-T7 gene1 ind1 Sam7 nin5]) 
(Sambrook et al., 
1989) 
S. cerevisiae strains 
AH109 MATa, trp1-901, leu2-3, 112, ura3-52, his3-200, 
gal4∆, gal80∆, LYS2::GAL1UAS-GAL1TATA-HIS3, 
GAL2UAS-GAL2TATA-ADE2,URA3::MEL1UAS-
MEL1TATA-lacZ 
Clontech 
MAV203 MATα; leu2-3,112; trp1-901; his3Δ200; ade2-101; 
cyh2R; can1R; gal4Δ; gal80Δ; GAL1::lacZ; 
HIS3UASGAL1::HIS3@LYS2; SPAL10::URA3. 
Invitrogen 
Plasmids   
pGBT9 GAL4(1-147) DNA-binding domain, TRP1 (Apr) Clontech 
pACT2 GAL4(768-881) activation domain, LEU2 (Apr) Clontech 
pACT2-A arsA gene cloned in pACT2 (Apr) (Lin et al., 2006) 
pACT2-D arsD gene cloned in pACT2 (Apr) (Lin et al., 2006) 
pGBT9-D arsD gene cloned in pGBT9 (Apr) (Lin et al., 2006) 
pGBT9-k Kanamycin resistance gene is amplified from 
pET28a and inserted into pGBT9 at AatII site 
(Kanar) 
This study 
pGBT9-k-D Kanamycin resistance gene is amplified from 
pET28a and inserted into pGBT9-D at AatII 
site (Kanar) 
This study 
pGBT9-k-D G86E Selected by yeast two-hybrid (Kanar) This study 
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Table 3-1 
Strains and plasmids used in CHAPTER 3 (continued) 
Strains/Plasmids Genotype/description Reference 
Plasmids   
pAlter-dAhB Six histidine codons added to the 3’-
end of arsA gene (Apr) 
(Li and Rosen, 
2000) 
pET28a For expression of his-tagged protein 
controlled by T7 promoter (Kanar) 
Novagen 
pET28a-ArsD109 arsD1-109 truncation was inserted into 
pET28a through EcoRI and SalI sites 
(Kanar) 
Chapter 2 
pET28a-ArsD109 
G86E 
Gly86 was mutated to Glu by site 
directed mutagenesis on pET28a-
ArsD109 (Kanar) 
This study 
pET28a-ArsD109 
S68A/R87A/R96A 
Ser68, Arg87 and Arg96 were 
mutated to Ala by site directed 
mutagenesis on pET28a-ArsD109 
(Kanar) 
This study 
pET28a-ArsD109 
S68A/R87A/R96A/E81A/T8
2A/V83A/M84A 
Ser68, Arg87, Arg96, Glu81, Thr82, 
Val83 and Met84 were mutated to Ala 
by site directed mutagenesis on 
pET28a-ArsD109 (Kanar) 
This study 
pMAL-ArsD109 arsD1-109 truncation was fused to the 
C-terminal of MBP (Apr) 
(Lin et al., 
2007a) 
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Table 3-2 
Oligonucleotide primers used in CHAPTER 3 
Primer Sequence (5’–3’) Target / Direction 
GAL4-BD 
sequencing primer 
GAGTAGTAACAAAGGTCAA pGBT9 Forward sequencing 
primer 
T7 promoter 
sequencing primer 
TAATACGACTCACTATAGGG pET28a forward sequencing 
primer 
T7 terminator 
sequencing primer 
GCTAGTTATTGCTCAGCGG pET28a reverse sequencing 
primer 
pET28a-3600-
AatII 
CTATGACGTCCAACCCGGTAA
GACACGACTTATC 
Sense primer for amplifying 
kanamycin resistance gene 
from pET28a 
pET28a-5300-
AatII 
CTATGACGTCCGCCCGCTCCT
TTCGCTTTCTTCC 
Antisense primer for 
amplifying kanamycin 
resistance gene from 
pET28a 
pGBT9-s TAAAGATGCCGTCACAGATAGA
TTG 
Sense primer for ep-PCR of 
ArsD on pGBT9-k-D  
pGBT9-a ACCTGACCTACAGGAAAGAGTT
ACT 
Antisense primer for ep-
PCR of ArsD on pGBT9-k-D 
D109-XhoI CAGCTCGAGTTAAGGCGCTAA
TCCCACTTTATCCAG 
Using with pGBT9-s to 
amplify ArsD mutant gene 
from pGBT-k-DX vector to 
put into pET28 vector  
between EcoRI and XhoI 
ArsD-S68A-s GTTTATTGAAGCTGCCGGGGC
AGAAGGTC 
Mutate ArsD Ser68 to Ala, 
sense 
ArsD-S68A-a GACCTTCTGCCCCGGCAGCTT
CAATAAAC 
Mutate ArsD Ser68 to Ala, 
antisense 
ArsD-R87A-s GAAACAGTGATGGCCGGGGCT
TACCCGAAACGCGC 
Mutate ArsD Arg87 to Ala, 
sense 
ArsD-R87A-a GCGCGTTTCGGGTAAGCCCCG
GCCATCACTGTTTC 
Mutate ArsD Arg87 to Ala, 
antisense 
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Table 3-2 
Oligonucleotide primers used in CHAPTER 3 (continued) 
Primer Sequence (5’–3’) Target / Direction 
ArsD-R96A-s CGCGCTGAGCTGGCTGCCTGG
TTTGGCATTCCACTG 
Mutate ArsD Arg96 to Ala, 
sense 
ArsD-R96A-a CAGTGGAATGCCAAACCAGGC
AGCCAGCTCAGCGCG 
Mutate ArsD Arg96 to Ala, 
antisense 
ArsD-81-84A-s CATTGTTGTTACTGGATGGCGC
AGCAGCGGCAGCCGGGGCTTA
CCCGAAACG 
Mutate ArsD residues from 
81 to 84 to Ala, sense 
ArsD-81-84A-a CGTTTCGGGTAAGCCCCGGCT
GCCGCTGCTGCGCCATCCAGT
AACAACAATG 
Mutate ArsD residues from 
81 to 84 to Ala, antisense 
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Table 4-1 
Summary of study of interaction between copper-chaperone proteins and their targets 
 
Species Chaperone Target protein Yeast-2-hybrid In vitro binding NMR 
Enterococcus 
hirae CopZ CopY    
  CopA  SPR (Multhaup et al., 2001)  
Yeast Atx1 Ccc2 (Pufahl et al., 1997)  
Complex detected
(Arnesano et al., 
2001) 
  CAOs (Peter et al., 2008)   
human HAH1 MNK (Larin et al., 1999) 
Co-IP 
(Hamza et al., 
1999) 
Complex Not-
detected 
(Banci et al., 
2005) 
  WLN (van Dongen et al., 2004) 
Pull-down, Co-IP 
(Hamza et al., 
1999) 
Lower ratio of 
complex 
(Achila et al., 
2006) 
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Table 4-2 
Strains and plasmids used in CHAPTER 4 
Strains/Plasmids Genotype/description Reference 
E.coli strains 
JM109 endA1, recA1, gyrA96, thi, hsdR17 (rk-, mk+), 
relA1, supE44, λ-, Δ(lac-proAB), [F’, 
traD36, proAB, lacIqZΔM15] 
(Sambrook et al., 
1989) 
BL21(DE3)  [F- ompT hsdSB (rB-mB-) gal dcm (DE3 [lacI 
lacUV5-T7 gene1 ind1 Sam7 nin5]) 
(Sambrook et al., 
1989) 
S. cerevisiae strains 
AH109 MATa, trp1-901, leu2-3, 112, ura3-52, his3-200, 
gal4∆, gal80∆, LYS2::GAL1UAS-GAL1TATA-HIS3, 
GAL2UAS-GAL2TATA-ADE2,URA3::MEL1UAS-
MEL1TATA-lacZ 
Clontech 
MAV203 MATα; leu2-3,112; trp1-901; his3Δ200; ade2-101; 
cyh2R; can1R; gal4Δ; gal80Δ; GAL1::lacZ; 
HIS3UASGAL1::HIS3@LYS2; SPAL10::URA3. 
Invitrogen 
Plasmids   
pGBT9 GAL4(1-147) DNA-binding domain, TRP1 (Apr) Clontech 
pACT2 GAL4(768-881) activation domain, LEU2 (Apr) Clontech 
pACT2-A arsA gene cloned in pACT2 (Apr) (Lin et al., 2006)
pACT2-D arsD gene cloned in pACT2 (Apr) (Lin et al., 2006)
pGBT9-A arsA gene cloned in pGBT9 (Apr) (Lin et al., 2006) 
pGBT9-D arsD gene cloned in pGBT9 (Apr) (Lin et al., 2006) 
pGBT9-k Kanamycin resistance gene is amplified 
from pET28a and inserted into pGBT9 at 
AatII site (Kanar) 
Chapter 3 
pGBT9-k-D Kanamycin resistance gene is amplified 
from pET28a and inserted into pGBT9-D at 
AatII site (Kanar) 
Chapter 3 
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Table 4-2 
Strains and plasmids used in CHAPTER 4 (continued) 
Strains/Plasmids Genotype/description Reference 
Plasmids   
pGBT9-k-D S14R Ser14 was mutated to Arg by site directed 
mutagenesis on pGBT9-k-D (Kanar) 
This study 
pGBT9-k-D T20I Thr20 was mutated to Ile by site directed 
mutagenesis on pGBT9-k-D (Kanar) 
This study 
pGBT9-k-D Q24L Gln24 was mutated to Leu by site directed 
mutagenesis on pGBT9-k-D (Kanar) 
This study 
pGBT9-k-D D28V Asp28 was mutated to Val by site directed 
mutagenesis on pGBT9-k-D (Kanar) 
This study 
pGBT9-k-D D28T Asp28 was mutated to Thr by site directed 
mutagenesis on pGBT9-k-D (Kanar) 
This study 
pGBT9-k-D T31A Thr31 was mutated to Ala by site directed 
mutagenesis on pGBT9-k-D (Kanar) 
This study 
pGBT9-k-D Q34R Gln34 was mutated to Arg by site directed 
mutagenesis on pGBT9-k-D (Kanar) 
This study 
pGBT9-k-D Q38R Gln38 was mutated to Arg by site directed 
mutagenesis on pGBT9-k-D (Kanar) 
This study 
pGBT9-k-D V61A Val61 was mutated to Ala by site directed 
mutagenesis on pGBT9-k-D (Kanar) 
This study 
pGBT9-k-D F55L Selected by yeast two-hybrid (Kanar) This study 
pGBT9-k-D Q51H Selected by yeast two-hybrid (Kanar) This study 
pGBT9-k-D V22A Val22 was mutated to Ala by site directed 
mutagenesis on pGBT9-k-D (Kanar) 
This study 
pGBT9-k-D V17A Val17 was mutated to Ala by site directed 
mutagenesis on pGBT9-k-D (Kanar) 
This study 
pGBT9-k-D V27D Selected by yeast two-hybrid (Kanar) This study 
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Table 4-2 
Strains and plasmids used in CHAPTER 4 (continued) 
Strains/Plasmids Genotype/description Reference 
Plasmids   
pAlter-dAhB Six histidine codons added to the 3’-end of 
arsA gene (Apr) 
(Li and Rosen, 
2000) 
pET28a For expression of his-tagged protein 
controlled by T7 promoter (Kanar) 
Novagen 
pET28a-ArsD109 arsD1-109 truncation was inserted into 
pET28a through EcoRI and SalI sites 
(Kanar) 
Chapter 2 
pET28a-ArsD109 
K2/104A 
Lys2 and Lys104 were mutated to Ala by 
site directed mutagenesis on pET28a-
ArsD109 (Kanar) 
This study 
pET28a-ArsD109 
K2/104A-K37/62A 
Lys37 and Lys62 were mutated to Ala by 
site directed mutagenesis on pET28a-
ArsD109 K2/104A  (Kanar) 
This study 
pET28a-ArsD109 
K2/104A-K37/62R 
Lys37 and Lys62 were mutated to Arg by 
site directed mutagenesis on pET28a-
ArsD109 K2/104A  (Kanar) 
This study 
pET28a-ArsD109 
K2/104A-K60/90A 
Lys60 and Lys90 were mutated to Ala by 
site directed mutagenesis on pET28a-
ArsD109 K60/90A  (Kanar) 
This study 
pGBT9-k-D K2/104A-
K37/62A 
arsD K2/104A-K37/62A inserted into pGBT9-k 
(Kanar) between EcoRI and BamHI 
This study 
pGBT9-k-D K2/104A-
K37/62R 
arsD K2/104A-K37/62R inserted into pGBT9-k 
(Kanar) between EcoRI and BamHI 
This study 
pGBT9-k-D K2/104A-
K60/90A 
arsD K2/104A-K60/90A inserted into pGBT9-k 
(Kanar) between EcoRI and BamHI 
This study 
pGBT9-k-D K2/104A-
K37A 
arsD K2/104A-K37A inserted into pGBT9-k 
(Kanar) between EcoRI and BamHI 
This study 
pGBT9-k-D K2/104A-
K62A 
arsD K2/104A-K62A inserted into pGBT9-k 
(Kanar) between EcoRI and BamHI 
This study 
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Table 4-3 
Oligonucleotide primers used in CHAPTER 4 
Primer Sequence (5’–3’) Target / Direction 
GAL4-BD   
sequencing primer 
GAGTAGTAACAAAGGTCAA pGBT9 Forward sequencing 
primer 
GAL4-AD 
sequencing primer 
AATACCACTACAATGGAT pACT2 Forward sequencing 
primer 
ArsA-100-s GTCCTGCCTGATGACGTTGTTT
CCA 
ArsA forwarding sequencing 
primer from 100th residue 
ArsA-220-s GTCGCCCGGACTCATCTGGAA
CTTG 
ArsA forwarding sequencing 
primer from 220th residue 
ArsA-420-s AAGAGGACTTACGCTCACCTTG
CAC 
ArsA forwarding sequencing 
primer from 420th residue 
ArsA-480-a CGTGACCAGTAACACTTTAGTG
CG 
ArsA reversing sequencing 
primer from 480th residue 
pET28a-3600-
AatII 
CTATGACGTCCAACCCGGTAA
GACACGACTTATC 
Sense primer for amplifying 
kanamycin resistance gene 
from pET28a 
pET28a-5300-
AatII 
CTATGACGTCCGCCCGCTCCT
TTCGCTTTCTTCC 
Antisense primer for 
amplifying kanamycin 
resistance gene from 
pET28a 
pGBT9-s TAAAGATGCCGTCACAGATAGA
TTG 
Sense primer for ep-PCR of 
ArsD on pGBT9-k-D  
pGBT9-a ACCTGACCTACAGGAAAGAGTT
ACT 
Antisense primer for ep-
PCR of ArsD on pGBT9-k-D 
 pACT2-s CTATTCGATGATGAAGATACCC
CACCAAACCC 
Sense primer for ep-PCR of 
ArsA on pACT2-A 
 pACT2-a AGGTTACATGGCCAAGATTGAA
ACTTAGAGGAG Antisense primer for ep-PCR of ArsA on pACT2-A 
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Table 4-3 
Oligonucleotide primers used in CHAPTER 4 (continued) 
Primer Sequence (5’–3’) Target / Direction 
ArsD-S14R-s ACCCGGCGATGTGTTGCAGAAC
CGGCGTCTGCGGTACAG 
Mutate ArsD Ser14 to Arg, 
sense 
ArsD-S14R-a CTGTACCGCAGACGCCGGTTCT
GCAACACATCGCCGGGT 
Mutate ArsD Ser14 to Arg, 
antisense 
ArsD-T20I-s CACCGGCGTCTGCGGTATAGAT
GTTGATCAGGCTCT 
Mutate ArsD Thr20 to Ile, 
sense 
ArsD-T20I-a AGAGCCTGATCAACATCTATAC
CGCAGACGCCGGTG 
Mutate ArsD Thr20 to Ile, 
antisense 
ArsD-Q24L-s GCGGTACAGATGTTGATCTGGC
TCTGGTCGATTTTTC 
Mutate ArsD Gln24 to Leu, 
sense 
ArsD-Q24L-a GAAAAATCGACCAGAGCCAGAT
CAACATCTGTACCGC 
Mutate ArsD Gln24 to Leu, 
antisense 
ArsD-D28V-s GTTGATCAGGCTCTGGTCGTTT
TTTCTACAGATGTGCAAT 
Mutate ArsD Asp28 to Val, 
sense 
ArsD-D28V-a ATTGCACATCTGTAGAAAAAAC
GACCAGAGCCTGATCAAC 
Mutate ArsD Asp28 to Val, 
antisense 
ArsD-D28T-s TGATCAGGCTCTGGTCACTTTT
TCTACAGATGTGC 
Mutate ArsD Asp28 to Thr, 
sense 
ArsD-D28T-a GCACATCTGTAGAAAAAGTGAC
CAGAGCCTGATCA 
Mutate ArsD Asp28 to Thr, 
antisense 
ArsD-T31A-s GGCTCTGGTCGATTTTTCTGCA
GATGTGCAATGGCTCAA 
Mutate ArsD Thr31 to Ala, 
sense 
ArsD-T31A-a TTGAGCCATTGCACATCTGCAG
AAAAATCGACCAGAGCC 
Mutate ArsD Thr31 to Ala, 
antisense 
ArsD-Q34R-s CGATTTTTCTACAGATGTGCGA
TGGCTCAAACAATGCGG 
Mutate ArsD Gln34 to Arg, 
sense 
ArsD-Q34R-a CCGCATTGTTTGAGCCATCGCA
CATCTGTAGAAAAATCG 
Mutate ArsD Gln34 to Arg, 
antisense 
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Table 4-3 
Oligonucleotide primers used in CHAPTER 4 (continued) 
Primer Sequence (5’–3’) Target / Direction 
ArsD-Q38R-s GATGTGCAATGGCTCAAACGAT
GCGGTGTACAAATTGAG 
Mutate ArsD Gln38 to Arg, 
sense 
ArsD-Q38R-a CTCAATTTGTACACCGCATCGT
TTGAGCCATTGCACATC 
Mutate ArsD Gln38 to Arg, 
antisense 
ArsD-V61A-s CTTTGTACAGAACGAGAAGGCC
AAAGCGTTTATTGAAGCTT 
Mutate ArsD Val61 to AIa, 
sense 
ArsD-V61A-a AAGCTTCAATAAACGCTTTGGC
CTTCTCGTTCTGTACAAAG 
Mutate ArsD Val61 to AIa, 
antisense 
ArsD-K2A-s ATCCGAATTCCCGGGGGCAAC
GTTAATGGTATTTGA 
Mutate ArsD Lys2 to Ala on 
pET28a-ArsD109, sense 
ArsD-K2A-a TCAAATACCATTAACGTTGCCC
CCGGGAATTCGGAT 
Mutate ArsD Lys2 to Ala on 
pET28a-ArsD109, antisense
ArsD-K37A-s ACAGATGTGCAATGGCTCGCAC
AATGCGGTGTACAAAT 
Mutate ArsD Lys37 to Ala, 
sense 
ArsD-K37A-a ATTTGTACACCGCATTGTGCGA
GCCATTGCACATCTGT 
Mutate ArsD Lys37 to Ala, 
antisense 
ArsD-K62A-s TACAGAACGAGAAGGTCGCAG
CGTTTATTGAAGCTTC 
Mutate ArsD Lys62 to Ala, 
sense 
ArsD-K62A-a GAAGCTTCAATAAACGCTGCGA
CCTTCTCGTTCTGTA 
Mutate ArsD Lys62 to Ala, 
antisense 
ArsD-K104A-s TTGGCATTCCACTGGATGCAGT
GGGATTAGCGCCTT 
Mutate ArsD Lys104 to Ala, 
sense 
ArsD-K104A-a AAGGCGCTAATCCCACTGCATC
CAGTGGAATGCCAA 
Mutate ArsD Lys104 to Ala, 
antisense 
ArsD-K60A-s AGCTTTGTACAGAACGAGGCGG
TCAAAGCGTTTATTGA 
Mutate ArsD Lys60 to Ala, 
sense 
ArsD-K60A-a TCAATAAACGCTTTGACCGCCT
CGTTCTGTACAAAGCT 
Mutate ArsD Lys60 to Ala, 
antisense 
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Table 4-3 
Oligonucleotide primers used in CHAPTER 4 (continued) 
Primer Sequence (5’–3’) Target / Direction 
ArsD-K90A-s ATGGCCGGGCGTTACCCGGCA
CGCGCTGAGCTGGCTCGC 
Mutate ArsD Lys90 to Ala, 
sense 
ArsD-K90A-a GCGAGCCAGCTCAGCGCGTGC
CGGGTAACGCCCGGCCAT 
Mutate ArsD Lys90 to Ala, 
antisense 
ArsD-K37R-s ACAGATGTGCAATGGCTCAGAC
AATGCGGTGTACAAAT 
Mutate ArsD Lys37 to Arg, 
sense 
ArsD-K37R-a ATTTGTACACCGCATTGTCTGA
GCCATTGCACATCTGT 
Mutate ArsD Lys37 to Arg, 
antisense 
ArsD-K62R-s TACAGAACGAGAAGGTCAGAGC
GTTTATTGAAGCTTC 
Mutate ArsD Lys62 to Arg, 
sense 
ArsD-K62R-a GAAGCTTCAATAAACGCTCTGA
CCTTCTCGTTCTGTA 
Mutate ArsD Lys62 to Arg, 
antisense 
Ec-N-ArsD-K2A-s TCCGGAATTCATGGCAACGTTA
ATGGTATTTG 
Sense primer for amplifying 
ArsD K2/104A mutants to put 
into pGBT9-k between 
EcoRI and BamHI 
Bm-D109-K104A-a CGCGGATCCTTAAGGCGCTAAT
CCCACTGCATCCAG 
Antisense primer for 
amplifying ArsD K2/104A 
mutants to put into pGBT9-k 
between EcoRI and BamHI 
T7 promoter 
sequencing primer 
TAATACGACTCACTATAGGG pET28a forward sequencing 
primer 
T7 terminator 
sequencing primer 
GCTAGTTATTGCTCAGCGG pET28a reverse sequencing 
primer 
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Table 4-4 
ArsD mutations increasing or decreasing ArsA-ArsD interaction  
method effect mutations 
yeast two-hybrid stronger interaction with ArsA S14R, T20I, Q24L, D28T, 
D28V, T31A, Q34R, Q38R, 
V61A 
yeast two-hybrid weaker interaction with ArsA V17A, V22A, V27D, Q51H, 
F55L 
site-directed 
mutagenesis 
weaker interaction with ArsA K37A, K62A 
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Figure 1-1. Structure of R773 ArsA ATPase (Lin et al., 2007b).   
 
(A): The overall structure of ArsA is shown as a ribbon diagram.  Mg2+-ADP is bound to 
each of the two NBDs in the A1 and A2 halves of ArsA, while three Sb(III) are bound at 
the single MBD.   
(B)  The metalloid binding domain composed of three 3-coordinate As(III)/Sb(III) binding 
sites. Each site has two protein ligands, one from A1 and one from A2, plus a non-
protein ligand that appears to be a chloride in the crystal structure but could be a 
hydroxyl in the native protein.  The high affinity site is composed of Cys-113 from A1 
and Cys-422 from A2.  The other two sites are composed of His-148 from A1 and Ser-
420 from A2 and Cys-172 from A1 and His-453 from A2.  The two histidines come from 
the signal transduction domains (D142/447TAPTGH148/453) that connect the two nucleotide 
binding domains, NBD1 and NBD2, to the MBD.  Binding of metalloid acts like 
molecular glue to hold A1 and A2 in a conformation in which residues from both 
contribute to the formation of NBD1 and NBD2.  Thus metalloid binding increases the 
affinity of NBD1 and NBD2 and activates catalysis. 
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MBD
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Figure 2-1. Normalized XANES spectra of ArsD and its derivatives.  
 
Spectra from top to bottom include: C18G (A), C13G (B), C12G (C) and wild type 
ArsD109 (D). Spectra were offset for clarity. 
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Figure 2-2. ArsD EXAFS data and simulations.   
 
Raw EXAFS data and phase shifted Fourier Transforms of As bound to C18G (A, B), 
C13G (C, D), C12G (E, F) and wild type ArsD109 (G, H). Raw unfiltered data is given as 
solid lines, while the best-fit simulated data are shown as dotted lines. 
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Figure 2-3. ArsD109 tryptophan mutants fold normally and have same activity as 
wild type.  
 
(A) Circular CD spectra were collected with (●) 10 μM ArsD109, (Δ) tryptophan-free 
ArsD109-W35Y/W97Y, (■) T15W and (◊) V17W.  
(B) ArsA ATPase activity was assayed at the indicated concentrations of sodium 
arsenite in the presence or absence of ArsD derivatives. ArsA ATPase activity was 
assayed as described under “Materials and Methods”. (●), no addition; (○), ArsD109; 
(▼), tryptophan-free ArsD109-W35Y/W97Y; , T15W. The curves were fitted using 
SigmaPlot 9.0, with error bars represent standard deviation. 
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Figure 2-4. Protein fluorescence of single tryptophan derivatives T15W and 
V17W reports metalloid binding.   
 
Emission scans were performed with excitation at 295 nm, as described under Materials 
and Methods. 
(A) (▼), 1 µM tryptophan; (●), tryptophan-free W35Y/97Y; (■), T15W; (▲), V17W; (○), 
W35Y/97Y + 6 M guanidine-HCl; (□), T15W + 6 M guanidine-HCl; (Δ), V17W + 6 M 
guanidine-HCl.   
(B) (○), T15W; (V), T15W + 5 mM As(III); (□), T15W + 0.1 mM Sb(III);  (●), V17W; (▼), 
V17W + 5 mM As(III); (■), V17W + 0.1 mM Sb(III); (◊), tryptophan-free W35Y/97Y. 
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Figure 2-5. Binding of As(III) by single tryptophan derivatives T15W and V17W 
and cysteine mutants.   
 
(A) Time course of 1 µM V17W fluorescence quenched by different concentration of 
As(III). The data were fitted using SigmaPlot 9.0 with function F=F0-Fm*(1-e-kobst), in 
which Kobs is the binding rate used in Fig B. 
(B) The rate of fluorescence quenching, Kobs, was determined as a function of arsenite 
concentration with excitation and emission wavelengths of 295 and 345 nm, 
respectively.  (●), T15W; (○), V17W; (■), T15W/C12G; (Δ), T15W/C13G; (▼), 
T15W/C18G.  The data were fitted using SigmaPlot 9.0, with error bars representing the 
standard deviation from three assays. 
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Figure 2-6. GSH accelerates binding of As(III) binding by V17W.    
 
The rate of fluorescence quenching, Kobs, was determined as a function of pH in the 
presence (○) or absence (●) of 5 mM GSH. 
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Figure 2-7. As(GS)3 is the metalloid donor to ArsD.   
 
Fluorescence of V17W was measured with excitation and emission wavelengths of 295 
and 345 nm, respectively.   
(A) At the arrow the following additions were made:  (▲), 50 µM As(III); (V), 0.2 mM 
GSH followed by 50 µM As(III); (◊), 5 mM TCEP followed by 50 µM As(III); (●), 5 mM 
GSH followed by 50 µM As(III); (■), 50 µM As(GS)3.  
(B) At the arrow the following additions were made:  (●), 50 µM As(III); (○), 5 mM L-
cysteine followed by 50 µM As(III); (▼), 5 mM β-mercaptoethanol followed by 50 µM 
As(III); (Δ), 2.5 µM Sb(III). 
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Figure 2-8. As(GS)3 does not activate ArsA. 
 
Activated ATPase activity of 0.3 µM ArsA was determined at the indicated 
concentrations of sodium arsenite, as described under Materials and Methods. (●), no 
addition; (○), 5 mM GSH; (■), 6 µM ArsD.  The data were fitted using SigmaPlot 9.0, 
with error bars representing the standard deviation from three assays. 
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Figure 2-9. GSH helps cooperation of ArsA and ArsD. 
 
(A) ATPase activity of 0.3 µM ArsA was determined at the indicated concentrations of 
sodium arsenite in the presence of 3 µM ArsD in buffer with or without 5mM GSH. ArsA 
ATPase activity was assayed as described under “Materials and Methods”. (●), no 
addition; (○), 5 mM GSH. The curves were fitted using SigmaPlot 9.0, with error bars 
representing standard deviation from three assays. 
(B) The apparent affinity of ArsA for As(III), in ArsA ATPase activity assay, was 
determined at different concentrations of ArsD in different buffers. The enhancement of 
apparent affinity of ArsA for As(III) by ArsD was measured in buffers supplemented with 
or without TCEP and GSH. (●), buffer alone; (▼), buffer supplemented with 5mM TCEP; 
(○), buffer supplemented with 5mM glutathione.   
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Figure 2-10. ArsD channels As(III) to ArsA.   
 
The effect of the As(III) chelator DMSA on metalloid transfer from ArsD to ArsA was 
estimated from the activation of ATPase activity of 0.3 μM ArsA, as described under 
Materials and Methods.  ATP hydrolysis was measured in the presence of the indicated 
concentrations of DMSA with (●) ArsA alone, (V) ArsA + 0.5 mM sodium arsenite or (■) 
ArsA + 0.5 mM sodium arsenite plus 6 μM ArsD.  The error bars represent the standard 
deviation from three assays. 
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Figure 2-11. Metalloid transfer from ArsD occurs during ArsA catalysis. 
 
As(III) transfer assays were performed as described under Materials and Methods.  
MBP-ArsD was bound to an amylose resin, following the column was charged with 
sodium arsenite to saturate ArsD.  Next purified ArsA or BSA were applied to the 
columns with the indicated nucleotides (5 mM) at room temperature unless otherwise 
noted. Experiments were done at room temperature, except experiment in F was done 
at 4ºC.  (A), 10 fractions were collected and analyzed by SDS PAGE. Nearly all of the 
BSA or ArsA eluted in fraction 2, and fraction 9 contained nearly all of the MBP–ArsD.   
Nucleotides:  (B), ArsA + MgATP; (C), BSA + MgATP, (D), ArsA + MgADP; (E), ArsA + 
MgATP-γ-S; (F), ArsA + MgATP at 4ºC. The concentration of protein (open bar) and 
As(III) (●) was quantified in each fraction.  The error bars represent the standard 
deviation from three assays. 
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Figure 2-12. Model of transfer from As(GS)3 to ArsD to ArsA.  
 
In the first step As(OH)3 forms As(GS)3 with intracellular GSH. In the next step ArsD 
extracts As(III) from As(GS)3 by thiol exchange with residues Cys12, Cys13 and Cys18. 
In a step-wise series of thol exchanges (with an unknown order), the bound As(III) is 
transferred to the thiolates Cys113, Cys172 and Cys422 of ArsA when the two 
nucleotide binding domains, NBD1 and NBD2, hydrolyze ATP.  Binding of As(III) and 
ATP induces a series of conformational changes in ArsA resulting in activation of 
catalysis, with final extrusion of the metalloid out of the cells. 
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Figure 3-1. MBP-ArsD109 and His6-ArsD109 both stimulate ArsA ATPase activity.  
 
ArsA ATPase activity was assayed at the indicated concentrations of sodium arsenite in 
the presence or absence of ArsD derivatives. ArsA ATPase activity was assayed as 
described under “Materials and Methods”. (●), no addition; (○), MBP-ArsD109; (▼), 
His6-ArsD109. The curves were fitted using SigmaPlot 9.0, with error bars representing 
standard deviation from three assays. 
[As(III)] (μM)
0 200 400 600 800 1000
A
rs
A
 A
TP
as
e 
ac
tiv
ity
 (n
m
ol
.m
in
-1
.m
g-
1 )
0
100
200
300
400
0.3μM ArsA, K1/2=522μM
0.3μM ArsA + 6μM MBP-ArsD109, K1/2=13μM
0.3μM ArsA + 6μM His-tag ArsD109, K1/2=18μM
  
 
127
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-2. Dimerization equilibrium states of MBP-ArsD109 and His6-ArsD109.  
 
(A) 2.4 mg of MBP-ArsD109 in 1 ml of buffer was loaded to a 1.5 cm diameter column 
filled with 165 ml Sephacryl-200 gel-filtration column on a Bio-rad Biological LP 
chromatography system as described under “Materials and Methods”. 1.5 mg aldolase, 
1.5 mg conalbumin, and 1.5 mg albumine were used as internal standards. The column 
was washed with 200 ml of column buffer. Elutions were collected as 1.5 ml each 
fraction. Fractions 59-83 were analyzed by 12 % SDS-PAGE.  
 (B) 2 mg of His6-ArsD109 in 1 ml of buffer was separated by Superdex-75 
chromatography as above. 1.5mg ovalbumin, 1.5mg carbonic anhydrase and 1.5mg 
ribonuclease were used as internal standards. The column was washed with 200ml of 
column buffer. Elutions were collected as 1.5ml each fraction. Fractions 66-102 were 
analyzed by 16 % SDS-PAGE.  
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Figure 3-3. ArsD dimerization interface in crystal structure.  
 
The ArsD dimerization interface was rendered with Pymol software. Subunit A is colored 
in green and subunit B is colored in cyan. The residues involved in potential hydrogen 
and salt bridge were shown in stick form and labeled. The distances of hydrogen bond 
and the salt bridge was measured, with distances labeled in blue. The unit for distance 
is Å.  
(A) Cartoon view. 
(B) Ribbon view. 
(C) Ribbon view of magnified dimerization interface. 
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Figure 3-4. His6-ArsD109S68A/R87A/R96A shifts equilibrium to monomer and still 
activates ArsA ATPase activity.  
 
(A) 2 mg His6-ArsD109S68A/R87A/R96A in 1 ml of buffer was separated by Superdex-75 gel 
chromatography, as described above. Fractions 66-102 were analyzed by 16% SDS-
PAGE. 
(B) 2 mg His6-ArsD109S68A/R87A/R96A/E81A/T82A/V83A/M84A in 1 ml of buffer was separated by 
Superdex-75 gel chromatography, as described above. Fractions 66-105 were analyzed 
by 16 % SDS-PAGE. 
(C) ArsA ATPase activity was assayed at the indicated concentrations of sodium 
arsenite in the presence or absence of ArsD derivatives. ArsA ATPase activity was 
assayed as described under “Materials and Methods”. (●), no addition; (Δ), His6-
ArsD109; (■), His6-ArsD109S68A/R87A/R96A/E81A/T82A/V83A/M84A. The curves were fitted using 
SigmaPlot 9.0, with error bars representing standard deviation from three assays. 
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Figure 3-5. Dimerization equilibrium of His6-ArsD109G86E shifts to monomer. 
 
(A) Yeast two-hybrid analysis was performed as described under “Materials and 
Methods.” S. cerevisiae strain AH109 bearing both GAL4 activation domain (AD) and 
binding domain (BD) fusion plasmids was grown in SD medium overnight and 
inoculated on agar plates with SD lacking histidine with 10-fold serial dilutions. The first 
row was cells with the empty vector serving as control. ArsD and ArsD mutants were 
fused to BD domain, as indicated on the left side. They are tested with ArsA fused to AD 
(left panel) or ArsD fused to AD (right panel). 
(B) 2 mg His6-ArsD109G86E in 1 ml of buffer was separated by Superdex-75 gel 
chromatography, as described above.. Fractions 69-108 were analyzed by 16 % SDS-
PAGE. 
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Figure 3-6. His6-ArsD109G86E activates ArsA ATPase.  
 
ArsA ATPase activity was assayed at the indicated concentrations of sodium arsenite in 
the presence or absence of ArsD derivatives. ArsA ATPase activity was assayed as 
described under “Materials and Methods”. (●), no addition; (Δ), His6-ArsD109; (■), His6-
ArsD109G86E. The curves were fitted using SigmaPlot 9.0, with error bars representing 
standard deviation from three assays. 
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Figure 3-7. Comparison of R773 ArsD structure and Bacteroides vulgatus ATCC 8482 ArsD.  
 
R773 ArsD structure (pdb: 3KGK) and Bacteroides vulgatus ATCC 8482 ArsD structure (pdb: 3KTB) were compared and 
presented in cartoon view with Pymol software.  
(A) R773 ArsD structure (pdb: 3KGK) in cartoon view. 
(B) Alignment of chain A of R773 ArsD (3KGK) with chain A of Bacteroides vulgatus ATCC 8482 ArsD (3KTB) with 
cysteine residues shown in stick. 
(C) Bacteroides vulgatus ATCC 8482 ArsD structure (pdb: 3KTB) in cartoon view with cysteine residues shown in stick. 
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Figure 3-8. ArsDP52L dimerize more strongly with wild type ArsD in yeast two-hybrid.  
 
S. cerevisiae strain AH109 bearing both GAL4 activation domain (AD) and binding domain (BD) fusion plasmids was 
grown in SD medium overnight and inoculated with 10-fold serial dilutions on SD agar plates, lacking histidine and 
supplemented with different concentrations of 3-AT. Top panel shows wild-type ArsD and ArsD P52L fused to BD co-
transformed with wild-type ArsD fused to AD. Bottom panel shows wild-type ArsD and ArsD P52L fused with BD co-
transformed with wild-type ArsA fused to AD.  
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Figure 3-9. A hypothetic dimerization interface.  
 
R773 ArsD structure (pdb: 3KGK) was rendered by Pymol, with backbone shown as cartoon. A patch of residues 
including Leu48, Phe52, Met53, Phe55, Val56, Val61, Ile66 and Ala70 was shown with stick and labeled. These residues 
are colored in magenta in one subunit and blue in another subunit. 
(A) Full view of a second dimerization interface between subunits from different asymmetric units. 
(B) Magnified view of the interface. 
(C) and (D) view of the hydrophobic patch from the top. 
(E) Interface shown with the surface of the hydrophobic patch. 
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Figure 4-1. ArsD mutants showing stronger interaction with ArsA.  
 
S. cerevisiae strain AH109 bearing both GAL4 activation domain (AD) and binding domain (BD) fusion plasmids was 
grown in SD medium overnight and inoculated with 10-fold serial dilutions on SD agar plates, lacking histidine and 
supplemented with different concentrations of 3-AT. Left 4 strips show wild-type ArsD or ArsD mutants fused to BD co-
transformed with wild-type ArsA fused to AD. Right 4 strips show wild-type or ArsD mutants fused with BD co-transformed 
with wild-type ArsD fused to AD. The ArsD mutants were indicated on the left. 
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Figure 4-2. Mutating Lys37 and Lys62 to alanine abolishes ArsD function as an 
arsenic chaperone.  
 
ArsA ATPase activity was assayed at the indicated concentrations of sodium arsenite in 
the presence or absence of ArsD derivatives. ArsA ATPase activity was assayed as 
described under “Materials and Methods”. The curves were fitted using SigmaPlot 9.0, 
with error bars represent standard deviation. 
(A) (○), no addition; (●), ArsD109; (▼), ArsD109K2/104A-K37/62A; (Δ), ArsD109K2/104A; (□), 
ArsD109K37A; (■), ArsD109K62A. 
(B) (●), no addition; (○), ArsD109; (▲), ArsD109K2/104A-K60/90A; (Δ), ArsD109K2/104A-K37/62A; 
(▼), ArsD109K2/104A-K37/62R.  
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Figure 4-3. Acetylation of Lys37 and Lys62 sabotages ArsD metallochaperone 
function.  
 
ArsA ATPase activity was assayed at the indicated concentrations of sodium arsenite in 
the presence or absence of ArsD derivatives. ArsA ATPase activity was assayed as 
described under “Materials and Methods”. (●), no addition; (□), ArsD109; (■), acetylated 
ArsD109; (▲), ArsD109K2/104A-K60/90A; (Δ), acetylated ArsD109K2/104A-K60/90A; (▼), 
ArsD109K2/104A-K37/62R; (▼), acetylated ArsD109K2/104A-K37/62R. The curves were fitted 
using SigmaPlot 9.0, with error bars represent standard deviation. 
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Figure 4-4. ArsD K2/104A-K37/62A still binds As(III) but does not interact with ArsA. 
 
(A) The antimony binding ability of ArsD and ArsD mutants was measured by mixing 
100 μM of ArsD and 300 μM of potassium antimonyl tartrate. After incubation, the 
mixture was passed through gel-filtration column to remove free antimony. Then protein 
concentration and antimony concentration was determined to get the antimony binding 
molar ratio. Details were described under “Materials and Methods”, and error bars 
represent standard deviation. 
(B) Yeast two-hybrid analysis was performed as described under “Materials and 
Methods.” S. cerevisiae strain AH109 bearing both GAL4 activation domain (AD) and 
binding domain (BD) fusion plasmids was grown in SD medium overnight and 
inoculated on agar plates with SD lacking histidine with 10-fold serial dilutions. The first 
row was cells with the vector serving as control. ArsD and ArsD mutants were fused to 
BD domain, as indicated on the left side. They are tested with ArsA fused to AD (left 
panel) or ArsD fused to AD (right panel). 
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Figure 4-5. ArsD mutants showing weaker interaction with ArsA and the corresponding complementary ArsA 
mutants.  
 
Yeast two-hybrid analysis was performed as described under “Materials and Methods.” S. cerevisiae strain AH109 
bearing both GAL4 activation domain (AD) and binding domain (BD) fusion plasmids was grown in SD medium overnight 
and inoculated on agar plates with SD lacking histidine with 10-fold serial dilutions. 
 
(A) wild-type ArsD or ArsD mutants fused with BD domain were co-transformed with AD-ArsA (ArsA fused with AD) or 
AD-ArsD (ArsD fused with AD). As a negative control, AD vector (pACT2) and BD vector (pGBT9) were co-transformed. 
(B) ArsA complementary mutants restore interaction with ArsDV22A. Wild-type ArsA or ArsA mutants fused with AD domain 
were co-transformed with BD-ArsD (ArsD fused with BD) or BD-ArsDV22A (ArsDV22A fused with BD). 
(C) ArsA complementary mutants restore interaction with ArsDF55L. Wild-type ArsA or ArsA mutants fused with AD domain 
were co-transformed with BD-ArsD (ArsD fused with BD) or BD-ArsDF55L (ArsDF55L fused with BD). 
(D) ArsA complementary mutants restore interaction with ArsDQ51H. Wild-type ArsA or ArsA mutants fused with AD domain 
were co-transformed with BD-ArsD (ArsD fused with BD) or BD-ArsDQ51H (ArsDQ51H fused with BD). 
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Figure 4-6. ArsA mutants showing stronger interaction with ArsD.  
 
S. cerevisiae strain AH109 bearing both GAL4 activation domain (AD) and binding domain (BD) fusion plasmids was 
grown in SD medium overnight and inoculated with 10-fold serial dilutions on SD agar plates, lacking histidine and 
supplemented with different concentrations of 3-AT. Wild-type ArsA and ArsA mutants fused with AD domain were co-
transformed with BD-ArsD (ArsD fused with BD domain). 
 
• ArsA mutant 4: F54L, F120L, H219R, E254V, F443L, K475R, A533T
• ArsA mutant 7: D121G,E405V,E415V,H558R
• ArsA mutant 8: P9L, L74H, D121G, F123L, E425A
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Figure 4-7. Mapping mutations on ArsD structure.  
 
An ArsD structure model based on R773 ArsD structure (pdb: 3KGK) was used to show all mutations with effect on ArsA-
ArsD interaction (Ye et al., 2010). The figures are generated with Pymol software. Three cysteine residues Cys12, Cys13 
and Cys18 are colored in magenta. Residues Val17, Val22, Val27, Lys37, Gln51, Phe55 and Lys62, lowing down the 
interaction strength, are colored in red. Residues Ser14, Thr20, Gln24, Asp28, Thr31, Gln34, Gln38 and Val61, increasing 
interaction strength, are colored in blue. All these residues are shown with stick. 
(A) in cartoon view. 
(B) in cartoon view with surface. 
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Figure 4-8. Mapping mutations on ArsA structure.  
 
ArsA structure (pdb: 1F48) was used to show all mutations with effect on ArsA-ArsD interaction. The figures are 
generated with Pymol software. ArsA-A1 part (residues 1-297) is shown in green. ArsA-A2 part (residues 308-586) is 
shown in orange. Three cysteine residues Cys113, Cys172 and Cys422 are colored in magenta. Residues Phe120, 
Asp121 and Glu425, increasing interaction strength, are colored in blue. All these residues are shown with stick. 
(A) front view. 
(B) bottom view. 
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Figure 4-9. Comparison of ArsA and Get3 structure (Ye et al., 2010).  
 
ArsA was superimposed with closed and open Get3. 
(A) Superimposition of ArsA (PDB ID: 1IHU) with Get3 closed structure (PDB ID: 2WOJ).  ArsA-A1 (green), ArsA-A2 
(orange), Get3 monomer-1 (Blue) and Get3 monomer-2 (light-blue) are shown as cartoon.  
(B) Superimposition of ArsA-A1 (residues 1-297) and ArsA-A2 (residues 298-583) with Get3 open structure 
(2WOO).  ArsA-A1 (green), ArsA-A2 (orange), Get3 monomer-1 (Blue) and Get3 monomer-2 (gray) are shown as 
cartoon.  
(C) ArsA open structure was modeled based on the Get3 open structure. ArsA-A1 (green) and ArsA-A2 (orange) are 
shown as a cartoon representation.  Cysteine residues are shown in ball and stick with yellow color. 
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Figure 4-10. Structure model of ArsA-ArsD complex (Ye et al., 2010).  
 
ArsA-ArsD model was calculated with Cluspro docking server. One of the best models is shown here.  ArsA is rendered 
as cartoon with green and orange color. ArsD model is shown in cyan.  As(III)/Sb(III) atom is shown as solid sphere in 
magenta color and cysteines (yellow) are shown as ball and stick.   
(A) In cartoon view. 
(B) Figure 8A is shown in surface representation with 40% transparency. 
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 Arsenic is a metalloid toxicant that is widely distributed throughout the earth’s 
crust and causes a variety of health and environment problems. As an adaptation to 
arsenic-contaminated environments, organisms have developed resistance systems. In 
bacteria and archaea various ars operons encode ArsAB ATPases that pump the 
trivalent metalloids As(III) or Sb(III) out of cells. In these operons, an arsD gene is 
almost always adjacent to the arsA gene, suggesting a related function. ArsA is the 
catalytic subunit of the pump that hydrolyzes ATP in the presence of arsenite or 
antimonite.  ArsB is a membrane protein which containing arsenite-conducting pathway. 
ArsA forms complex with ArsB, therefore ATP hydrolysis is coupled to extrusion of As(III) 
or Sb(III) through ArsB.  
 Most transition and heavy metal ions do not exist as free ions in the cytosol but 
are sequestered by a variety of proteins called metal ion chaperones, scaffolds or 
intracellular carriers. ArsD was recently shown to be a chaperone for transfer of 
cytosolic As(III) to the 583-residue ArsA ATPase, the catalytic subunit of the efflux pump. 
ArsD is a 120-residue protein with three conserved cysteine residues, Cys12, Cys13 
and Cys18 required for chaperone activity. ArsA exhibits a low, basal rate of ATPase 
  
 
174
activity in the absence of As(III) or Sb(III) and a higher, activated rate in their presence.  
ArsA has a high affinity metalloid binding site composed of Cys113 and Cys422 and a 
third residue, Cys172, which participates in high affinity binding and activation of ATP 
hydrolysis. By directly transferring As(III) to ArsA, ArsD also increased ArsA ATPase 
activity at environmental concentrations of arsenic. Therefore, ArsAB pump efficiency is 
increased and less As(III) will be accumulated in the cells. In analogy with the 
mechanism of copper transfer from chaperones to copper pumps or enzymes, a step-
wise transfer of As(III) from the cysteines of ArsD to the cysteines of ArsA, was 
proposed.    
 The properties of As(III) binding by ArsD and subsequent transfer to ArsA were 
examined. X-ray absorption spectroscopy was used to show that As(III) is coordinated 
with three sulfur atoms, consistent with Cys12, Cys13 and Cys18 forming the As(III) 
binding site. An assay using intrinsic protein fluorescence was developed as a probe of 
metalloid binding to ArsD.  Two single tryptophan derivatives of ArsD were constructed 
by changing either Thr15 or Val17 to tryptophan in a tryptophan-free background. Both 
exhibited quenching of fluorescence upon binding of As(III) or Sb(III), from which the 
apparent affinity for metalloid could be estimated. Since it is likely that cytosolic As(III) is 
bound to reduced glutathione (GSH), the effect of GSH on binding to ArsD was 
examined.  GSH greatly increased the rate of binding As(III) to ArsD, suggesting that 
ArsD accepts metalloid from the As(GS)3 complex. In contrast, GSH did not affect the 
As(III)-stimulated ArsA ATPase activity, suggesting that As(III) is directly transferred 
from ArsD to ArsA, as opposed to release from ArsD, binding to GSH and then 
interaction of ArsA with the As(GS)3 complex.  To differentiate between these two 
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possibilities, the effect of the As(III) chelator dimercaptosuccinic acid (DMSA) was 
examined. The chelator did not affect transfer, indicating channeling of As(III) from ArsD 
to ArsA.  Transfer occurs only under conditions where ArsA hydrolyzes ATP, suggesting 
that ArsD transfer As(III) to an ArsA conformation transiently formed during catalysis 
and not simply to the closed conformation that ArsA adopts when As(III) and MgATP 
are bound. 
 R773 ArsD was shown to be a dimer in crystal structure. Whether the 
dimerization form is a physiological one existing in the solution, was studied by 
mutagenesis. Residues, Ser68, Arg87 and Arg96, involved in dimerization were 
mutated to alanine. ArsD dimerization equilibrium was shifted to the monomer direction 
by mutating these residues to alanine, but not totally a monomeric form. One mutant 
ArsDG86E was selected from reverse yeast two-hybrid analysis, showing no dimerization 
with wild-type ArsD. Gel-filtration chromatography confirmed mutation G86E shifts ArsD 
dimerization equilibrium to the monomer direction, but not totally change ArsD to a 
monomeric form. Since Gly86 sits on the dimerization interface in the crystal structure, it 
is most likely the crystallographic ArsD dimer forms in the solution. All these mutants 
still retain the ability to stimulate ArsA ATPase activity, suggesting dimerization is not 
strictly required for ArsD metallochaperone function. 
 ArsA and ArsD crystal structure have been solved individually. But little is known 
about ArsA-ArsD interaction interface. Yeast two-hybrid and reverse yeast two-hybrid 
are combined to select for totally 14 ArsD mutants with weaker or stronger interaction 
with ArsA. Additionally, Lys37 and Lys62 were shown to be important for ArsD function 
by site-directed mutagenesis. ArsD loses function when Lys37 and Lys62 were mutated 
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to alanine as well as acetylated by Sulfo-NHS acetate. The charge carried by Lys37 and 
Lys6 was shown to be important since protein is still active when they are mutated to 
arginine. Yeast two-hybrid confirmed mutating Lys37 and Lys62 to alanine has effect on 
ArsA-ArsD interaction. Mapping all the mutations on ArsD structure gives us information 
on ArsA-ArsD interaction interface. Four residues, Ser14, Val17, Thr20 and Val22, are 
in the loop containing the important metal binding site Cys12-Cys13-Cys18. This 
suggests the metal binding site may be directly involved in the interaction with ArsA. 
Seven residues, Gln24, Val27, Asp28, Thr31, Gln34, Lys37 and Gln38 are located on 
helix α1. They are aligned at one side of helix α1 and solvent exposed, suggesting this 
region might be directly involved in interaction. A structure model of ArsA-ArsD complex 
was generated by docking. The model suggested an extensive interaction interface at 
multiple directions, consistent with most of the yeast two-hybrid results.  
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